<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01276639</url>
  </required_header>
  <id_info>
    <org_study_id>A3921078</org_study_id>
    <nct_id>NCT01276639</nct_id>
  </id_info>
  <brief_title>A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis</brief_title>
  <official_title>Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The Efficacy And Safety Of 2 Oral Doses Of CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to compare the effects of CP-690,550 with the effects of
      placebo in patients being treated for moderate to severe chronic plaque psoriasis. This
      one-year study will also evaluate the safety and tolerability of CP-690,550 versus placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 [no symptom] to 4 [severe symptom]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With a Psoriasis Area and Severity Index 75 (PASI 75) Response at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>The PASI quantifies the severity of a participant's psoriasis based on both, &quot;lesion severity&quot; and the &quot;percent of body surface area (BSA)&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 75 response was defined as at least a 75 percent (%) reduction in PASI relative to Baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Total Body Surface Area (BSA) With Psoriasis at Week 16</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>Assessment of BSA with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. Body regions are assigned specific number of handprints with percentage [Head and neck = 10% (10 handprints), upper extremities = 20% (20 handprints), Trunk (including axillae and groin) = 30% (30 handprints), lower extremities (including buttocks) = 40% (40 handprints)]. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis. The total BSA affected was the summation of individual regions affected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI 90) Response at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>The PASI quantifies the severity of a participant's psoriasis based on both, lesion severity and the percent of BSA affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 90 response was defined as at least a 90% reduction in PASI relative to Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dermatology Life Quality Index (DLQI) Total Score</measure>
    <time_frame>Baseline</time_frame>
    <description>The DLQI is a 10 item general dermatology questionnaire that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI item response options are rated by the participant from 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 4 and 16</measure>
    <time_frame>Week 4, 16</time_frame>
    <description>The DLQI is a 10 item general dermatology questionnaire that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI item response options are rated by the participant from 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 [no symptom] to 4 [severe symptom]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Psoriasis Area and Severity Index 75 (PASI 75) Response at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>The PASI quantifies the severity of a participant's psoriasis based on both, lesion severity and the percent of BSA affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 75 response was defined as at least 75% reduction in PASI relative to Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Nail Psoriasis Severity Index (NAPSI) at Week 16</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop [salmon patch dyschromia]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 [absence of psoriasis] to 4 [presence of psoriasis in all 4 quadrants]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores = more severe psoriasis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Probability of Participants Maintaining Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' at Week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 [no symptom] to 4 [severe symptom]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear). Maintenance of PGA response at Week 52 among participants achieving PGA response at Week 16 is reported. Percent probability and 95% confidence interval (CI) were estimated based on the product limit estimator in survival analyses. Event is loss of response. Probability of maintaining response is (1-probability of loss of response).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Probability of Participants Maintaining Psoriasis Area and Severity Index 75 (PASI 75) Response at Week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>The PASI quantifies severity of a participant's psoriasis based on both, lesion severity and percent of BSA affected. PASI is a composite scoring by investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 75 response = at least 75% reduction in PASI relative to Baseline. Maintenance of PASI 75 response at Week 52 among participants achieving PASI 75 response at Week 16 is reported. Percent probability and 95% CI were estimated based on the product limit estimator in survival analyses. Event is loss of response. Probability of maintaining response is (1-probability of loss of response).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Probability of Participants Maintaining Psoriasis Area and Severity Index 90 (PASI 90) Response at Week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>The PASI quantifies severity of a participant's psoriasis based on both, lesion severity and percent of BSA affected. PASI is a composite scoring by investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 90 response = at least 90% reduction in PASI relative to Baseline. Maintenance of PASI 90 response at Week 52 among participants achieving PASI 90 response at Week 16 is reported. Percent probability and 95% CI were estimated based on the product limit estimator in survival analyses. Event is loss of response. Probability of maintaining response is (1-probability of loss of response).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Achieve a Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear'</measure>
    <time_frame>Baseline up to Week 16</time_frame>
    <description>The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 [no symptom] to 4 [severe symptom]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear). Median time to achieve a PGA response up to week 16 is reported. The median time to event was estimated based on the probability of event-rate based on life table estimates (not the observed rate as in outcome measure 1). Median time to event is not estimable if the estimated probability of response by Week 16 is less than 50%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Achieve Psoriasis Area and Severity Index 75 (PASI 75) Response</measure>
    <time_frame>Baseline up to Week 16</time_frame>
    <description>The PASI quantifies the severity of a participant's psoriasis based on both, &quot;lesion severity&quot; and &quot;percent of BSA&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 75 response was defined as at least 75% reduction in PASI relative to Baseline. The median time to event was estimated based on the probability of event-rate based on life table estimates (not the observed rate as in outcome measure 2). Median time to event is not estimable if the estimated probability of response by Week 16 is less than 50%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Achieve Psoriasis Area and Severity Index 50 (PASI 50) Response</measure>
    <time_frame>Baseline up to Week 16</time_frame>
    <description>The PASI quantifies the severity of a participant's psoriasis based on both, &quot;lesion severity&quot; and &quot;percent of BSA&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 50 response was defined as at least 50% reduction in PASI relative to Baseline. The median time to event was estimated based on the probability of event-rate based on life table estimates (not the observed rate as in outcome measure 26). Median time to event is not estimable if the estimated probability of response by Week 16 is less than 50%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear'</measure>
    <time_frame>Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
    <description>The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 [no symptom] to 4 [severe symptom]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score</measure>
    <time_frame>Baseline, Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
    <description>The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 [no symptom] to 4 [severe symptom]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). Percentage of participants with each PGA score is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Psoriasis Area and Severity Index 75 (PASI 75) Response</measure>
    <time_frame>Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
    <description>The PASI quantifies the severity of a participant's psoriasis based on both, &quot;lesion severity&quot; and &quot;percent of BSA&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 75 response was defined as at least 75% reduction in PASI relative to Baseline. Percentage of participants with PASI 75 response is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psoriasis Area and Severity Index (PASI) Score</measure>
    <time_frame>Baseline, Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
    <description>The PASI quantifies the severity of a participant's psoriasis based on both, &quot;lesion severity&quot; and &quot;percent of BSA&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52</measure>
    <time_frame>Baseline, Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
    <description>The PASI quantifies the severity of a participant's psoriasis based on both, &quot;lesion severity&quot; and &quot;percent of BSA&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psoriasis Area and Severity Index (PASI) Component Scores</measure>
    <time_frame>Baseline, Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
    <description>The PASI quantifies the severity of a participant's psoriasis based on both, &quot;lesion severity&quot; and the &quot;percent of BSA&quot; affected. Basic characteristics of psoriatic lesions: erythema, induration, and scaling (PASI components) are scored separately for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]) according to a 5-point scale: 0 (no involvement); 1 (slight); 2 (moderate); 3 (marked); 4 (very marked). PASI component score range from 0 to 4, where higher scores indicate greater severity of psoriatic lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52</measure>
    <time_frame>Baseline, Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
    <description>The PASI quantifies the severity of a participant's psoriasis based on both, &quot;lesion severity&quot; and the &quot;percent of body surface area (BSA)&quot; affected. Basic characteristics of psoriatic lesions: erythema, induration, and scaling (PASI components) are scored separately for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]) according to a 5-point scale: 0 (no involvement); 1 (slight); 2 (moderate); 3 (marked); 4 (very marked). PASI component score range from 0 to 4, where higher scores indicate greater severity of psoriatic lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52</measure>
    <time_frame>Baseline, Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
    <description>The PASI quantifies the severity of a participant's psoriasis based on both, &quot;lesion severity&quot; and &quot;percent of BSA&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Body Surface Area (BSA) With Psoriasis</measure>
    <time_frame>Baseline, Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
    <description>Assessment of BSA with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. Body regions are assigned specific number of handprints with percentage [Head and neck = 10% (10 handprints), upper extremities = 20% (20 handprints), Trunk (including axillae and groin) = 30% (30 handprints), lower extremities (including buttocks) = 40% (40 handprints)]. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis. The total BSA affected was the summation of individual regions affected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Total Body Surface Area (BSA) With Psoriasis at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52</measure>
    <time_frame>Baseline, Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
    <description>Assessment of BSA with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. Body regions are assigned specific number of handprints with percentage [Head and neck = 10% (10 handprints), upper extremities = 20% (20 handprints), Trunk (including axillae and groin) = 30% (30 handprints), lower extremities (including buttocks) = 40% (40 handprints)]. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis. The total BSA affected was the summation of individual regions affected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Psoriasis Area and Severity Index 50 (PASI 50) Response</measure>
    <time_frame>Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
    <description>The PASI quantifies the severity of a participant's psoriasis based on both, &quot;lesion severity&quot; and &quot;percent of BSA&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 50 response was defined as at least 50% reduction in PASI relative to Baseline. Percentage of participants with PASI 50 response is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Psoriasis Area and Severity Index 90 (PASI 90) Response</measure>
    <time_frame>Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
    <description>The PASI quantifies the severity of a participant's psoriasis based on both, &quot;lesion severity&quot; and &quot;percent of BSA&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 90 response was defined as at least 90% reduction in PASI relative to Baseline. Percentage of participants with PASI 90 response up to Week 52 is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Psoriasis Area and Severity Index (PASI) Score of at Least 125% of Baseline PASI Score</measure>
    <time_frame>Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
    <description>The PASI quantifies the severity of a participant's psoriasis based on both, &quot;lesion severity&quot; and &quot;percent of BSA&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. Percentage of participants with PASI score of at least 125% of baseline PASI score are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nail Psoriasis Severity Index (NAPSI) Score</measure>
    <time_frame>Baseline, Week 8, 16, 20, 28, 40, 52</time_frame>
    <description>The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop [salmon patch dyschromia]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 [absence of psoriasis] to 4 [presence of psoriasis in all 4 quadrants]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores = more severe psoriasis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score at Week 8, 16, 20, 28, 40 and 52</measure>
    <time_frame>Baseline, Week 8, 16, 20, 28, 40, 52</time_frame>
    <description>The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop [salmon patch dyschromia]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 [absence of psoriasis] to 4 [presence of psoriasis in all 4 quadrants]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores = more severe psoriasis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Affected Nails</measure>
    <time_frame>Baseline, Week 8, 16, 20, 28, 40, 52</time_frame>
    <description>Nail psoriasis is evaluated by the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop [salmon patch dyschromia]). Total number psoriasis affected nails (presence of psoriatic manifestations on the nail matrix/nail bed) were assessed and reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score at Week 8, 16, 20, 28, 40 and 52</measure>
    <time_frame>Baseline, Week 8, 16, 20, 28, 40, 52</time_frame>
    <description>The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop [salmon patch dyschromia]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 [absence of psoriasis] to 4 [presence of psoriasis in all 4 quadrants]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores = more severe psoriasis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Nail Psoriasis Severity Index 75 (NAPSI 75) Response</measure>
    <time_frame>Week 8, 16, 20, 28, 40, 52</time_frame>
    <description>The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop [salmon patch dyschromia]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 [absence of psoriasis] to 4 [presence of psoriasis in all 4 quadrants]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores = more severe psoriasis. NAPSI 75 response was defined as at least a 75% reduction in NAPSI relative to Baseline. Percentage of participants with NAPSI 75 response is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Nail Psoriasis Severity Index 100 (NAPSI 100) Response</measure>
    <time_frame>Week 8, 16, 20, 28, 40, 52</time_frame>
    <description>The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop [salmon patch dyschromia]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 [absence of psoriasis] to 4 [presence of psoriasis in all 4 quadrants]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores = more severe psoriasis. NAPSI 100 response was defined as at least a 100% reduction in NAPSI relative to Baseline. Percentage of participants with NAPSI 100 response is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Itch Severity Item (ISI) Score</measure>
    <time_frame>Baseline, Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
    <description>ISI assessed severity of itch (pruritus) due to psoriasis. ISI is a single item, horizontal numeric rating scale. Participants were asked to rate &quot;your worst itching due to psoriasis over the past 24 hours&quot; on a numeric rating scale anchored by the terms &quot;No itching&quot; (0) and &quot;Worst possible itching&quot; (10) at the ends for post baseline time points. Baseline ISI is average of scores on 7 days prior to start of study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Itch Severity Item (ISI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52</measure>
    <time_frame>Baseline, Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
    <description>ISI assessed severity of itch (pruritus) due to psoriasis. ISI is a single item, horizontal numeric rating scale. Participants were asked to rate &quot;your worst itching due to psoriasis over the past 24 hours&quot; on a numeric rating scale anchored by the terms &quot;No itching&quot; (0) and &quot;Worst possible itching&quot; (10) at the ends.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dermatology Life Quality Index (DLQI) Score</measure>
    <time_frame>Baseline, Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
    <description>The DLQI is a 10 item general dermatology questionnaire that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI item response options are rated by the participant from 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52</measure>
    <time_frame>Baseline, Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
    <description>The DLQI is a 10 item general dermatology questionnaire that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI item response options are rated by the participant from 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>36-Item Short-Form Health Survey Version 2, Acute (SF-36)</measure>
    <time_frame>Baseline, Week 16, 28, 52</time_frame>
    <description>36-Item Short-Form Health Survey (SF-36) is a standardized survey evaluating 8 aspects of functional health and well-being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. These 8 aspects are summarized as physical and mental health summary scores. The score range for the physical and mental health scores is 0-100 (100=highest level of functioning).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Anxiety and Depression Scale (HADS) Score</measure>
    <time_frame>Baseline, Week 4, 16, 28, 52</time_frame>
    <description>HADS: 14-item questionnaire that screens for the presence of anxiety and depression symptoms. There are 7 items comprising the anxiety subscale, and 7 items comprising the depression subscale. Each item has response option ranging from 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score ranges from 0 to 21 for each subscale; higher score indicates greater severity of anxiety or depression symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Work Limitation Questionnaire (WLQ) Index Score</measure>
    <time_frame>Baseline, Week 4, 16, 28, 52</time_frame>
    <description>WLQ: participant-reported 25-item scale to evaluate degree to which health problems interfere with an ability to perform job roles along 4 dimensions: Time Management scale (5 items); Physical Demands scale (6 items); Mental-Interpersonal Demands Scale (9 items); Output Demands Scale (5 items). All the scales ranged from 0 (limited none of the time) to 100 (limited all of the time). The WLQ Index score is the weighted sum of the scores from the 4 WLQ scales (total score: 0 [no loss] to 100 [complete loss of work]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Patient Global Assessment (PtGA) Scale Response</measure>
    <time_frame>Baseline, Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
    <description>The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5-point scale (0=clear [no psoriasis]; 1=almost clear; 2=mild; 3=moderate; 4=severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response</measure>
    <time_frame>Week 16, 28, 52</time_frame>
    <description>The PSSM is a single, 7 point item that evaluates overall participant satisfaction with the study treatment. Response options range from &quot;very dissatisfied&quot; to &quot;very satisfied&quot; with the study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Joint Pain Assessment (JPA) Score</measure>
    <time_frame>Baseline, Week 4, 16, 28, 52</time_frame>
    <description>The JPA assesses severity of joint pain. The JPA is a horizontal numeric rating scale. Participants were asked to &quot;select the number that best describes any joint pain that participant may have experienced over the past 24 hours&quot; with response options ranging from &quot;0-no joint pain&quot; to &quot;10-worst possible joint pain.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Euro Quality of Life 5 Dimensions (EQ-5D) - Health State Profile Utility Score</measure>
    <time_frame>Baseline, Week 16, 28, 40, 52</time_frame>
    <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (&quot;confined to bed&quot;). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Euro Quality of Life 5 Dimensions (EQ-5D) - Visual Analog Scale (VAS)</measure>
    <time_frame>Baseline, Week 16, 28, 40, 52</time_frame>
    <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 millimeter (mm) (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Interaction With Healthcare Professional</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>The Psoriasis Health Care Resource Utilization (Ps-HCRU) questionnaire is a short questionnaire designed to assess healthcare resource use and the impact of psoriasis on work. The first section assesses direct costs associated with healthcare resource use (interactions with healthcare providers such as general practitioners, Dermatologist, Rheumatologist). Baseline is the latest pre-dose measurement. Week 16 includes all reported log data to Week 16 (excluding Baseline). Participants may have response in more than 1 category. Data was not analyzed beyond Week 16 as per study team's decision because Week 0 - 16 period was considered sufficient to provide clear reflection of Ps-HCRU endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Impact of Psoriasis on Work</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>The Psoriasis Health Care Resource Utilization (Ps-HCRU) questionnaire is a short questionnaire designed to assess healthcare resource use and the impact of psoriasis on work. The second section assesses indirect costs associated with absenteeism due to psoriasis and the impact of psoriasis on productivity at work. Participants employed at the time of assessment answered (Yes/No [Y/N]): &quot;Were you absent or on sick leave from work due to psoriasis today?&quot;, and participants unemployed (UEmp) at the time of assessment answered (Yes/No): &quot;Are you unemployed due to your psoriasis?&quot; Baseline is the latest pre-dose measurement. Week 16 includes all reported log up to Week 16 (excluding Baseline). Data was not analyzed beyond Week 16 as per study team's decision because Week 0 - 16 period was considered sufficient to provide clear reflection of Ps-HCRU endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Healthcare Resource Use Events and Employment Status</measure>
    <time_frame>Week 16</time_frame>
    <description>The Psoriasis Health Care Resource Utilization (Ps-HCRU) questionnaire is a short questionnaire designed to assess healthcare resource use and the impact of psoriasis on work. The first section assesses direct costs associated with healthcare resource use, and the second section assesses indirect costs associated with absenteeism due to psoriasis and the impact of psoriasis on productivity at work. Percentage of participants reporting healthcare resource use events and employment status, work impacted events due to psoriasis, and absence or sick leave for work due to psoriasis at Week 16 are reported. Data was not analyzed beyond Week 16 as per study team's decision because Week 0 - 16 period was considered sufficient to provide clear reflection of Ps-HCRU endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Work Hours and Absent Hours</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>The Psoriasis Health Care Resource Utilization (Ps-HCRU) questionnaire is a short questionnaire designed to assess healthcare resource use and the impact of psoriasis on work. The first section assesses direct costs associated with healthcare resource use, and the second section assesses indirect costs associated with absenteeism due to psoriasis and the impact of psoriasis on productivity at work. Baseline is the latest pre-dose measurement. Participants reported hours scheduled to work and hours absent from work. Data was not analyzed beyond Week 16 as per study team's decision because Week 0 - 16 period was considered sufficient to provide clear reflection of Ps-HCRU endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Percent Absent Hours</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>The Psoriasis Health Care Resource Utilization (Ps-HCRU) questionnaire is a short questionnaire designed to assess healthcare resource use and the impact of psoriasis on work. The first section assesses direct costs associated with healthcare resource use, and the second section assesses indirect costs associated with absenteeism due to psoriasis and the impact of psoriasis on productivity at work. Baseline is the latest pre-dose measurement. Participants reported hours scheduled to work and hours absent from work. Percent absent hours = (hours absent from work/hours scheduled to work) multiplied by 100. Data was not analyzed beyond Week 16 as per study team's decision because Week 0 - 16 period was considered sufficient to provide clear reflection of Ps-HCRU endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Psoriasis Affecting Ability to Work</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>The Psoriasis Health Care Resource Utilization (Ps-HCRU) questionnaire is a short questionnaire designed to assess healthcare resource use and the impact of psoriasis on work. The first section assesses direct costs associated with healthcare resource use, and the second section assesses indirect costs associated with absenteeism due to psoriasis and the impact of psoriasis on productivity at work. Baseline is the latest pre-dose measurement. Participants rate how much psoriasis affected their ability to work by reporting a number from 0 to 10, where 0 means &quot;ability to work was not affected by psoriasis&quot;, and 10 means &quot;ability to work was completely affected by psoriasis&quot;. Data was not analyzed beyond Week 16 as per study team's decision because Week 0 - 16 period was considered sufficient to provide clear reflection of Ps-HCRU endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Family Dermatology Life Quality Index (FDLQI) Score</measure>
    <time_frame>Baseline, Week 16, 52</time_frame>
    <description>The FDLQI is a 10-item questionnaire that examine the impact of health-related quality of life issues associated with living with a person with a skin condition (example, emotional distress, personal relationships, reactions of other people, social life, caregiving) over the last month. The FDLQI need to be completed by a family member (for example, spouse or partner, parent) who currently lives with the participant. Each question is scored on a scale from 0 (Not at all/ Not relevant) to 3 (Very much). Total score is calculated by summing the score of each item resulting in a maximum score of '30' and a minimum score of '0'. Higher scores indicate greater impairment to quality of life.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">901</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Active Treatment 10 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ActiveTreatment 5 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Treatment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-690,550</intervention_name>
    <description>10 mg oral BID, Continuous treatment for 52 Weeks</description>
    <arm_group_label>Active Treatment 10 mg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-690,550</intervention_name>
    <description>5 mg oral BID, Continuous treatment for 52 Weeks</description>
    <arm_group_label>ActiveTreatment 5 mg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo/CP-690,550</intervention_name>
    <description>0 mg oral BID, Continuous treatment for 16 Weeks; 10 mg oral BID, Continuous Treatment for 36 Weeks (after completion of 16 Weeks of Placebo)</description>
    <arm_group_label>Placebo Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo/CP-690,550</intervention_name>
    <description>0 mg oral BID, Continuous treatment for 16 Weeks; 5 mg oral BID, Continuous Treatment for 36 Weeks (after completion of 16 Weeks of Placebo)</description>
    <arm_group_label>Placebo Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Are 18 years or older with diagnosis for at least 12 months of moderate to severe
             plaque psoriasis covering as least 10%of body surface area

          -  a Psoriasis Area and Severity Index (PASI) score of 12 and are considered to be
             candidates for systemic or light therapy

          -  No evidence of active or latent tuberculosis

        Exclusion Criteria:

          -  Non-plaque or drug induced forms of psoriasis

          -  cannot discontinue current oral, injectible or topical therapy for psoriasis or cannot
             discontinue phototherapy (PUVA or UVB)

          -  any uncontrolled significant medical condition
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radiant Research, Inc.</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Irvine - Dermatology Research</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Surgery Medical Group, Inc.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Science Institute</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cherry Creek Research, Inc.</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Savin Center, P.C.</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renstar Medical Research</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Alliance in Dermatology</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Dermatology, Vein &amp; Research Center, P.C.</name>
      <address>
        <city>Alpharetta</city>
        <state>Georgia</state>
        <zip>30022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peachtree Dermatology Associates Research Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30327</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedaPhase Inc.</name>
      <address>
        <city>Newnan</city>
        <state>Georgia</state>
        <zip>30263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Illinois University School of Medicine</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dawes Fretzin Clinical Research Group, LLC</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital - Clinical Unit for Research Trials and Outcomes in Skin</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Specialists, P.C.</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Search of Rochester, Inc.</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Raleigh Radiology Blue Ridge</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Research Associates</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Sooner Research</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <zip>73071</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baker Allergy, Asthma and Dermatology Research Center, LLC</name>
      <address>
        <city>Lake Oswego</city>
        <state>Oregon</state>
        <zip>97035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center - Department of Dermatology</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Partners, LLC</name>
      <address>
        <city>Johnston</city>
        <state>Rhode Island</state>
        <zip>02919</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Associates of Knoxville, PC</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37917</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Modern Research Associates, PLLC</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Menter Dermatology Research Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Studies</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rockwood Dermatology Center</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rockwood Research Center</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wenatchee Valley Medical Center - Clinical Research Department</name>
      <address>
        <city>Wenatchee</city>
        <state>Washington</state>
        <zip>98801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Madison Skin and Research, Inc.</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53719</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermadvances Research</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3C 1R4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Zohair Tomi PMC Inc.</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B 4S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Canada Cutaneous Research Associates Ltd.</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ultranova Skincare</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 6L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynderm Research Inc.</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L3P 1A8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Bay Dermatology Centre</name>
      <address>
        <city>North Bay</city>
        <state>Ontario</state>
        <zip>P1B 3Z7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oakville Dermatology Laser Centre</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6J 7W5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Dr. Michael Robern</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K2G 6E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>K.Papp Clinical Research Inc.</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRCMRGilbert Inc., Centre de Dermatologie Maizerets</name>
      <address>
        <city>Quebec</city>
        <zip>G1J 1X7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Reumatologia y Ortopedia</name>
      <address>
        <city>Barranquilla</city>
        <state>Atlantico</state>
        <zip>0000</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riesgo de Fractura S.A</name>
      <address>
        <city>Bogot</city>
        <state>Cundinamarca</state>
        <zip>0000</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite - Universitaetsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aerztehaus &quot;Rudolf Virchow&quot;</name>
      <address>
        <city>Berlin</city>
        <zip>13055</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik fuer Dermatologie und Allergologie der Universitaet Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinik Carl Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinische Forschung Hamburg GmbH</name>
      <address>
        <city>Hamburg</city>
        <zip>20253</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Schleswig-Holstein, Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Muenster</name>
      <address>
        <city>Muenster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinische Forschung Schwerin GmbH</name>
      <address>
        <city>Schwerin</city>
        <zip>19055</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxisklinik fuer Dermatologie, Allergologie und Venenheilkunde</name>
      <address>
        <city>Vechta</city>
        <zip>49377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facharzt fuer Dermatologie und Venerologie, Allergologie</name>
      <address>
        <city>Wuppertal</city>
        <zip>42275</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bacs-Kiskun Megyei Onkormanyzat Korhaza Szegedi Tudomanyegyetem AOK Oktato Korhaza</name>
      <address>
        <city>Kecskemet</city>
        <zip>6000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Josa Andras Oktatokorhaz, Borgyogyaszat</name>
      <address>
        <city>Nyiregyhaza</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pecsi Tudomanyegyetem/Bor-, Nemikortani es Onkodermatologiai Klinika</name>
      <address>
        <city>Pecs</city>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gunma University Hospital</name>
      <address>
        <city>Maebashi-shi</city>
        <state>Gunma</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JR Sapporo hospital</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kobe University Hospital</name>
      <address>
        <city>Chuo-ku</city>
        <state>Kobe</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kumamoto University Hospital</name>
      <address>
        <city>Kumamoto-shi</city>
        <state>Kumamoto</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Social Insurance Chuo General Hospital</name>
      <address>
        <city>Shinjyuku-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Dermatologia de Monterrey</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poznanski Osrodek Medyczny</name>
      <address>
        <city>Poznan</city>
        <zip>60-773</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Katedra i Klinika Chorob Skornych i Wenerycznych, Pomorski Uniwersytet Medyczny</name>
      <address>
        <city>Szczecin</city>
        <zip>70-111</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Katedra i Klinika Dermatologii, Wenerologii i Alergologii Akademii Medycznej we Wroclawiu</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-368</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oddzial Dermatologiczny</name>
      <address>
        <city>Wroclaw</city>
        <zip>51-124</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Center Zvezdara</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cheng-Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>110</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept of Dermatology and Venerology of SI &quot;Crimean State Medical University n.a. S.I. Georgiyevskyj&quot;</name>
      <address>
        <city>Simferopol</city>
        <state>Crimea</state>
        <zip>95006</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept of Dermatology, Infectious and Parasitic Skin Diseases</name>
      <address>
        <city>Kharkiv</city>
        <zip>61057</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept of Dermatology and Venereology of National Medical University n.a. O.O. Bogomolets</name>
      <address>
        <city>Kyiv</city>
        <zip>01032</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ternopil Regional Clinical Dermatovenerologic Dispensary</name>
      <address>
        <city>Ternopil</city>
        <zip>46006</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Colombia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Japan</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Serbia</country>
    <country>Taiwan</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3921078&amp;StudyName=A%20One-Year%20Study%20To%20Evaluate%20The%20Effects%20And%20Safety%20Of%20CP-690%2C550%20In%20Patients%20With%20Moderate%20To%20Severe%20Chronic%20Plaque%20Psoriasis</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2011</study_first_submitted>
  <study_first_submitted_qc>January 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2011</study_first_posted>
  <results_first_submitted>July 24, 2014</results_first_submitted>
  <results_first_submitted_qc>September 18, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 19, 2014</results_first_posted>
  <disposition_first_submitted>February 3, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>February 3, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">March 6, 2014</disposition_first_posted>
  <last_update_submitted>September 18, 2014</last_update_submitted>
  <last_update_submitted_qc>September 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Xeljanz</keyword>
  <keyword>tofacitinib</keyword>
  <keyword>chronic</keyword>
  <keyword>Pruritus</keyword>
  <keyword>Itch</keyword>
  <keyword>DLQI</keyword>
  <keyword>severe</keyword>
  <keyword>moderate</keyword>
  <keyword>treatment</keyword>
  <keyword>safety</keyword>
  <keyword>efficacy</keyword>
  <keyword>CP-690,550</keyword>
  <keyword>Plaque Psoriasis</keyword>
  <keyword>Psoriasis Vulgaris</keyword>
  <keyword>Jax-inhibitor</keyword>
  <keyword>Oral Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tofacitinib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Outcome measures reporting results up to week 16 consist of single placebo arm as reporting group while outcome measures reporting results up to week 52 consist of 2 separate arms (for participants re-randomized at week 16 to receive CP-690,550 5 milligram [mg] or 10 mg).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>CP-690,550 5 mg</title>
          <description>CP-690,550 (tofacitinib) 5 milligram (mg) tablet orally twice daily up to Week 52.</description>
        </group>
        <group group_id="P2">
          <title>CP-690,550 10 mg</title>
          <description>CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo matched to CP-690,550 tablet orally twice daily up to Week 16. Participants in this group were re-randomized to CP-690,550 5 mg or CP-690,550 10 mg treatment at Week 16.</description>
        </group>
        <group group_id="P4">
          <title>Placebo, CP-690,550 5 mg</title>
          <description>Participants who were re-assigned to this group from placebo at Week 16 and thereafter received CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
        </group>
        <group group_id="P5">
          <title>Placebo, CP-690,550 10 mg</title>
          <description>Participants who were re-assigned to this group from placebo at Week 16 and thereafter received CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Week 0 to 16</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="363"/>
                <participants group_id="P2" count="361"/>
                <participants group_id="P3" count="177"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="363"/>
                <participants group_id="P2" count="360"/>
                <participants group_id="P3" count="177"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="313"/>
                <participants group_id="P2" count="320"/>
                <participants group_id="P3" count="132"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="45"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized, But Not Treated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Week 16 to 52</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="313"/>
                <participants group_id="P2" count="320"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="66"/>
                <participants group_id="P5" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="186"/>
                <participants group_id="P2" count="219"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="50"/>
                <participants group_id="P5" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="127"/>
                <participants group_id="P2" count="101"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="16"/>
                <participants group_id="P5" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="99"/>
                <participants group_id="P2" count="71"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="14"/>
                <participants group_id="P5" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety analysis set included all participants who received at least 1 dose of investigational drug (CP-690,550 or placebo).</population>
      <group_list>
        <group group_id="B1">
          <title>CP-690,550 5 mg</title>
          <description>CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
        </group>
        <group group_id="B2">
          <title>CP-690,550 10 mg</title>
          <description>CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo matched to CP-690,550 tablet orally twice daily up to Week 16. Participants in this group were re-randomized to CP-690,550 5 mg or CP-690,550 10 mg treatment at Week 16.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="363"/>
            <count group_id="B2" value="360"/>
            <count group_id="B3" value="177"/>
            <count group_id="B4" value="900"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.6" spread="13.4"/>
                    <measurement group_id="B2" value="45.2" spread="12.8"/>
                    <measurement group_id="B3" value="45.0" spread="12.6"/>
                    <measurement group_id="B4" value="45.3" spread="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                    <measurement group_id="B2" value="99"/>
                    <measurement group_id="B3" value="56"/>
                    <measurement group_id="B4" value="257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="261"/>
                    <measurement group_id="B2" value="261"/>
                    <measurement group_id="B3" value="121"/>
                    <measurement group_id="B4" value="643"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of Clear or Almost Clear at Week 16</title>
        <description>The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 [no symptom] to 4 [severe symptom]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear).</description>
        <time_frame>Week 16</time_frame>
        <population>Full analysis set (FAS) included all participants who were randomized to the study and received at least 1 dose of the randomized investigational drug (CP-690,550 or placebo). Non-Responder Imputation (NRI) method (participants with missing values considered as non-responders) was used to impute missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 tablet orally twice daily up to Week 16. Participants in this group were re-randomized to CP-690,550 5 mg or CP-690,550 10 mg treatment at Week 16.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of Clear or Almost Clear at Week 16</title>
          <description>The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 [no symptom] to 4 [severe symptom]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear).</description>
          <population>Full analysis set (FAS) included all participants who were randomized to the study and received at least 1 dose of the randomized investigational drug (CP-690,550 or placebo). Non-Responder Imputation (NRI) method (participants with missing values considered as non-responders) was used to impute missing values.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="363"/>
                <count group_id="O2" value="360"/>
                <count group_id="O3" value="177"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.87"/>
                    <measurement group_id="O2" value="59.17"/>
                    <measurement group_id="O3" value="9.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>For primary endpoint, step-down procedure used to preserve Type I error, sequential order of testing: PGA response for CP-690,550 10 mg versus (vs) placebo at Week 16; Psoriasis Area and Severity Index 75 (PASI75) response for CP-690,550 10 mg vs placebo at Week 16; PGA response for CP-690,550 5 mg vs placebo at Week 16; PASI75 response for CP-690,550 5 mg vs placebo at Week 16. If comparison at preceding step was significant, only then subsequent comparisons were significant.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Cochran-Mantel-Haenszel statistics adjusted for pooled investigator sites was used for the analysis. Each hypothesis was tested against placebo at significance level of 0.05 (2-sided).</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>6.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.40</ci_lower_limit>
            <ci_upper_limit>15.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>For primary endpoint, step-down procedure used to preserve Type I error, sequential order of testing: PGA response for CP-690,550 10 mg versus (vs) placebo at Week 16; Psoriasis Area and Severity Index 75 (PASI75) response for CP-690,550 10 mg vs placebo at Week 16; PGA response for CP-690,550 5 mg vs placebo at Week 16; PASI75 response for CP-690,550 5 mg vs placebo at Week 16. If comparison at preceding step was significant, only then subsequent comparisons were significant.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Cochran-Mantel-Haenszel statistics adjusted for pooled investigator sites was used for the analysis. Each hypothesis was tested against placebo at significance level of 0.05 (2-sided).</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>12.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.01</ci_lower_limit>
            <ci_upper_limit>31.88</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Normal approximation</method>
            <param_type>Percent difference</param_type>
            <param_value>17.29</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.66</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.11</ci_lower_limit>
            <ci_upper_limit>24.47</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a Psoriasis Area and Severity Index 75 (PASI 75) Response at Week 16</title>
        <description>The PASI quantifies the severity of a participant's psoriasis based on both, &quot;lesion severity&quot; and the &quot;percent of body surface area (BSA)&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 75 response was defined as at least a 75 percent (%) reduction in PASI relative to Baseline.</description>
        <time_frame>Week 16</time_frame>
        <population>FAS included all participants who were randomized to the study and received at least 1 dose of the randomized investigational drug (CP-690,550 or placebo). NRI method (participants with missing values considered as non-responders) was used to impute missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 tablet orally twice daily up to Week 16. Participants in this group were re-randomized to CP-690,550 5 mg or CP-690,550 10 mg treatment at Week 16.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Psoriasis Area and Severity Index 75 (PASI 75) Response at Week 16</title>
          <description>The PASI quantifies the severity of a participant's psoriasis based on both, &quot;lesion severity&quot; and the &quot;percent of body surface area (BSA)&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 75 response was defined as at least a 75 percent (%) reduction in PASI relative to Baseline.</description>
          <population>FAS included all participants who were randomized to the study and received at least 1 dose of the randomized investigational drug (CP-690,550 or placebo). NRI method (participants with missing values considered as non-responders) was used to impute missing values.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="363"/>
                <count group_id="O2" value="360"/>
                <count group_id="O3" value="177"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.94"/>
                    <measurement group_id="O2" value="59.17"/>
                    <measurement group_id="O3" value="6.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>For primary endpoint, step-down procedure used to preserve Type I error, sequential order of testing: PGA response for CP-690,550 10 mg versus (vs) placebo at Week 16; Psoriasis Area and Severity Index 75 (PASI75) response for CP-690,550 10 mg vs placebo at Week 16; PGA response for CP-690,550 5 mg vs placebo at Week 16; PASI75 response for CP-690,550 5 mg vs placebo at Week 16. If comparison at preceding step was significant, only then subsequent comparisons were significant.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Cochran-Mantel-Haenszel statistics adjusted for pooled investigator sites was used for the analysis. Each hypothesis was tested against placebo at significance level of 0.05 (2-sided).</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>8.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.25</ci_lower_limit>
            <ci_upper_limit>21.84</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>For primary endpoint, step-down procedure used to preserve Type I error, sequential order of testing: PGA response for CP-690,550 10 mg versus (vs) placebo at Week 16; Psoriasis Area and Severity Index 75 (PASI75) response for CP-690,550 10 mg vs placebo at Week 16; PGA response for CP-690,550 5 mg vs placebo at Week 16; PASI75 response for CP-690,550 5 mg vs placebo at Week 16. If comparison at preceding step was significant, only then subsequent comparisons were significant.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Cochran-Mantel-Haenszel statistics adjusted for pooled investigator sites was used for the analysis. Each hypothesis was tested against placebo at significance level of 0.05 (2-sided).</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>20.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>11.90</ci_lower_limit>
            <ci_upper_limit>49.86</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Normal approximation</method>
            <param_type>Percent difference</param_type>
            <param_value>19.22</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.65</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>12.07</ci_lower_limit>
            <ci_upper_limit>26.37</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Total Body Surface Area (BSA) With Psoriasis at Week 16</title>
        <description>Assessment of BSA with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. Body regions are assigned specific number of handprints with percentage [Head and neck = 10% (10 handprints), upper extremities = 20% (20 handprints), Trunk (including axillae and groin) = 30% (30 handprints), lower extremities (including buttocks) = 40% (40 handprints)]. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis. The total BSA affected was the summation of individual regions affected.</description>
        <time_frame>Baseline, Week 16</time_frame>
        <population>FAS included all participants who were randomized to the study and received at least 1 dose of the randomized investigational drug (CP-690,550 or placebo). Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 tablet orally twice daily up to Week 16. Participants in this group were re-randomized to CP-690,550 5 mg or CP-690,550 10 mg treatment at Week 16.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Total Body Surface Area (BSA) With Psoriasis at Week 16</title>
          <description>Assessment of BSA with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. Body regions are assigned specific number of handprints with percentage [Head and neck = 10% (10 handprints), upper extremities = 20% (20 handprints), Trunk (including axillae and groin) = 30% (30 handprints), lower extremities (including buttocks) = 40% (40 handprints)]. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis. The total BSA affected was the summation of individual regions affected.</description>
          <population>FAS included all participants who were randomized to the study and received at least 1 dose of the randomized investigational drug (CP-690,550 or placebo). Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="359"/>
                <count group_id="O2" value="358"/>
                <count group_id="O3" value="177"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-51.94" spread="2.45"/>
                    <measurement group_id="O2" value="-67.20" spread="2.44"/>
                    <measurement group_id="O3" value="1.62" spread="3.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>For key secondary endpoint, family-wise step-down procedure was used to control Type I error. Sequential order of testing: percent change in BSA at Week 16,PASI90 response at Week 16, change in Dermatology Life Quality Index(DLQI) total score at Week 16,PGA response at Week 4,PASI75 at Week 4, change in DLQI total score at Week 4, percent change in Nail Psoriasis Severity Index(NAPSI) score at Week 16. If comparison at preceding step was significant, then subsequent comparisons were significant.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed model analysis with fixed effects for treatment, visit, treatment-by-visit interaction,baseline value and repeated measures for visit. Unstructured covariance matrix was used. Each hypothesis was tested at significance level of 0.025 (2-sided).</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Least squares (LS) mean difference</param_type>
            <param_value>-53.56</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.34</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-62.08</ci_lower_limit>
            <ci_upper_limit>-45.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>For key secondary endpoint, family-wise step-down procedure was used to control Type I error. Sequential order of testing: percent change in BSA at Week 16,PASI90 response at Week 16, change in Dermatology Life Quality Index(DLQI) total score at Week 16,PGA response at Week 4,PASI75 at Week 4, change in DLQI total score at Week 4, percent change in Nail Psoriasis Severity Index(NAPSI) score at Week 16. If comparison at preceding step was significant, then subsequent comparisons were significant.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed model analysis with fixed effects for treatment, visit, treatment-by-visit interaction,baseline value and repeated measures for visit. Unstructured covariance matrix was used. Each hypothesis was tested at significance level of 0.025 (2-sided).</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS mean difference</param_type>
            <param_value>-68.82</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.34</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-77.33</ci_lower_limit>
            <ci_upper_limit>-60.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>LS mean difference was derived from mixed model with fixed effects for treatment, visit, treatment-by-visit interaction, baseline value and repeated measures for visit. Unstructured covariance matrix was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LS mean difference</param_type>
            <param_value>-15.26</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.46</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.04</ci_lower_limit>
            <ci_upper_limit>-8.48</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI 90) Response at Week 16</title>
        <description>The PASI quantifies the severity of a participant's psoriasis based on both, lesion severity and the percent of BSA affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 90 response was defined as at least a 90% reduction in PASI relative to Baseline.</description>
        <time_frame>Week 16</time_frame>
        <population>FAS included all participants who were randomized to the study and received at least 1 dose of the randomized investigational drug (CP-690,550 or placebo). NRI method (participants with missing values considered as non-responders) was used to impute missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 tablet orally twice daily up to Week 16. Participants in this group were re-randomized to CP-690,550 5 mg or CP-690,550 10 mg treatment at Week 16.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI 90) Response at Week 16</title>
          <description>The PASI quantifies the severity of a participant's psoriasis based on both, lesion severity and the percent of BSA affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 90 response was defined as at least a 90% reduction in PASI relative to Baseline.</description>
          <population>FAS included all participants who were randomized to the study and received at least 1 dose of the randomized investigational drug (CP-690,550 or placebo). NRI method (participants with missing values considered as non-responders) was used to impute missing values.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="363"/>
                <count group_id="O2" value="360"/>
                <count group_id="O3" value="177"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.83"/>
                    <measurement group_id="O2" value="39.44"/>
                    <measurement group_id="O3" value="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>For key secondary endpoint, family-wise step-down procedure was used to control Type I error. Sequential order of testing: percent change in BSA at Week 16, PASI90 response at Week 16, change in DLQI total score at Week 16, PGA response at Week 4, PASI75 response at Week 4, change in DLQI total score at Week 4, percent change in NAPSI score at Week 16. If comparison at preceding step was significant, then subsequent comparisons were significant.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Cochran-Mantel-Haenszel statistics adjusted for pooled investigator sites was used for the analysis. Each hypothesis was tested at significance level of 0.025 (2-sided).</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>34.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.46</ci_lower_limit>
            <ci_upper_limit>1786.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>For key secondary endpoint, family-wise step-down procedure was used to control Type I error. Sequential order of testing: percent change in BSA at Week 16, PASI90 response at Week 16, change in DLQI total score at Week 16, PGA response at Week 4, PASI75 response at Week 4, change in DLQI total score at Week 4, percent change in NAPSI score at Week 16. If comparison at preceding step was significant, then subsequent comparisons were significant.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Cochran-Mantel-Haenszel statistics adjusted for pooled investigator sites was used for the analysis. Each hypothesis was tested at significance level of 0.025 (2-sided).</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>98.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>23.49</ci_lower_limit>
            <ci_upper_limit>5689.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Normal approximation</method>
            <param_type>Percent difference</param_type>
            <param_value>19.61</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.32</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>13.10</ci_lower_limit>
            <ci_upper_limit>26.11</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dermatology Life Quality Index (DLQI) Total Score</title>
        <description>The DLQI is a 10 item general dermatology questionnaire that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI item response options are rated by the participant from 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.</description>
        <time_frame>Baseline</time_frame>
        <population>FAS included all participants who were randomized to the study and received at least 1 dose of the randomized investigational drug (CP-690,550 or placebo). Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 tablet orally twice daily up to Week 16. Participants in this group were re-randomized to CP-690,550 5 mg or CP-690,550 10 mg treatment at Week 16.</description>
          </group>
        </group_list>
        <measure>
          <title>Dermatology Life Quality Index (DLQI) Total Score</title>
          <description>The DLQI is a 10 item general dermatology questionnaire that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI item response options are rated by the participant from 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.</description>
          <population>FAS included all participants who were randomized to the study and received at least 1 dose of the randomized investigational drug (CP-690,550 or placebo). Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="363"/>
                <count group_id="O2" value="359"/>
                <count group_id="O3" value="177"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.46" spread="6.89"/>
                    <measurement group_id="O2" value="12.87" spread="6.91"/>
                    <measurement group_id="O3" value="14.01" spread="7.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 4 and 16</title>
        <description>The DLQI is a 10 item general dermatology questionnaire that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI item response options are rated by the participant from 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.</description>
        <time_frame>Week 4, 16</time_frame>
        <population>FAS included all participants who were randomized to the study and received at least 1 dose of the randomized investigational drug (CP-690,550 or placebo). Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 tablet orally twice daily up to Week 16. Participants in this group were re-randomized to CP-690,550 5 mg or CP-690,550 10 mg treatment at Week 16.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 4 and 16</title>
          <description>The DLQI is a 10 item general dermatology questionnaire that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI item response options are rated by the participant from 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.</description>
          <population>FAS included all participants who were randomized to the study and received at least 1 dose of the randomized investigational drug (CP-690,550 or placebo). Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="358"/>
                <count group_id="O2" value="357"/>
                <count group_id="O3" value="177"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.59" spread="0.25"/>
                    <measurement group_id="O2" value="-6.40" spread="0.25"/>
                    <measurement group_id="O3" value="-1.69" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.91" spread="0.30"/>
                    <measurement group_id="O2" value="-8.90" spread="0.29"/>
                    <measurement group_id="O3" value="-1.93" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week4: For key secondary endpoint, family-wise step-down procedure was used to control Type I error. Sequential order of testing: percent change in BSA at Week 16, PASI90 response at Week 16, change in DLQI total score at Week 16, PGA response at Week 4, PASI75 response at Week 4, change in DLQI total score at Week 4, percent change in NAPSI score at Week 16. If comparison at preceding step was significant, then subsequent comparisons were significant.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed model analysis with fixed effects for treatment, visit, treatment-by-visit interaction,baseline value and repeated measures for visit. Unstructured covariance matrix was used. Each hypothesis was tested at significance level of 0.025 (2-sided).</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS mean difference</param_type>
            <param_value>-3.90</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.43</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.75</ci_lower_limit>
            <ci_upper_limit>-3.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 4: For key secondary endpoint, family-wise step-down procedure was used to control Type I error. Sequential order of testing: percent change in BSA at Week 16, PASI90 response at Week 16, change in DLQI total score at Week 16, PGA response at Week 4, PASI75 response at Week 4, change in DLQI total score at Week 4, percent change in NAPSI score at Week 16. If comparison at preceding step was significant, then subsequent comparisons were significant.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed model analysis with fixed effects for treatment, visit, treatment-by-visit interaction,baseline value and repeated measures for visit. Unstructured covariance matrix was used. Each hypothesis was tested at significance level of 0.025 (2-sided).</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS mean difference</param_type>
            <param_value>-4.71</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.43</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.56</ci_lower_limit>
            <ci_upper_limit>-3.86</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 4: LS mean difference was derived from mixed model with fixed effects for treatment, visit, treatment-by-visit interaction, baseline value and repeated measures for visit. Unstructured covariance matrix was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0212</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LS mean difference</param_type>
            <param_value>-0.81</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.35</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.50</ci_lower_limit>
            <ci_upper_limit>-0.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 16: For key secondary endpoint, family-wise step-down procedure was used to control Type I error. Sequential order of testing: percent change in BSA at Week 16, PASI90 response at Week 16, change in DLQI total score at Week 16, PGA response at Week 4, PASI75 response at Week 4, change in DLQI total score at Week 4, percent change in NAPSI score at Week 16. If comparison at preceding step was significant, then subsequent comparisons were significant.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed model analysis with fixed effects for treatment, visit, treatment-by-visit interaction,baseline value and repeated measures for visit. Unstructured covariance matrix was used. Each hypothesis was tested at significance level of 0.025 (2-sided).</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS mean difference</param_type>
            <param_value>-4.98</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.53</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.02</ci_lower_limit>
            <ci_upper_limit>-3.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 16: For key secondary endpoint, family-wise step-down procedure was used to control Type I error. Sequential order of testing: percent change in BSA at Week 16, PASI90 response at Week 16, change in DLQI total score at Week 16, PGA response at Week 4, PASI75 response at Week 4, change in DLQI total score at Week 4, percent change in NAPSI score at Week 16. If comparison at preceding step was significant, then subsequent comparisons were significant.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed model analysis with fixed effects for treatment, visit, treatment-by-visit interaction,baseline value and repeated measures for visit. Unstructured covariance matrix was used. Each hypothesis was tested at significance level of 0.025 (2-sided).</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS mean difference</param_type>
            <param_value>-6.97</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.53</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.00</ci_lower_limit>
            <ci_upper_limit>-5.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 16: LS mean difference was derived from mixed model with fixed effects for treatment, visit, treatment-by-visit interaction, baseline value and repeated measures for visit. Unstructured covariance matrix was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LS mean difference</param_type>
            <param_value>-1.99</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.42</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.80</ci_lower_limit>
            <ci_upper_limit>-1.17</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of Clear or Almost Clear at Week 4</title>
        <description>The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 [no symptom] to 4 [severe symptom]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear).</description>
        <time_frame>Week 4</time_frame>
        <population>FAS included all participants who were randomized to the study and received at least 1 dose of the randomized investigational drug (CP-690,550 or placebo). NRI method (participants with missing values considered as non-responders) was used to impute missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 tablet orally twice daily up to Week 16. Participants in this group were re-randomized to CP-690,550 5 mg or CP-690,550 10 mg treatment at Week 16.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of Clear or Almost Clear at Week 4</title>
          <description>The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 [no symptom] to 4 [severe symptom]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear).</description>
          <population>FAS included all participants who were randomized to the study and received at least 1 dose of the randomized investigational drug (CP-690,550 or placebo). NRI method (participants with missing values considered as non-responders) was used to impute missing values.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="363"/>
                <count group_id="O2" value="360"/>
                <count group_id="O3" value="177"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.08"/>
                    <measurement group_id="O2" value="23.06"/>
                    <measurement group_id="O3" value="2.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>For key secondary endpoint, family-wise step-down procedure was used to control Type I error. Sequential order of testing: percent change in BSA at Week 16, PASI90 response at Week 16, change in DLQI total score at Week 16, PGA response at Week 4, PASI75 response at Week 4, change in DLQI total score at Week 4, percent change in NAPSI score at Week 16. If comparison at preceding step was significant, then subsequent comparisons were significant.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Cochran-Mantel-Haenszel statistics adjusted for pooled investigator sites was used for the analysis. Each hypothesis was tested at significance level of 0.025 (2-sided).</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>8.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.23</ci_lower_limit>
            <ci_upper_limit>35.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>For key secondary endpoint, family-wise step-down procedure was used to control Type I error. Sequential order of testing: percent change in BSA at Week 16, PASI90 response at Week 16, change in DLQI total score at Week 16, PGA response at Week 4, PASI75 response at Week 4, change in DLQI total score at Week 4, percent change in NAPSI score at Week 16. If comparison at preceding step was significant, then subsequent comparisons were significant.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Cochran-Mantel-Haenszel statistics adjusted for pooled investigator sites was used for the analysis. Each hypothesis was tested at significance level of 0.025 (2-sided).</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>11.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.06</ci_lower_limit>
            <ci_upper_limit>54.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0443</p_value>
            <method>Normal approximation</method>
            <param_type>Percent difference</param_type>
            <param_value>5.98</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.97</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.15</ci_lower_limit>
            <ci_upper_limit>11.80</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Psoriasis Area and Severity Index 75 (PASI 75) Response at Week 4</title>
        <description>The PASI quantifies the severity of a participant's psoriasis based on both, lesion severity and the percent of BSA affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 75 response was defined as at least 75% reduction in PASI relative to Baseline.</description>
        <time_frame>Week 4</time_frame>
        <population>FAS included all participants who were randomized to the study and received at least 1 dose of the randomized investigational drug (CP-690,550 or placebo). NRI method (participants with missing values considered as non-responders) was used to impute missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 tablet orally twice daily up to Week 16. Participants in this group were re-randomized to CP-690,550 5 mg or CP-690,550 10 mg treatment at Week 16.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Psoriasis Area and Severity Index 75 (PASI 75) Response at Week 4</title>
          <description>The PASI quantifies the severity of a participant's psoriasis based on both, lesion severity and the percent of BSA affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 75 response was defined as at least 75% reduction in PASI relative to Baseline.</description>
          <population>FAS included all participants who were randomized to the study and received at least 1 dose of the randomized investigational drug (CP-690,550 or placebo). NRI method (participants with missing values considered as non-responders) was used to impute missing values.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="363"/>
                <count group_id="O2" value="360"/>
                <count group_id="O3" value="177"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.47"/>
                    <measurement group_id="O2" value="15.56"/>
                    <measurement group_id="O3" value="1.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>For key secondary endpoint, family-wise step-down procedure was used to control Type I error. Sequential order of testing: percent change in BSA at Week 16, PASI90 response at Week 16, change in DLQI total score at Week 16, PGA response at Week 4, PASI75 response at Week 4, change in DLQI total score at Week 4, percent change in NAPSI score at Week 16. If comparison at preceding step was significant, then subsequent comparisons were significant.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <p_value_desc>Cochran-Mantel-Haenszel statistics adjusted for pooled investigator sites was used for the analysis. Each hypothesis was tested at significance level of 0.025 (2-sided).</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>6.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.11</ci_lower_limit>
            <ci_upper_limit>35.77</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>For key secondary endpoint, family-wise step-down procedure was used to control Type I error. Sequential order of testing: percent change in BSA at Week 16, PASI90 response at Week 16, change in DLQI total score at Week 16, PGA response at Week 4, PASI75 response at Week 4, change in DLQI total score at Week 4, percent change in NAPSI score at Week 16. If comparison at preceding step was significant, then subsequent comparisons were significant.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Cochran-Mantel-Haenszel statistics adjusted for pooled investigator sites was used for the analysis. Each hypothesis was tested at significance level of 0.025 (2-sided).</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>11.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.64</ci_lower_limit>
            <ci_upper_limit>59.98</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0415</p_value>
            <method>Normal approximation</method>
            <param_type>Percent difference</param_type>
            <param_value>5.09</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.50</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.19</ci_lower_limit>
            <ci_upper_limit>9.98</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Nail Psoriasis Severity Index (NAPSI) at Week 16</title>
        <description>The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop [salmon patch dyschromia]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 [absence of psoriasis] to 4 [presence of psoriasis in all 4 quadrants]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores = more severe psoriasis.</description>
        <time_frame>Baseline, Week 16</time_frame>
        <population>FAS included all participants who were randomized to the study and received at least 1 dose of the randomized investigational drug (CP-690,550 or placebo). Here 'N' (number of participants analyzed) signifies those participants who were evaluable (had nail psoriasis at Baseline and had at least one measurement during follow up) for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 tablet orally twice daily up to Week 16. Participants in this group were re-randomized to CP-690,550 5 mg or CP-690,550 10 mg treatment at Week 16.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Nail Psoriasis Severity Index (NAPSI) at Week 16</title>
          <description>The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop [salmon patch dyschromia]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 [absence of psoriasis] to 4 [presence of psoriasis in all 4 quadrants]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores = more severe psoriasis.</description>
          <population>FAS included all participants who were randomized to the study and received at least 1 dose of the randomized investigational drug (CP-690,550 or placebo). Here 'N' (number of participants analyzed) signifies those participants who were evaluable (had nail psoriasis at Baseline and had at least one measurement during follow up) for this measure.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="237"/>
                <count group_id="O2" value="242"/>
                <count group_id="O3" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.15" spread="9.47"/>
                    <measurement group_id="O2" value="-41.48" spread="9.22"/>
                    <measurement group_id="O3" value="55.55" spread="14.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>For key secondary endpoint, family-wise step-down procedure was used to control Type I error. Sequential order of testing: percent change in BSA at Week 16, PASI90 response at Week 16, change in DLQI total score at Week 16, PGA response at Week 4, PASI75 response at Week 4, change in DLQI total score at Week 4, percent change in NAPSI score at Week 16. If comparison at preceding step was significant, then subsequent comparisons were significant.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed model analysis with fixed effects for treatment, visit, treatment-by-visit interaction,baseline value and repeated measures for visit. Unstructured covariance matrix was used. Each hypothesis was tested at significance level of 0.025 (2-sided).</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS mean difference</param_type>
            <param_value>-69.70</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>17.60</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-104.27</ci_lower_limit>
            <ci_upper_limit>-35.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>For key secondary endpoint, family-wise step-down procedure was used to control Type I error. Sequential order of testing: percent change in BSA at Week 16, PASI90 response at Week 16, change in DLQI total score at Week 16, PGA response at Week 4, PASI75 response at Week 4, change in DLQI total score at Week 4, percent change in NAPSI score at Week 16. If comparison at preceding step was significant, then subsequent comparisons were significant.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed model analysis with fixed effects for treatment, visit, treatment-by-visit interaction,baseline value and repeated measures for visit. Unstructured covariance matrix was used. Each hypothesis was tested at significance level of 0.025 (2-sided).</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS mean difference</param_type>
            <param_value>-97.03</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>17.47</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-131.35</ci_lower_limit>
            <ci_upper_limit>-62.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>LS mean difference was derived from mixed model with fixed effects for treatment, visit, treatment-by-visit interaction, baseline value and repeated measures for visit. Unstructured covariance matrix was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0391</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LS mean difference</param_type>
            <param_value>-27.33</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>13.22</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-53.29</ci_lower_limit>
            <ci_upper_limit>-1.37</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Probability of Participants Maintaining Physician Global Assessment (PGA) of Psoriasis Score of Clear or Almost Clear at Week 52</title>
        <description>The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 [no symptom] to 4 [severe symptom]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear). Maintenance of PGA response at Week 52 among participants achieving PGA response at Week 16 is reported. Percent probability and 95% confidence interval (CI) were estimated based on the product limit estimator in survival analyses. Event is loss of response. Probability of maintaining response is (1-probability of loss of response).</description>
        <time_frame>Week 52</time_frame>
        <population>FAS participants who had PGA response at Week 16. Data was not analyzed for participants initially randomized to placebo arm as they were re-randomized to active treatment group at Week 16 and thus maintaining response at Week 52 was not relevant. 'N' (number of participants analyzed) = participants with non-missing post-baseline response data.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>Participants who received CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>Participants who received CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Probability of Participants Maintaining Physician Global Assessment (PGA) of Psoriasis Score of Clear or Almost Clear at Week 52</title>
          <description>The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 [no symptom] to 4 [severe symptom]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear). Maintenance of PGA response at Week 52 among participants achieving PGA response at Week 16 is reported. Percent probability and 95% confidence interval (CI) were estimated based on the product limit estimator in survival analyses. Event is loss of response. Probability of maintaining response is (1-probability of loss of response).</description>
          <population>FAS participants who had PGA response at Week 16. Data was not analyzed for participants initially randomized to placebo arm as they were re-randomized to active treatment group at Week 16 and thus maintaining response at Week 52 was not relevant. 'N' (number of participants analyzed) = participants with non-missing post-baseline response data.</population>
          <units>percent probability of response</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="209"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.17" lower_limit="51.80" upper_limit="67.56"/>
                    <measurement group_id="O2" value="71.56" lower_limit="64.81" upper_limit="77.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Probability of Participants Maintaining Psoriasis Area and Severity Index 75 (PASI 75) Response at Week 52</title>
        <description>The PASI quantifies severity of a participant's psoriasis based on both, lesion severity and percent of BSA affected. PASI is a composite scoring by investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 75 response = at least 75% reduction in PASI relative to Baseline. Maintenance of PASI 75 response at Week 52 among participants achieving PASI 75 response at Week 16 is reported. Percent probability and 95% CI were estimated based on the product limit estimator in survival analyses. Event is loss of response. Probability of maintaining response is (1-probability of loss of response).</description>
        <time_frame>Week 52</time_frame>
        <population>FAS participants who had PASI 75 response at Week 16. Data was not analyzed for participants initially randomized to placebo arm as they were re-randomized to active treatment group at Week 16 and thus maintaining response at Week 52 was not relevant. 'N' (number of participants analyzed) = participants with non-missing post-baseline response data.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>Participants who received CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>Participants who received CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Probability of Participants Maintaining Psoriasis Area and Severity Index 75 (PASI 75) Response at Week 52</title>
          <description>The PASI quantifies severity of a participant's psoriasis based on both, lesion severity and percent of BSA affected. PASI is a composite scoring by investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 75 response = at least 75% reduction in PASI relative to Baseline. Maintenance of PASI 75 response at Week 52 among participants achieving PASI 75 response at Week 16 is reported. Percent probability and 95% CI were estimated based on the product limit estimator in survival analyses. Event is loss of response. Probability of maintaining response is (1-probability of loss of response).</description>
          <population>FAS participants who had PASI 75 response at Week 16. Data was not analyzed for participants initially randomized to placebo arm as they were re-randomized to active treatment group at Week 16 and thus maintaining response at Week 52 was not relevant. 'N' (number of participants analyzed) = participants with non-missing post-baseline response data.</population>
          <units>percent probability of response</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="209"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.75" lower_limit="65.47" upper_limit="80.33"/>
                    <measurement group_id="O2" value="79.94" lower_limit="73.75" upper_limit="84.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Probability of Participants Maintaining Psoriasis Area and Severity Index 90 (PASI 90) Response at Week 52</title>
        <description>The PASI quantifies severity of a participant's psoriasis based on both, lesion severity and percent of BSA affected. PASI is a composite scoring by investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 90 response = at least 90% reduction in PASI relative to Baseline. Maintenance of PASI 90 response at Week 52 among participants achieving PASI 90 response at Week 16 is reported. Percent probability and 95% CI were estimated based on the product limit estimator in survival analyses. Event is loss of response. Probability of maintaining response is (1-probability of loss of response).</description>
        <time_frame>Week 52</time_frame>
        <population>FAS participants who had PASI 90 response at Week 16. Data was not analyzed for participants initially randomized to placebo arm as they were re-randomized to active treatment group at Week 16 and thus maintaining response at Week 52 was not relevant. 'N' (number of participants analyzed) = participants with non-missing post-baseline response data.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>Participants who received CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>Participants who received CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Probability of Participants Maintaining Psoriasis Area and Severity Index 90 (PASI 90) Response at Week 52</title>
          <description>The PASI quantifies severity of a participant's psoriasis based on both, lesion severity and percent of BSA affected. PASI is a composite scoring by investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 90 response = at least 90% reduction in PASI relative to Baseline. Maintenance of PASI 90 response at Week 52 among participants achieving PASI 90 response at Week 16 is reported. Percent probability and 95% CI were estimated based on the product limit estimator in survival analyses. Event is loss of response. Probability of maintaining response is (1-probability of loss of response).</description>
          <population>FAS participants who had PASI 90 response at Week 16. Data was not analyzed for participants initially randomized to placebo arm as they were re-randomized to active treatment group at Week 16 and thus maintaining response at Week 52 was not relevant. 'N' (number of participants analyzed) = participants with non-missing post-baseline response data.</population>
          <units>percent probability of response</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.79" lower_limit="49.37" upper_limit="72.01"/>
                    <measurement group_id="O2" value="70.58" lower_limit="62.12" upper_limit="77.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Achieve a Physician Global Assessment (PGA) of Psoriasis Score of Clear or Almost Clear</title>
        <description>The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 [no symptom] to 4 [severe symptom]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear). Median time to achieve a PGA response up to week 16 is reported. The median time to event was estimated based on the probability of event-rate based on life table estimates (not the observed rate as in outcome measure 1). Median time to event is not estimable if the estimated probability of response by Week 16 is less than 50%.</description>
        <time_frame>Baseline up to Week 16</time_frame>
        <population>FAS included all participants who were randomized to the study and received at least 1 dose of the randomized investigational drug (CP-690,550 or placebo). Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 tablet orally twice daily up to Week 16. Participants in this group were re-randomized to CP-690,550 5 mg or CP-690,550 10 mg treatment at Week 16.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Achieve a Physician Global Assessment (PGA) of Psoriasis Score of Clear or Almost Clear</title>
          <description>The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 [no symptom] to 4 [severe symptom]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear). Median time to achieve a PGA response up to week 16 is reported. The median time to event was estimated based on the probability of event-rate based on life table estimates (not the observed rate as in outcome measure 1). Median time to event is not estimable if the estimated probability of response by Week 16 is less than 50%.</description>
          <population>FAS included all participants who were randomized to the study and received at least 1 dose of the randomized investigational drug (CP-690,550 or placebo). Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="359"/>
                <count group_id="O2" value="358"/>
                <count group_id="O3" value="177"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0" lower_limit="12.0">Upper limit was not estimable based on the log-log transformation method.</measurement>
                    <measurement group_id="O2" value="12.0" lower_limit="8.0" upper_limit="12.0"/>
                    <measurement group_id="O3" value="NA">Data was not estimable because estimated probability of response by Week 16 was less than 50%.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Achieve Psoriasis Area and Severity Index 75 (PASI 75) Response</title>
        <description>The PASI quantifies the severity of a participant's psoriasis based on both, &quot;lesion severity&quot; and &quot;percent of BSA&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 75 response was defined as at least 75% reduction in PASI relative to Baseline. The median time to event was estimated based on the probability of event-rate based on life table estimates (not the observed rate as in outcome measure 2). Median time to event is not estimable if the estimated probability of response by Week 16 is less than 50%.</description>
        <time_frame>Baseline up to Week 16</time_frame>
        <population>FAS included all participants who were randomized to the study and received at least 1 dose of the randomized investigational drug (CP-690,550 or placebo). Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 tablet orally twice daily up to Week 16. Participants in this group were re-randomized to CP-690,550 5 mg or CP-690,550 10 mg treatment at Week 16.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Achieve Psoriasis Area and Severity Index 75 (PASI 75) Response</title>
          <description>The PASI quantifies the severity of a participant's psoriasis based on both, &quot;lesion severity&quot; and &quot;percent of BSA&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 75 response was defined as at least 75% reduction in PASI relative to Baseline. The median time to event was estimated based on the probability of event-rate based on life table estimates (not the observed rate as in outcome measure 2). Median time to event is not estimable if the estimated probability of response by Week 16 is less than 50%.</description>
          <population>FAS included all participants who were randomized to the study and received at least 1 dose of the randomized investigational drug (CP-690,550 or placebo). Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="359"/>
                <count group_id="O2" value="358"/>
                <count group_id="O3" value="177"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="16.0">Data was not estimable because estimated probability of response by Week 16 was less than 50%.</measurement>
                    <measurement group_id="O2" value="12.0">Upper and lower limits were not estimable based on the log-log transformation method.</measurement>
                    <measurement group_id="O3" value="NA">Data was not estimable because estimated probability of response by Week 16 was less than 50%.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Achieve Psoriasis Area and Severity Index 50 (PASI 50) Response</title>
        <description>The PASI quantifies the severity of a participant's psoriasis based on both, &quot;lesion severity&quot; and &quot;percent of BSA&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 50 response was defined as at least 50% reduction in PASI relative to Baseline. The median time to event was estimated based on the probability of event-rate based on life table estimates (not the observed rate as in outcome measure 26). Median time to event is not estimable if the estimated probability of response by Week 16 is less than 50%.</description>
        <time_frame>Baseline up to Week 16</time_frame>
        <population>FAS included all participants who were randomized to the study and received at least 1 dose of the randomized investigational drug (CP-690,550 or placebo). Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 tablet orally twice daily up to Week 16. Participants in this group were re-randomized to CP-690,550 5 mg or CP-690,550 10 mg treatment at Week 16.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Achieve Psoriasis Area and Severity Index 50 (PASI 50) Response</title>
          <description>The PASI quantifies the severity of a participant's psoriasis based on both, &quot;lesion severity&quot; and &quot;percent of BSA&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 50 response was defined as at least 50% reduction in PASI relative to Baseline. The median time to event was estimated based on the probability of event-rate based on life table estimates (not the observed rate as in outcome measure 26). Median time to event is not estimable if the estimated probability of response by Week 16 is less than 50%.</description>
          <population>FAS included all participants who were randomized to the study and received at least 1 dose of the randomized investigational drug (CP-690,550 or placebo). Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="359"/>
                <count group_id="O2" value="358"/>
                <count group_id="O3" value="177"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" lower_limit="8.0" upper_limit="12.0"/>
                    <measurement group_id="O2" value="8.0">Upper and lower limits were not estimable based on the log-log transformation method.</measurement>
                    <measurement group_id="O3" value="NA">Data was not estimable because estimated probability of response by Week 16 was less than 50%.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of Clear or Almost Clear</title>
        <description>The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 [no symptom] to 4 [severe symptom]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear).</description>
        <time_frame>Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
        <population>FAS: all randomized participants who received at least 1 dose of the randomized investigational drug (CP-690,550 or placebo). Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. NRI method was used to impute missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, CP-690,550 5 mg</title>
            <description>Participants who were re-assigned to this group from placebo at Week 16 and thereafter received CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, CP-690,550 10 mg</title>
            <description>Participants who were re-assigned to this group from placebo at Week 16 and thereafter received CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of Clear or Almost Clear</title>
          <description>The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 [no symptom] to 4 [severe symptom]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear).</description>
          <population>FAS: all randomized participants who received at least 1 dose of the randomized investigational drug (CP-690,550 or placebo). Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. NRI method was used to impute missing values.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="363"/>
                <count group_id="O2" value="360"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.23" lower_limit="2.94" upper_limit="7.53"/>
                    <measurement group_id="O2" value="10.00" lower_limit="6.90" upper_limit="13.10"/>
                    <measurement group_id="O3" value="3.03" lower_limit="0.00" upper_limit="7.17"/>
                    <measurement group_id="O4" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.08" lower_limit="13.21" upper_limit="20.95"/>
                    <measurement group_id="O2" value="23.06" lower_limit="18.70" upper_limit="27.41"/>
                    <measurement group_id="O3" value="6.06" lower_limit="0.30" upper_limit="11.82"/>
                    <measurement group_id="O4" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.40" lower_limit="26.63" upper_limit="36.18"/>
                    <measurement group_id="O2" value="46.39" lower_limit="41.24" upper_limit="51.54"/>
                    <measurement group_id="O3" value="9.09" lower_limit="2.16" upper_limit="16.03"/>
                    <measurement group_id="O4" value="6.06" lower_limit="0.30" upper_limit="11.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.74" lower_limit="32.75" upper_limit="42.73"/>
                    <measurement group_id="O2" value="56.67" lower_limit="51.55" upper_limit="61.79"/>
                    <measurement group_id="O3" value="12.12" lower_limit="4.25" upper_limit="20.00"/>
                    <measurement group_id="O4" value="9.09" lower_limit="2.16" upper_limit="16.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.87" lower_limit="36.80" upper_limit="46.95"/>
                    <measurement group_id="O2" value="59.17" lower_limit="54.09" upper_limit="64.24"/>
                    <measurement group_id="O3" value="13.64" lower_limit="5.36" upper_limit="21.92"/>
                    <measurement group_id="O4" value="10.61" lower_limit="3.18" upper_limit="18.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.45" lower_limit="40.33" upper_limit="50.58"/>
                    <measurement group_id="O2" value="56.67" lower_limit="51.55" upper_limit="61.79"/>
                    <measurement group_id="O3" value="39.39" lower_limit="27.61" upper_limit="51.18"/>
                    <measurement group_id="O4" value="30.30" lower_limit="19.22" upper_limit="41.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.76" lower_limit="43.62" upper_limit="53.90"/>
                    <measurement group_id="O2" value="62.22" lower_limit="57.21" upper_limit="67.23"/>
                    <measurement group_id="O3" value="66.67" lower_limit="55.29" upper_limit="78.04"/>
                    <measurement group_id="O4" value="65.15" lower_limit="53.66" upper_limit="76.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.70" lower_limit="37.61" upper_limit="47.79"/>
                    <measurement group_id="O2" value="53.06" lower_limit="47.90" upper_limit="58.21"/>
                    <measurement group_id="O3" value="53.03" lower_limit="40.99" upper_limit="65.07"/>
                    <measurement group_id="O4" value="63.64" lower_limit="52.03" upper_limit="75.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.54" lower_limit="30.61" upper_limit="40.46"/>
                    <measurement group_id="O2" value="46.67" lower_limit="41.51" upper_limit="51.82"/>
                    <measurement group_id="O3" value="43.94" lower_limit="31.97" upper_limit="55.91"/>
                    <measurement group_id="O4" value="59.09" lower_limit="47.23" upper_limit="70.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score</title>
        <description>The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 [no symptom] to 4 [severe symptom]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). Percentage of participants with each PGA score is reported.</description>
        <time_frame>Baseline, Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
        <population>FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. NRI method was used to impute missing values. Here n signifies those participants who were evaluable for this measure at specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, CP-690,550 5 mg</title>
            <description>Participants who were re-assigned to this group from placebo at Week 16 and thereafter received CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, CP-690,550 10 mg</title>
            <description>Participants who were re-assigned to this group from placebo at Week 16 and thereafter received CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score</title>
          <description>The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 [no symptom] to 4 [severe symptom]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). Percentage of participants with each PGA score is reported.</description>
          <population>FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. NRI method was used to impute missing values. Here n signifies those participants who were evaluable for this measure at specified time point for each arm, respectively.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="363"/>
                <count group_id="O2" value="360"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Clear (n = 363, 360, 66, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="0.00"/>
                    <measurement group_id="O4" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Almost Clear (n = 363, 360, 66, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="0.00"/>
                    <measurement group_id="O4" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Mild (n = 363, 360, 66, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3"/>
                    <measurement group_id="O2" value="0.3"/>
                    <measurement group_id="O3" value="0.00"/>
                    <measurement group_id="O4" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Moderate (n = 363, 360, 66, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.2"/>
                    <measurement group_id="O2" value="88.9"/>
                    <measurement group_id="O3" value="97.0"/>
                    <measurement group_id="O4" value="92.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Severe (n = 363, 360, 66, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6"/>
                    <measurement group_id="O2" value="10.8"/>
                    <measurement group_id="O3" value="3.0"/>
                    <measurement group_id="O4" value="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Clear (n = 358, 358, 66, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="0.00"/>
                    <measurement group_id="O4" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Almost Clear (n = 358, 358, 66, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3"/>
                    <measurement group_id="O2" value="10.1"/>
                    <measurement group_id="O3" value="3.0"/>
                    <measurement group_id="O4" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Mild (n = 358, 358, 66, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.7"/>
                    <measurement group_id="O2" value="38.8"/>
                    <measurement group_id="O3" value="30.3"/>
                    <measurement group_id="O4" value="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Moderate (n = 358, 358, 66, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.0"/>
                    <measurement group_id="O2" value="46.1"/>
                    <measurement group_id="O3" value="63.6"/>
                    <measurement group_id="O4" value="70.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Severe (n = 358, 358, 66, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0"/>
                    <measurement group_id="O2" value="5.0"/>
                    <measurement group_id="O3" value="3.0"/>
                    <measurement group_id="O4" value="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Clear (n = 352, 350, 65, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                    <measurement group_id="O2" value="3.4"/>
                    <measurement group_id="O3" value="0.00"/>
                    <measurement group_id="O4" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Almost Clear (n = 352, 350, 65, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.2"/>
                    <measurement group_id="O2" value="20.3"/>
                    <measurement group_id="O3" value="6.2"/>
                    <measurement group_id="O4" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Mild (n = 352, 350, 65, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.8"/>
                    <measurement group_id="O2" value="45.4"/>
                    <measurement group_id="O3" value="33.8"/>
                    <measurement group_id="O4" value="21.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Moderate (n = 352, 350, 65, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.5"/>
                    <measurement group_id="O2" value="28.3"/>
                    <measurement group_id="O3" value="55.4"/>
                    <measurement group_id="O4" value="71.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Severe (n = 352, 350, 65, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1"/>
                    <measurement group_id="O2" value="2.6"/>
                    <measurement group_id="O3" value="4.6"/>
                    <measurement group_id="O4" value="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Clear (n = 347, 350, 65, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7"/>
                    <measurement group_id="O2" value="10.6"/>
                    <measurement group_id="O3" value="0.00"/>
                    <measurement group_id="O4" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Almost Clear (n = 347, 350, 65, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.1"/>
                    <measurement group_id="O2" value="37.1"/>
                    <measurement group_id="O3" value="9.2"/>
                    <measurement group_id="O4" value="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Mild (n = 347, 350, 65, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.3"/>
                    <measurement group_id="O2" value="36.0"/>
                    <measurement group_id="O3" value="33.8"/>
                    <measurement group_id="O4" value="24.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Moderate (n = 347, 350, 65, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.2"/>
                    <measurement group_id="O2" value="14.6"/>
                    <measurement group_id="O3" value="53.8"/>
                    <measurement group_id="O4" value="65.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Severe (n = 347, 350, 65, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6"/>
                    <measurement group_id="O2" value="1.7"/>
                    <measurement group_id="O3" value="3.1"/>
                    <measurement group_id="O4" value="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Clear (n = 345, 345, 65, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8"/>
                    <measurement group_id="O2" value="17.4"/>
                    <measurement group_id="O3" value="1.5"/>
                    <measurement group_id="O4" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Almost Clear (n = 345, 345, 65, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.9"/>
                    <measurement group_id="O2" value="41.7"/>
                    <measurement group_id="O3" value="10.8"/>
                    <measurement group_id="O4" value="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Mild (n = 345, 345, 65, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.0"/>
                    <measurement group_id="O2" value="26.1"/>
                    <measurement group_id="O3" value="43.1"/>
                    <measurement group_id="O4" value="25.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Moderate (n = 345, 345, 65, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.4"/>
                    <measurement group_id="O2" value="13.0"/>
                    <measurement group_id="O3" value="41.5"/>
                    <measurement group_id="O4" value="54.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Severe (n = 345, 345, 65, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9"/>
                    <measurement group_id="O2" value="1.7"/>
                    <measurement group_id="O3" value="3.1"/>
                    <measurement group_id="O4" value="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Clear (n = 323, 335, 66, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.1"/>
                    <measurement group_id="O2" value="25.7"/>
                    <measurement group_id="O3" value="0.00"/>
                    <measurement group_id="O4" value="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Almost Clear (n = 323, 335, 66, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.0"/>
                    <measurement group_id="O2" value="37.9"/>
                    <measurement group_id="O3" value="13.6"/>
                    <measurement group_id="O4" value="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Mild (n = 323, 335, 66, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.8"/>
                    <measurement group_id="O2" value="23.6"/>
                    <measurement group_id="O3" value="47.0"/>
                    <measurement group_id="O4" value="21.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Moderate (n = 323, 335, 66, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.6"/>
                    <measurement group_id="O2" value="11.3"/>
                    <measurement group_id="O3" value="34.8"/>
                    <measurement group_id="O4" value="62.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Severe (n = 323, 335, 66, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5"/>
                    <measurement group_id="O2" value="1.5"/>
                    <measurement group_id="O3" value="4.5"/>
                    <measurement group_id="O4" value="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Clear (n = 312, 321, 66, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.3"/>
                    <measurement group_id="O2" value="31.2"/>
                    <measurement group_id="O3" value="7.6"/>
                    <measurement group_id="O4" value="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Almost Clear (n = 312, 321, 66, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.5"/>
                    <measurement group_id="O2" value="32.4"/>
                    <measurement group_id="O3" value="31.8"/>
                    <measurement group_id="O4" value="21.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Mild (n = 312, 321, 66, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.7"/>
                    <measurement group_id="O2" value="24.3"/>
                    <measurement group_id="O3" value="53.0"/>
                    <measurement group_id="O4" value="43.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Moderate (n = 312, 321, 66, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.7"/>
                    <measurement group_id="O2" value="11.5"/>
                    <measurement group_id="O3" value="7.6"/>
                    <measurement group_id="O4" value="23.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Severe (n = 312, 321, 66, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6"/>
                    <measurement group_id="O2" value="0.6"/>
                    <measurement group_id="O3" value="0.00"/>
                    <measurement group_id="O4" value="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28: Clear (n = 300, 307, 61, 61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.3"/>
                    <measurement group_id="O2" value="34.2"/>
                    <measurement group_id="O3" value="14.8"/>
                    <measurement group_id="O4" value="29.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28: Almost Clear (n = 300, 307, 61, 61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.7"/>
                    <measurement group_id="O2" value="38.8"/>
                    <measurement group_id="O3" value="57.4"/>
                    <measurement group_id="O4" value="41.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28: Mild (n = 300, 307, 61, 61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.7"/>
                    <measurement group_id="O2" value="17.6"/>
                    <measurement group_id="O3" value="23.0"/>
                    <measurement group_id="O4" value="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28: Moderate (n = 300, 307, 61, 61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3"/>
                    <measurement group_id="O2" value="8.8"/>
                    <measurement group_id="O3" value="4.9"/>
                    <measurement group_id="O4" value="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28: Severe (n = 300, 307, 61, 61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                    <measurement group_id="O2" value="0.7"/>
                    <measurement group_id="O3" value="0.00"/>
                    <measurement group_id="O4" value="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Clear (n = 203, 242, 53, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.5"/>
                    <measurement group_id="O2" value="45.9"/>
                    <measurement group_id="O3" value="18.9"/>
                    <measurement group_id="O4" value="55.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Almost Clear (n = 203, 242, 53, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.9"/>
                    <measurement group_id="O2" value="33.1"/>
                    <measurement group_id="O3" value="47.2"/>
                    <measurement group_id="O4" value="34.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Mild (n = 203, 242, 53, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.2"/>
                    <measurement group_id="O2" value="15.3"/>
                    <measurement group_id="O3" value="26.4"/>
                    <measurement group_id="O4" value="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Moderate (n = 203, 242, 53, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9"/>
                    <measurement group_id="O2" value="5.4"/>
                    <measurement group_id="O3" value="7.5"/>
                    <measurement group_id="O4" value="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Severe (n = 203, 242, 53, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="0.4"/>
                    <measurement group_id="O3" value="0.00"/>
                    <measurement group_id="O4" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Clear (n = 180, 219, 47, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.7"/>
                    <measurement group_id="O2" value="43.4"/>
                    <measurement group_id="O3" value="19.1"/>
                    <measurement group_id="O4" value="54.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Almost Clear (n = 180, 219, 47, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.0"/>
                    <measurement group_id="O2" value="33.3"/>
                    <measurement group_id="O3" value="42.6"/>
                    <measurement group_id="O4" value="30.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Mild (n = 180, 219, 47, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.4"/>
                    <measurement group_id="O2" value="19.6"/>
                    <measurement group_id="O3" value="36.2"/>
                    <measurement group_id="O4" value="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Moderate (n = 180, 219, 47, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9"/>
                    <measurement group_id="O2" value="3.7"/>
                    <measurement group_id="O3" value="2.1"/>
                    <measurement group_id="O4" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Severe (n = 180, 219, 47, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="0.00"/>
                    <measurement group_id="O4" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Psoriasis Area and Severity Index 75 (PASI 75) Response</title>
        <description>The PASI quantifies the severity of a participant's psoriasis based on both, &quot;lesion severity&quot; and &quot;percent of BSA&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 75 response was defined as at least 75% reduction in PASI relative to Baseline. Percentage of participants with PASI 75 response is reported.</description>
        <time_frame>Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
        <population>FAS: all randomized participants who received at least 1 dose of the randomized investigational drug (CP-690,550 or placebo). Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. NRI method was used to impute missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, CP-690,550 5 mg</title>
            <description>Participants who were re-assigned to this group from placebo at Week 16 and thereafter received CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, CP-690,550 10 mg</title>
            <description>Participants who were re-assigned to this group from placebo at Week 16 and thereafter received CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Psoriasis Area and Severity Index 75 (PASI 75) Response</title>
          <description>The PASI quantifies the severity of a participant's psoriasis based on both, &quot;lesion severity&quot; and &quot;percent of BSA&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 75 response was defined as at least 75% reduction in PASI relative to Baseline. Percentage of participants with PASI 75 response is reported.</description>
          <population>FAS: all randomized participants who received at least 1 dose of the randomized investigational drug (CP-690,550 or placebo). Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. NRI method was used to impute missing values.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="363"/>
                <count group_id="O2" value="360"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.38" lower_limit="0.18" upper_limit="2.58"/>
                    <measurement group_id="O2" value="2.22" lower_limit="0.70" upper_limit="3.74"/>
                    <measurement group_id="O3" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O4" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.47" lower_limit="7.32" upper_limit="13.62"/>
                    <measurement group_id="O2" value="15.56" lower_limit="11.81" upper_limit="19.30"/>
                    <measurement group_id="O3" value="4.55" lower_limit="0.00" upper_limit="9.57"/>
                    <measurement group_id="O4" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.69" lower_limit="19.32" upper_limit="28.07"/>
                    <measurement group_id="O2" value="36.67" lower_limit="31.69" upper_limit="41.64"/>
                    <measurement group_id="O3" value="6.06" lower_limit="0.30" upper_limit="11.82"/>
                    <measurement group_id="O4" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.54" lower_limit="30.61" upper_limit="40.46"/>
                    <measurement group_id="O2" value="55.28" lower_limit="50.14" upper_limit="60.41"/>
                    <measurement group_id="O3" value="6.06" lower_limit="0.30" upper_limit="11.82"/>
                    <measurement group_id="O4" value="7.58" lower_limit="1.19" upper_limit="13.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.94" lower_limit="34.91" upper_limit="44.98"/>
                    <measurement group_id="O2" value="59.17" lower_limit="54.09" upper_limit="64.24"/>
                    <measurement group_id="O3" value="9.09" lower_limit="2.16" upper_limit="16.03"/>
                    <measurement group_id="O4" value="7.58" lower_limit="1.19" upper_limit="13.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.18" lower_limit="40.06" upper_limit="50.30"/>
                    <measurement group_id="O2" value="59.44" lower_limit="54.37" upper_limit="64.52"/>
                    <measurement group_id="O3" value="31.82" lower_limit="20.58" upper_limit="43.06"/>
                    <measurement group_id="O4" value="24.24" lower_limit="13.90" upper_limit="34.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.86" lower_limit="44.72" upper_limit="55.01"/>
                    <measurement group_id="O2" value="63.06" lower_limit="58.07" upper_limit="68.04"/>
                    <measurement group_id="O3" value="59.09" lower_limit="47.23" upper_limit="70.95"/>
                    <measurement group_id="O4" value="68.18" lower_limit="56.94" upper_limit="79.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.45" lower_limit="40.33" upper_limit="50.58"/>
                    <measurement group_id="O2" value="56.94" lower_limit="51.83" upper_limit="62.06"/>
                    <measurement group_id="O3" value="65.15" lower_limit="53.66" upper_limit="76.65"/>
                    <measurement group_id="O4" value="68.18" lower_limit="56.94" upper_limit="79.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.84" lower_limit="33.83" upper_limit="43.86"/>
                    <measurement group_id="O2" value="51.39" lower_limit="46.23" upper_limit="56.55"/>
                    <measurement group_id="O3" value="54.55" lower_limit="42.53" upper_limit="66.56"/>
                    <measurement group_id="O4" value="65.15" lower_limit="53.66" upper_limit="76.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Psoriasis Area and Severity Index (PASI) Score</title>
        <description>The PASI quantifies the severity of a participant's psoriasis based on both, &quot;lesion severity&quot; and &quot;percent of BSA&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.</description>
        <time_frame>Baseline, Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
        <population>FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Here n signifies those participants who were evaluable for this measure at specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, CP-690,550 5 mg</title>
            <description>Participants who were re-assigned to this group from placebo at Week 16 and thereafter received CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, CP-690,550 10 mg</title>
            <description>Participants who were re-assigned to this group from placebo at Week 16 and thereafter received CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Psoriasis Area and Severity Index (PASI) Score</title>
          <description>The PASI quantifies the severity of a participant's psoriasis based on both, &quot;lesion severity&quot; and &quot;percent of BSA&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.</description>
          <population>FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Here n signifies those participants who were evaluable for this measure at specified time point for each arm, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="363"/>
                <count group_id="O2" value="360"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=363,360,66,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.95" spread="8.99"/>
                    <measurement group_id="O2" value="22.73" spread="8.82"/>
                    <measurement group_id="O3" value="21.19" spread="8.54"/>
                    <measurement group_id="O4" value="23.03" spread="8.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n=358,358,66,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.28" spread="9.63"/>
                    <measurement group_id="O2" value="17.30" spread="9.06"/>
                    <measurement group_id="O3" value="19.81" spread="10.28"/>
                    <measurement group_id="O4" value="22.11" spread="9.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=352,350,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.39" spread="8.75"/>
                    <measurement group_id="O2" value="13.10" spread="8.90"/>
                    <measurement group_id="O3" value="18.36" spread="10.86"/>
                    <measurement group_id="O4" value="20.63" spread="9.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=347,350,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.41" spread="9.08"/>
                    <measurement group_id="O2" value="8.97" spread="8.00"/>
                    <measurement group_id="O3" value="17.17" spread="10.32"/>
                    <measurement group_id="O4" value="20.13" spread="10.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=345,345,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.85" spread="9.38"/>
                    <measurement group_id="O2" value="6.94" spread="7.59"/>
                    <measurement group_id="O3" value="16.52" spread="10.45"/>
                    <measurement group_id="O4" value="19.38" spread="10.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=323,335,66,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.42" spread="9.05"/>
                    <measurement group_id="O2" value="5.74" spread="7.21"/>
                    <measurement group_id="O3" value="16.08" spread="10.41"/>
                    <measurement group_id="O4" value="19.71" spread="11.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=312,321,66,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.82" spread="7.23"/>
                    <measurement group_id="O2" value="4.95" spread="6.30"/>
                    <measurement group_id="O3" value="9.18" spread="7.21"/>
                    <measurement group_id="O4" value="11.79" spread="8.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 (n=300,307,61,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.80" spread="6.87"/>
                    <measurement group_id="O2" value="4.01" spread="5.28"/>
                    <measurement group_id="O3" value="5.20" spread="5.95"/>
                    <measurement group_id="O4" value="5.23" spread="6.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40 (n=203,242,53,47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.05" spread="3.71"/>
                    <measurement group_id="O2" value="2.64" spread="3.85"/>
                    <measurement group_id="O3" value="3.22" spread="3.70"/>
                    <measurement group_id="O4" value="1.64" spread="2.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=180,219,47,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.28" spread="3.71"/>
                    <measurement group_id="O2" value="2.47" spread="3.21"/>
                    <measurement group_id="O3" value="3.16" spread="3.22"/>
                    <measurement group_id="O4" value="1.64" spread="2.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52</title>
        <description>The PASI quantifies the severity of a participant's psoriasis based on both, &quot;lesion severity&quot; and &quot;percent of BSA&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.</description>
        <time_frame>Baseline, Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
        <population>FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, CP-690,550 5 mg</title>
            <description>Participants who were re-assigned to this group from placebo at Week 16 and thereafter received CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, CP-690,550 10 mg</title>
            <description>Participants who were re-assigned to this group from placebo at Week 16 and thereafter received CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52</title>
          <description>The PASI quantifies the severity of a participant's psoriasis based on both, &quot;lesion severity&quot; and &quot;percent of BSA&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.</description>
          <population>FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="359"/>
                <count group_id="O2" value="358"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.87" spread="0.29"/>
                    <measurement group_id="O2" value="-5.31" spread="0.29"/>
                    <measurement group_id="O3" value="-1.79" spread="0.66"/>
                    <measurement group_id="O4" value="-0.81" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.61" spread="0.35"/>
                    <measurement group_id="O2" value="-9.48" spread="0.35"/>
                    <measurement group_id="O3" value="-3.14" spread="0.81"/>
                    <measurement group_id="O4" value="-2.18" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.61" spread="0.41"/>
                    <measurement group_id="O2" value="-13.58" spread="0.41"/>
                    <measurement group_id="O3" value="-4.45" spread="0.95"/>
                    <measurement group_id="O4" value="-2.68" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.02" spread="0.44"/>
                    <measurement group_id="O2" value="-15.62" spread="0.44"/>
                    <measurement group_id="O3" value="-4.97" spread="1.02"/>
                    <measurement group_id="O4" value="-3.43" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.90" spread="0.48"/>
                    <measurement group_id="O2" value="-16.55" spread="0.48"/>
                    <measurement group_id="O3" value="-5.51" spread="1.09"/>
                    <measurement group_id="O4" value="-3.10" spread="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.36" spread="0.44"/>
                    <measurement group_id="O2" value="-17.11" spread="0.44"/>
                    <measurement group_id="O3" value="-12.41" spread="1.00"/>
                    <measurement group_id="O4" value="-11.18" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.53" spread="0.44"/>
                    <measurement group_id="O2" value="-18.02" spread="0.43"/>
                    <measurement group_id="O3" value="-16.21" spread="0.98"/>
                    <measurement group_id="O4" value="-17.63" spread="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.15" spread="0.47"/>
                    <measurement group_id="O2" value="-17.51" spread="0.46"/>
                    <measurement group_id="O3" value="-16.16" spread="1.03"/>
                    <measurement group_id="O4" value="-18.54" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.70" spread="0.48"/>
                    <measurement group_id="O2" value="-17.16" spread="0.47"/>
                    <measurement group_id="O3" value="-15.69" spread="1.04"/>
                    <measurement group_id="O4" value="-18.62" spread="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Psoriasis Area and Severity Index (PASI) Component Scores</title>
        <description>The PASI quantifies the severity of a participant's psoriasis based on both, lesion severity and the percent of BSA affected. Basic characteristics of psoriatic lesions: erythema, induration, and scaling (PASI components) are scored separately for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]) according to a 5-point scale: 0 (no involvement); 1 (slight); 2 (moderate); 3 (marked); 4 (very marked). PASI component score range from 0 to 4, where higher scores indicate greater severity of psoriatic lesions.</description>
        <time_frame>Baseline, Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
        <population>FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Here n signifies those participants who were evaluable for this measure at specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, CP-690,550 5 mg</title>
            <description>Participants who were re-assigned to this group from placebo at Week 16 and thereafter received CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, CP-690,550 10 mg</title>
            <description>Participants who were re-assigned to this group from placebo at Week 16 and thereafter received CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Psoriasis Area and Severity Index (PASI) Component Scores</title>
          <description>The PASI quantifies the severity of a participant's psoriasis based on both, lesion severity and the percent of BSA affected. Basic characteristics of psoriatic lesions: erythema, induration, and scaling (PASI components) are scored separately for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]) according to a 5-point scale: 0 (no involvement); 1 (slight); 2 (moderate); 3 (marked); 4 (very marked). PASI component score range from 0 to 4, where higher scores indicate greater severity of psoriatic lesions.</description>
          <population>FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Here n signifies those participants who were evaluable for this measure at specified time point for each arm, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="363"/>
                <count group_id="O2" value="360"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Erythema (Head\Neck) (n=363,360,66,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.31" spread="0.99"/>
                    <measurement group_id="O2" value="2.23" spread="1.01"/>
                    <measurement group_id="O3" value="2.38" spread="0.99"/>
                    <measurement group_id="O4" value="2.26" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Erythema (Upper Limbs) (n=363,360,66,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.87" spread="0.64"/>
                    <measurement group_id="O2" value="2.88" spread="0.64"/>
                    <measurement group_id="O3" value="2.83" spread="0.54"/>
                    <measurement group_id="O4" value="2.92" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Erythema (Trunk) (n=363,360,66,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.85" spread="0.77"/>
                    <measurement group_id="O2" value="2.91" spread="0.73"/>
                    <measurement group_id="O3" value="2.79" spread="0.85"/>
                    <measurement group_id="O4" value="3.08" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Erythema (Lower Limbs) (n=363,360,66,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.21" spread="0.60"/>
                    <measurement group_id="O2" value="3.19" spread="0.62"/>
                    <measurement group_id="O3" value="3.14" spread="0.58"/>
                    <measurement group_id="O4" value="3.27" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Induration (Head\Neck) (n=363,360,66,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.08" spread="0.97"/>
                    <measurement group_id="O2" value="1.96" spread="1.01"/>
                    <measurement group_id="O3" value="2.14" spread="0.97"/>
                    <measurement group_id="O4" value="2.02" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:Induration (Upper Limbs)(n=363,360,66,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.69" spread="0.71"/>
                    <measurement group_id="O2" value="2.65" spread="0.67"/>
                    <measurement group_id="O3" value="2.71" spread="0.58"/>
                    <measurement group_id="O4" value="2.68" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Induration (Trunk) (n=363,360,66,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.60" spread="0.80"/>
                    <measurement group_id="O2" value="2.63" spread="0.77"/>
                    <measurement group_id="O3" value="2.53" spread="0.83"/>
                    <measurement group_id="O4" value="2.71" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:Induration (Lower Limbs)(n=363,360,66,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.91" spread="0.69"/>
                    <measurement group_id="O2" value="2.90" spread="0.66"/>
                    <measurement group_id="O3" value="2.83" spread="0.69"/>
                    <measurement group_id="O4" value="2.98" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Scaling (Head\Neck) (n=363,360,66,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.32" spread="1.05"/>
                    <measurement group_id="O2" value="2.23" spread="1.08"/>
                    <measurement group_id="O3" value="2.33" spread="1.10"/>
                    <measurement group_id="O4" value="2.24" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Scaling (Upper Limbs) (n=363,360,66,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.75" spread="0.78"/>
                    <measurement group_id="O2" value="2.71" spread="0.75"/>
                    <measurement group_id="O3" value="2.55" spread="0.59"/>
                    <measurement group_id="O4" value="2.76" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Scaling (Trunk) (n=363,360,66,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.60" spread="0.86"/>
                    <measurement group_id="O2" value="2.60" spread="0.83"/>
                    <measurement group_id="O3" value="2.36" spread="0.82"/>
                    <measurement group_id="O4" value="2.77" spread="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Scaling (Lower Limbs) (n=363,360,66,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.98" spread="0.72"/>
                    <measurement group_id="O2" value="2.91" spread="0.72"/>
                    <measurement group_id="O3" value="2.77" spread="0.72"/>
                    <measurement group_id="O4" value="2.97" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Erythema (Head\Neck) (n=358,358,66,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.84" spread="1.05"/>
                    <measurement group_id="O2" value="1.72" spread="1.05"/>
                    <measurement group_id="O3" value="2.14" spread="0.99"/>
                    <measurement group_id="O4" value="2.17" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Erythema (Upper Limbs) (n=358,358,66,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.40" spread="0.80"/>
                    <measurement group_id="O2" value="2.26" spread="0.86"/>
                    <measurement group_id="O3" value="2.64" spread="0.62"/>
                    <measurement group_id="O4" value="2.83" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Erythema (Trunk) (n=358,358,66,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.39" spread="0.92"/>
                    <measurement group_id="O2" value="2.28" spread="0.89"/>
                    <measurement group_id="O3" value="2.58" spread="0.88"/>
                    <measurement group_id="O4" value="2.91" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Erythema (Lower Limbs) (n=358,358,66,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.75" spread="0.81"/>
                    <measurement group_id="O2" value="2.60" spread="0.83"/>
                    <measurement group_id="O3" value="2.98" spread="0.64"/>
                    <measurement group_id="O4" value="3.14" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Induration (Head\Neck) (n=358,358,66,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.70" spread="1.05"/>
                    <measurement group_id="O2" value="1.48" spread="1.03"/>
                    <measurement group_id="O3" value="1.94" spread="0.99"/>
                    <measurement group_id="O4" value="1.92" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Induration (Upper Limbs) (n=358,358,66,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.27" spread="0.83"/>
                    <measurement group_id="O2" value="2.11" spread="0.86"/>
                    <measurement group_id="O3" value="2.36" spread="0.76"/>
                    <measurement group_id="O4" value="2.58" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Induration (Trunk) (n=358,358,66,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.20" spread="0.90"/>
                    <measurement group_id="O2" value="2.10" spread="0.92"/>
                    <measurement group_id="O3" value="2.32" spread="0.90"/>
                    <measurement group_id="O4" value="2.58" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Induration (Lower Limbs) (n=358,358,66,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.50" spread="0.82"/>
                    <measurement group_id="O2" value="2.38" spread="0.84"/>
                    <measurement group_id="O3" value="2.62" spread="0.80"/>
                    <measurement group_id="O4" value="2.72" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Scaling (Head\Neck) (n=358,358,66,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.85" spread="1.11"/>
                    <measurement group_id="O2" value="1.67" spread="1.11"/>
                    <measurement group_id="O3" value="2.03" spread="1.07"/>
                    <measurement group_id="O4" value="2.08" spread="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Scaling (Upper Limbs) (n=358,358,66,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.29" spread="0.93"/>
                    <measurement group_id="O2" value="2.08" spread="0.91"/>
                    <measurement group_id="O3" value="2.26" spread="0.75"/>
                    <measurement group_id="O4" value="2.58" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Scaling (Trunk) (n=358,358,66,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.12" spread="1.00"/>
                    <measurement group_id="O2" value="2.00" spread="1.00"/>
                    <measurement group_id="O3" value="2.14" spread="1.04"/>
                    <measurement group_id="O4" value="2.50" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Scaling (Lower Limbs) (n=358,358,66,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.50" spread="0.91"/>
                    <measurement group_id="O2" value="2.33" spread="0.92"/>
                    <measurement group_id="O3" value="2.53" spread="0.85"/>
                    <measurement group_id="O4" value="2.75" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Erythema (Head\Neck) (n=352,350,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.45" spread="1.03"/>
                    <measurement group_id="O2" value="1.33" spread="1.06"/>
                    <measurement group_id="O3" value="1.89" spread="1.11"/>
                    <measurement group_id="O4" value="1.92" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Erythema (Upper Limbs) (n=352,350,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" spread="0.88"/>
                    <measurement group_id="O2" value="1.85" spread="0.90"/>
                    <measurement group_id="O3" value="2.42" spread="0.81"/>
                    <measurement group_id="O4" value="2.73" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Erythema (Trunk) (n=352,350,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.99" spread="0.99"/>
                    <measurement group_id="O2" value="1.83" spread="1.00"/>
                    <measurement group_id="O3" value="2.42" spread="0.97"/>
                    <measurement group_id="O4" value="2.74" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Erythema (Lower Limbs) (n=352,350,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.35" spread="0.90"/>
                    <measurement group_id="O2" value="2.15" spread="0.91"/>
                    <measurement group_id="O3" value="2.78" spread="0.78"/>
                    <measurement group_id="O4" value="2.97" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Induration (Head\Neck) (n=352,350,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.28" spread="0.98"/>
                    <measurement group_id="O2" value="1.11" spread="0.99"/>
                    <measurement group_id="O3" value="1.74" spread="1.06"/>
                    <measurement group_id="O4" value="1.74" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Induration (Upper Limbs) (n=352,350,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.87" spread="0.90"/>
                    <measurement group_id="O2" value="1.73" spread="0.91"/>
                    <measurement group_id="O3" value="2.25" spread="0.83"/>
                    <measurement group_id="O4" value="2.53" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Induration (Trunk) (n=352,350,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.80" spread="0.95"/>
                    <measurement group_id="O2" value="1.66" spread="1.00"/>
                    <measurement group_id="O3" value="2.15" spread="1.03"/>
                    <measurement group_id="O4" value="2.53" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Induration (Lower Limbs) (n=352,350,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.06" spread="0.90"/>
                    <measurement group_id="O2" value="1.93" spread="0.92"/>
                    <measurement group_id="O3" value="2.48" spread="0.87"/>
                    <measurement group_id="O4" value="2.71" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Scaling (Head\Neck) (n=352,350,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.43" spread="1.10"/>
                    <measurement group_id="O2" value="1.23" spread="1.07"/>
                    <measurement group_id="O3" value="1.80" spread="1.16"/>
                    <measurement group_id="O4" value="1.94" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Scaling (Upper Limbs) (n=352,350,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.88" spread="0.98"/>
                    <measurement group_id="O2" value="1.71" spread="0.93"/>
                    <measurement group_id="O3" value="2.14" spread="0.68"/>
                    <measurement group_id="O4" value="2.42" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Scaling (Trunk) (n=352,350,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.79" spread="1.03"/>
                    <measurement group_id="O2" value="1.57" spread="1.01"/>
                    <measurement group_id="O3" value="1.98" spread="1.01"/>
                    <measurement group_id="O4" value="2.41" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Scaling (Lower Limbs) (n=352,350,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.11" spread="0.96"/>
                    <measurement group_id="O2" value="1.93" spread="1.00"/>
                    <measurement group_id="O3" value="2.32" spread="0.92"/>
                    <measurement group_id="O4" value="2.64" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Erythema (Head\Neck) (n=347,350,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.23" spread="1.05"/>
                    <measurement group_id="O2" value="0.95" spread="0.98"/>
                    <measurement group_id="O3" value="1.92" spread="1.11"/>
                    <measurement group_id="O4" value="1.86" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Erythema (Upper Limbs) (n=347,350,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.76" spread="0.98"/>
                    <measurement group_id="O2" value="1.48" spread="0.93"/>
                    <measurement group_id="O3" value="2.43" spread="0.77"/>
                    <measurement group_id="O4" value="2.61" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Erythema (Trunk) (n=347,350,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.67" spread="1.11"/>
                    <measurement group_id="O2" value="1.37" spread="1.02"/>
                    <measurement group_id="O3" value="2.31" spread="1.01"/>
                    <measurement group_id="O4" value="2.55" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Erythema (Lower Limbs) (n=347,350,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.99" spread="1.08"/>
                    <measurement group_id="O2" value="1.71" spread="0.98"/>
                    <measurement group_id="O3" value="2.62" spread="0.78"/>
                    <measurement group_id="O4" value="2.91" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Induration (Head\Neck) (n=347,350,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.04" spread="1.01"/>
                    <measurement group_id="O2" value="0.75" spread="0.88"/>
                    <measurement group_id="O3" value="1.68" spread="1.03"/>
                    <measurement group_id="O4" value="1.67" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Induration (Upper Limbs) (n=347,350,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.62" spread="0.93"/>
                    <measurement group_id="O2" value="1.39" spread="0.93"/>
                    <measurement group_id="O3" value="2.15" spread="0.80"/>
                    <measurement group_id="O4" value="2.44" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Induration (Trunk) (n=347,350,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.44" spread="1.02"/>
                    <measurement group_id="O2" value="1.26" spread="1.02"/>
                    <measurement group_id="O3" value="2.03" spread="1.07"/>
                    <measurement group_id="O4" value="2.38" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Induration (Lower Limbs) (n=347,350,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.74" spread="1.02"/>
                    <measurement group_id="O2" value="1.47" spread="0.97"/>
                    <measurement group_id="O3" value="2.35" spread="0.87"/>
                    <measurement group_id="O4" value="2.67" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Scaling (Head\Neck) (n=347,350,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.18" spread="1.12"/>
                    <measurement group_id="O2" value="0.83" spread="0.97"/>
                    <measurement group_id="O3" value="1.80" spread="1.11"/>
                    <measurement group_id="O4" value="1.88" spread="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Scaling (Upper Limbs) (n=347,350,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.66" spread="1.02"/>
                    <measurement group_id="O2" value="1.37" spread="0.96"/>
                    <measurement group_id="O3" value="2.05" spread="0.78"/>
                    <measurement group_id="O4" value="2.35" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Scaling (Trunk) (n=347,350,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.41" spread="1.09"/>
                    <measurement group_id="O2" value="1.19" spread="1.05"/>
                    <measurement group_id="O3" value="1.83" spread="1.01"/>
                    <measurement group_id="O4" value="2.20" spread="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Scaling (Lower Limbs) (n=347,350,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.80" spread="1.07"/>
                    <measurement group_id="O2" value="1.45" spread="1.03"/>
                    <measurement group_id="O3" value="2.22" spread="0.96"/>
                    <measurement group_id="O4" value="2.55" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Erythema (Head\Neck) (n=345,345,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.10" spread="1.09"/>
                    <measurement group_id="O2" value="0.83" spread="0.96"/>
                    <measurement group_id="O3" value="1.78" spread="0.96"/>
                    <measurement group_id="O4" value="1.85" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Erythema (Upper Limbs) (n=345,345,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.60" spread="1.07"/>
                    <measurement group_id="O2" value="1.28" spread="0.96"/>
                    <measurement group_id="O3" value="2.35" spread="0.76"/>
                    <measurement group_id="O4" value="2.53" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Erythema (Trunk) (n=345,345,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.53" spread="1.18"/>
                    <measurement group_id="O2" value="1.12" spread="1.07"/>
                    <measurement group_id="O3" value="2.35" spread="0.98"/>
                    <measurement group_id="O4" value="2.53" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Erythema (Lower Limbs) (n=345,345,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.81" spread="1.13"/>
                    <measurement group_id="O2" value="1.39" spread="1.06"/>
                    <measurement group_id="O3" value="2.54" spread="0.79"/>
                    <measurement group_id="O4" value="2.77" spread="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Induration (Head\Neck) (n=345,345,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.90" spread="1.02"/>
                    <measurement group_id="O2" value="0.65" spread="0.86"/>
                    <measurement group_id="O3" value="1.54" spread="0.97"/>
                    <measurement group_id="O4" value="1.56" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Induration (Upper Limbs)(n=345,345,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.48" spread="1.02"/>
                    <measurement group_id="O2" value="1.17" spread="0.95"/>
                    <measurement group_id="O3" value="2.05" spread="0.78"/>
                    <measurement group_id="O4" value="2.32" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Induration (Trunk) (n=345,345,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.34" spread="1.09"/>
                    <measurement group_id="O2" value="0.98" spread="1.03"/>
                    <measurement group_id="O3" value="1.89" spread="0.99"/>
                    <measurement group_id="O4" value="2.27" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Induration (Lower Limbs)(n=345,345,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.58" spread="1.08"/>
                    <measurement group_id="O2" value="1.17" spread="0.98"/>
                    <measurement group_id="O3" value="2.26" spread="0.82"/>
                    <measurement group_id="O4" value="2.55" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Scaling (Head\Neck) (n=345,345,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.03" spread="1.06"/>
                    <measurement group_id="O2" value="0.72" spread="0.91"/>
                    <measurement group_id="O3" value="1.77" spread="1.01"/>
                    <measurement group_id="O4" value="1.76" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Scaling (Upper Limbs) (n=345,345,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" spread="1.07"/>
                    <measurement group_id="O2" value="1.18" spread="0.98"/>
                    <measurement group_id="O3" value="2.03" spread="0.90"/>
                    <measurement group_id="O4" value="2.27" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Scaling (Trunk) (n=345,345,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.30" spread="1.12"/>
                    <measurement group_id="O2" value="0.95" spread="1.01"/>
                    <measurement group_id="O3" value="1.89" spread="1.05"/>
                    <measurement group_id="O4" value="2.26" spread="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Scaling (Lower Limbs) (n=345,345,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.56" spread="1.10"/>
                    <measurement group_id="O2" value="1.14" spread="0.98"/>
                    <measurement group_id="O3" value="2.14" spread="0.95"/>
                    <measurement group_id="O4" value="2.53" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Erythema (Head\Neck) (n=323,335,66,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.01" spread="1.07"/>
                    <measurement group_id="O2" value="0.75" spread="0.95"/>
                    <measurement group_id="O3" value="1.73" spread="1.05"/>
                    <measurement group_id="O4" value="1.91" spread="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Erythema (Upper Limbs) (n=323,335,66,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.46" spread="1.12"/>
                    <measurement group_id="O2" value="1.13" spread="1.00"/>
                    <measurement group_id="O3" value="2.30" spread="0.80"/>
                    <measurement group_id="O4" value="2.53" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Erythema (Trunk) (n=323,335,66,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.40" spread="1.17"/>
                    <measurement group_id="O2" value="1.01" spread="1.09"/>
                    <measurement group_id="O3" value="2.14" spread="1.11"/>
                    <measurement group_id="O4" value="2.58" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Erythema (Lower Limbs) (n=323,335,66,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.63" spread="1.19"/>
                    <measurement group_id="O2" value="1.25" spread="1.10"/>
                    <measurement group_id="O3" value="2.52" spread="0.83"/>
                    <measurement group_id="O4" value="2.82" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Induration (Head\Neck) (n=323,335,66,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.83" spread="0.97"/>
                    <measurement group_id="O2" value="0.60" spread="0.88"/>
                    <measurement group_id="O3" value="1.42" spread="1.01"/>
                    <measurement group_id="O4" value="1.58" spread="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Induration (Upper Limbs)(n=323,335,66,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.34" spread="1.10"/>
                    <measurement group_id="O2" value="1.06" spread="0.99"/>
                    <measurement group_id="O3" value="2.06" spread="0.87"/>
                    <measurement group_id="O4" value="2.33" spread="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Induration (Trunk) (n=323,335,66,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.22" spread="1.08"/>
                    <measurement group_id="O2" value="0.85" spread="1.05"/>
                    <measurement group_id="O3" value="1.83" spread="1.14"/>
                    <measurement group_id="O4" value="2.29" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Induration (Lower Limbs)(n=323,335,66,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.38" spread="1.07"/>
                    <measurement group_id="O2" value="1.01" spread="1.02"/>
                    <measurement group_id="O3" value="2.20" spread="0.92"/>
                    <measurement group_id="O4" value="2.52" spread="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Scaling (Head\Neck) (n=323,335,66,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.94" spread="1.04"/>
                    <measurement group_id="O2" value="0.67" spread="0.91"/>
                    <measurement group_id="O3" value="1.59" spread="1.02"/>
                    <measurement group_id="O4" value="1.76" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Scaling (Upper Limbs) (n=323,335,66,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.41" spread="1.09"/>
                    <measurement group_id="O2" value="1.07" spread="0.98"/>
                    <measurement group_id="O3" value="2.08" spread="0.90"/>
                    <measurement group_id="O4" value="2.29" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Scaling (Trunk) (n=323,335,66,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.15" spread="1.01"/>
                    <measurement group_id="O2" value="0.84" spread="0.99"/>
                    <measurement group_id="O3" value="1.83" spread="1.12"/>
                    <measurement group_id="O4" value="2.12" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Scaling (Lower Limbs) (n=323,335,66,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.42" spread="1.06"/>
                    <measurement group_id="O2" value="1.01" spread="1.02"/>
                    <measurement group_id="O3" value="2.15" spread="1.00"/>
                    <measurement group_id="O4" value="2.50" spread="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Erythema (Head\Neck) (n=312,321,66,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.94" spread="1.02"/>
                    <measurement group_id="O2" value="0.66" spread="0.94"/>
                    <measurement group_id="O3" value="1.08" spread="0.93"/>
                    <measurement group_id="O4" value="1.23" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Erythema (Upper Limbs) (n=312,321,66,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.29" spread="1.04"/>
                    <measurement group_id="O2" value="1.05" spread="1.01"/>
                    <measurement group_id="O3" value="1.48" spread="0.79"/>
                    <measurement group_id="O4" value="1.80" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Erythema (Trunk) (n=312,321,66,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.23" spread="1.09"/>
                    <measurement group_id="O2" value="0.89" spread="1.06"/>
                    <measurement group_id="O3" value="1.36" spread="0.97"/>
                    <measurement group_id="O4" value="1.68" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Erythema (Lower Limbs) (n=312,321,66,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.45" spread="1.17"/>
                    <measurement group_id="O2" value="1.13" spread="1.09"/>
                    <measurement group_id="O3" value="1.71" spread="0.82"/>
                    <measurement group_id="O4" value="1.94" spread="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Induration (Head\Neck) (n=312,321,66,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.78" spread="0.93"/>
                    <measurement group_id="O2" value="0.55" spread="0.83"/>
                    <measurement group_id="O3" value="0.83" spread="0.83"/>
                    <measurement group_id="O4" value="0.97" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Induration (Upper Limbs)(n=312,321,66,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.21" spread="1.03"/>
                    <measurement group_id="O2" value="0.99" spread="1.00"/>
                    <measurement group_id="O3" value="1.38" spread="0.78"/>
                    <measurement group_id="O4" value="1.52" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Induration (Trunk) (n=312,321,66,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.06" spread="1.03"/>
                    <measurement group_id="O2" value="0.78" spread="1.02"/>
                    <measurement group_id="O3" value="1.17" spread="1.02"/>
                    <measurement group_id="O4" value="1.43" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Induration (Lower Limbs)(n=312,321,66,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.24" spread="1.04"/>
                    <measurement group_id="O2" value="0.96" spread="1.03"/>
                    <measurement group_id="O3" value="1.52" spread="0.85"/>
                    <measurement group_id="O4" value="1.66" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Scaling (Head\Neck) (n=312,321,66,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.86" spread="0.97"/>
                    <measurement group_id="O2" value="0.63" spread="0.94"/>
                    <measurement group_id="O3" value="0.98" spread="0.90"/>
                    <measurement group_id="O4" value="1.09" spread="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Scaling (Upper Limbs) (n=312,321,66,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.23" spread="1.00"/>
                    <measurement group_id="O2" value="1.02" spread="1.03"/>
                    <measurement group_id="O3" value="1.50" spread="0.88"/>
                    <measurement group_id="O4" value="1.63" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Scaling (Trunk) (n=312,321,66,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.99" spread="0.94"/>
                    <measurement group_id="O2" value="0.76" spread="1.00"/>
                    <measurement group_id="O3" value="1.20" spread="1.03"/>
                    <measurement group_id="O4" value="1.49" spread="1.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Scaling (Lower Limbs) (n=312,321,66,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.30" spread="1.04"/>
                    <measurement group_id="O2" value="0.96" spread="1.03"/>
                    <measurement group_id="O3" value="1.55" spread="1.00"/>
                    <measurement group_id="O4" value="1.80" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28: Erythema (Head\Neck) (n=300,307,61,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.83" spread="0.99"/>
                    <measurement group_id="O2" value="0.65" spread="0.93"/>
                    <measurement group_id="O3" value="0.54" spread="0.81"/>
                    <measurement group_id="O4" value="0.51" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28: Erythema (Upper Limbs) (n=300,307,61,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.20" spread="1.08"/>
                    <measurement group_id="O2" value="0.96" spread="1.00"/>
                    <measurement group_id="O3" value="1.16" spread="0.92"/>
                    <measurement group_id="O4" value="1.05" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28: Erythema (Trunk) (n=300,307,61,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.09" spread="1.14"/>
                    <measurement group_id="O2" value="0.77" spread="1.04"/>
                    <measurement group_id="O3" value="0.92" spread="0.90"/>
                    <measurement group_id="O4" value="0.95" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28: Erythema (Lower Limbs) (n=300,307,61,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.27" spread="1.19"/>
                    <measurement group_id="O2" value="0.97" spread="1.09"/>
                    <measurement group_id="O3" value="1.21" spread="0.97"/>
                    <measurement group_id="O4" value="1.15" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28: Induration (Head\Neck) (n=300,307,61,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.66" spread="0.89"/>
                    <measurement group_id="O2" value="0.47" spread="0.76"/>
                    <measurement group_id="O3" value="0.44" spread="0.70"/>
                    <measurement group_id="O4" value="0.31" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28: Induration (Upper Limbs)(n=300,307,61,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.10" spread="1.05"/>
                    <measurement group_id="O2" value="0.90" spread="1.01"/>
                    <measurement group_id="O3" value="1.00" spread="0.84"/>
                    <measurement group_id="O4" value="0.79" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28: Induration (Trunk) (n=300,307,61,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.93" spread="1.03"/>
                    <measurement group_id="O2" value="0.69" spread="1.00"/>
                    <measurement group_id="O3" value="0.75" spread="0.85"/>
                    <measurement group_id="O4" value="0.80" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28: Induration (Lower Limbs)(n=300,307,61,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.09" spread="1.08"/>
                    <measurement group_id="O2" value="0.79" spread="0.99"/>
                    <measurement group_id="O3" value="0.98" spread="0.83"/>
                    <measurement group_id="O4" value="0.87" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28: Scaling (Head\Neck) (n=300,307,61,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77" spread="0.95"/>
                    <measurement group_id="O2" value="0.57" spread="0.85"/>
                    <measurement group_id="O3" value="0.56" spread="0.76"/>
                    <measurement group_id="O4" value="0.44" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28: Scaling (Upper Limbs) (n=300,307,61,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.15" spread="1.06"/>
                    <measurement group_id="O2" value="0.90" spread="0.99"/>
                    <measurement group_id="O3" value="1.08" spread="0.86"/>
                    <measurement group_id="O4" value="0.98" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28: Scaling (Trunk) (n=300,307,61,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.89" spread="0.97"/>
                    <measurement group_id="O2" value="0.64" spread="0.90"/>
                    <measurement group_id="O3" value="0.80" spread="0.87"/>
                    <measurement group_id="O4" value="0.90" spread="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28: Scaling (Lower Limbs) (n=300,307,61,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.15" spread="1.07"/>
                    <measurement group_id="O2" value="0.79" spread="0.99"/>
                    <measurement group_id="O3" value="1.02" spread="0.90"/>
                    <measurement group_id="O4" value="1.08" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Erythema (Head\Neck) (n=203,242,53,47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.55" spread="0.87"/>
                    <measurement group_id="O2" value="0.54" spread="0.85"/>
                    <measurement group_id="O3" value="0.51" spread="0.87"/>
                    <measurement group_id="O4" value="0.32" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Erythema (Upper Limbs) (n=203,242,53,47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.87" spread="0.97"/>
                    <measurement group_id="O2" value="0.76" spread="0.92"/>
                    <measurement group_id="O3" value="1.06" spread="0.93"/>
                    <measurement group_id="O4" value="0.55" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Erythema (Trunk) (n=203,242,53,47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.68" spread="0.95"/>
                    <measurement group_id="O2" value="0.52" spread="0.87"/>
                    <measurement group_id="O3" value="0.68" spread="0.89"/>
                    <measurement group_id="O4" value="0.57" spread="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Erythema (Lower Limbs) (n=203,242,53,47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.88" spread="1.05"/>
                    <measurement group_id="O2" value="0.72" spread="0.97"/>
                    <measurement group_id="O3" value="0.92" spread="1.00"/>
                    <measurement group_id="O4" value="0.55" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Induration (Head\Neck) (n=203,242,53,47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.44" spread="0.73"/>
                    <measurement group_id="O2" value="0.45" spread="0.76"/>
                    <measurement group_id="O3" value="0.43" spread="0.82"/>
                    <measurement group_id="O4" value="0.23" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Induration (Upper Limbs)(n=203,242,53,47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.79" spread="0.93"/>
                    <measurement group_id="O2" value="0.72" spread="0.87"/>
                    <measurement group_id="O3" value="1.00" spread="0.88"/>
                    <measurement group_id="O4" value="0.36" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Induration (Trunk) (n=203,242,53,47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.56" spread="0.80"/>
                    <measurement group_id="O2" value="0.48" spread="0.81"/>
                    <measurement group_id="O3" value="0.57" spread="0.75"/>
                    <measurement group_id="O4" value="0.32" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Induration (Lower Limbs)(n=203,242,53,47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.70" spread="0.91"/>
                    <measurement group_id="O2" value="0.62" spread="0.91"/>
                    <measurement group_id="O3" value="0.85" spread="0.77"/>
                    <measurement group_id="O4" value="0.32" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Scaling (Head\Neck) (n=203,242,53,47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.53" spread="0.82"/>
                    <measurement group_id="O2" value="0.52" spread="0.90"/>
                    <measurement group_id="O3" value="0.51" spread="0.78"/>
                    <measurement group_id="O4" value="0.30" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Scaling (Upper Limbs) (n=203,242,53,47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.85" spread="0.97"/>
                    <measurement group_id="O2" value="0.71" spread="0.91"/>
                    <measurement group_id="O3" value="1.06" spread="0.82"/>
                    <measurement group_id="O4" value="0.49" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Scaling (Trunk) (n=203,242,53,47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.53" spread="0.79"/>
                    <measurement group_id="O2" value="0.44" spread="0.77"/>
                    <measurement group_id="O3" value="0.58" spread="0.75"/>
                    <measurement group_id="O4" value="0.47" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Scaling (Lower Limbs) (n=203,242,53,47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.78" spread="0.97"/>
                    <measurement group_id="O2" value="0.62" spread="0.90"/>
                    <measurement group_id="O3" value="0.85" spread="0.86"/>
                    <measurement group_id="O4" value="0.45" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Erythema (Head\Neck) (n=180,219,47,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" spread="0.76"/>
                    <measurement group_id="O2" value="0.42" spread="0.78"/>
                    <measurement group_id="O3" value="0.55" spread="0.83"/>
                    <measurement group_id="O4" value="0.39" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Erythema (Upper Limbs) (n=180,219,47,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.93" spread="0.95"/>
                    <measurement group_id="O2" value="0.72" spread="0.87"/>
                    <measurement group_id="O3" value="1.06" spread="0.94"/>
                    <measurement group_id="O4" value="0.50" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Erythema (Trunk) (n=180,219,47,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.64" spread="0.91"/>
                    <measurement group_id="O2" value="0.59" spread="0.93"/>
                    <measurement group_id="O3" value="0.66" spread="0.94"/>
                    <measurement group_id="O4" value="0.50" spread="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Erythema (Lower Limbs) (n=180,219,47,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.93" spread="1.05"/>
                    <measurement group_id="O2" value="0.67" spread="0.98"/>
                    <measurement group_id="O3" value="0.87" spread="0.99"/>
                    <measurement group_id="O4" value="0.63" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Induration (Head\Neck) (n=180,219,47,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.47" spread="0.71"/>
                    <measurement group_id="O2" value="0.32" spread="0.66"/>
                    <measurement group_id="O3" value="0.40" spread="0.68"/>
                    <measurement group_id="O4" value="0.24" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Induration (Upper Limbs)(n=180,219,47,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.86" spread="0.94"/>
                    <measurement group_id="O2" value="0.70" spread="0.87"/>
                    <measurement group_id="O3" value="0.98" spread="0.82"/>
                    <measurement group_id="O4" value="0.43" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Induration (Trunk) (n=180,219,47,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.56" spread="0.81"/>
                    <measurement group_id="O2" value="0.54" spread="0.86"/>
                    <measurement group_id="O3" value="0.53" spread="0.80"/>
                    <measurement group_id="O4" value="0.35" spread="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Induration (Lower Limbs)(n=180,219,47,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.84" spread="0.96"/>
                    <measurement group_id="O2" value="0.61" spread="0.89"/>
                    <measurement group_id="O3" value="0.79" spread="0.88"/>
                    <measurement group_id="O4" value="0.39" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Scaling (Head\Neck) (n=180,219,47,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.51" spread="0.77"/>
                    <measurement group_id="O2" value="0.42" spread="0.78"/>
                    <measurement group_id="O3" value="0.62" spread="0.87"/>
                    <measurement group_id="O4" value="0.39" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Scaling (Upper Limbs) (n=180,219,47,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.91" spread="0.97"/>
                    <measurement group_id="O2" value="0.74" spread="0.88"/>
                    <measurement group_id="O3" value="1.06" spread="0.87"/>
                    <measurement group_id="O4" value="0.57" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Scaling (Trunk) (n=180,219,47,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.54" spread="0.81"/>
                    <measurement group_id="O2" value="0.51" spread="0.79"/>
                    <measurement group_id="O3" value="0.57" spread="0.83"/>
                    <measurement group_id="O4" value="0.43" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Scaling (Lower Limbs) (n=180,219,47,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.89" spread="0.98"/>
                    <measurement group_id="O2" value="0.58" spread="0.90"/>
                    <measurement group_id="O3" value="0.91" spread="0.95"/>
                    <measurement group_id="O4" value="0.50" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52</title>
        <description>The PASI quantifies the severity of a participant's psoriasis based on both, lesion severity and the percent of body surface area (BSA) affected. Basic characteristics of psoriatic lesions: erythema, induration, and scaling (PASI components) are scored separately for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]) according to a 5-point scale: 0 (no involvement); 1 (slight); 2 (moderate); 3 (marked); 4 (very marked). PASI component score range from 0 to 4, where higher scores indicate greater severity of psoriatic lesions.</description>
        <time_frame>Baseline, Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
        <population>FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Here n signifies those participants who were evaluable for this measure at specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, CP-690,550 5 mg</title>
            <description>Participants who were re-assigned to this group from placebo at Week 16 and thereafter received CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, CP-690,550 10 mg</title>
            <description>Participants who were re-assigned to this group from placebo at Week 16 and thereafter received CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52</title>
          <description>The PASI quantifies the severity of a participant's psoriasis based on both, lesion severity and the percent of body surface area (BSA) affected. Basic characteristics of psoriatic lesions: erythema, induration, and scaling (PASI components) are scored separately for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]) according to a 5-point scale: 0 (no involvement); 1 (slight); 2 (moderate); 3 (marked); 4 (very marked). PASI component score range from 0 to 4, where higher scores indicate greater severity of psoriatic lesions.</description>
          <population>FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Here n signifies those participants who were evaluable for this measure at specified time point for each arm, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="363"/>
                <count group_id="O2" value="360"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2: Erythema (Head\Neck) (n=358,358,66,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.45" spread="0.78"/>
                    <measurement group_id="O2" value="-0.51" spread="0.82"/>
                    <measurement group_id="O3" value="-0.24" spread="0.61"/>
                    <measurement group_id="O4" value="-0.06" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Erythema (Upper Limbs) (n=358,358,66,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.46" spread="0.68"/>
                    <measurement group_id="O2" value="-0.63" spread="0.71"/>
                    <measurement group_id="O3" value="-0.20" spread="0.47"/>
                    <measurement group_id="O4" value="-0.09" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Erythema (Trunk) (n=358,358,66,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.46" spread="0.69"/>
                    <measurement group_id="O2" value="-0.63" spread="0.74"/>
                    <measurement group_id="O3" value="-0.21" spread="0.51"/>
                    <measurement group_id="O4" value="-0.17" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Erythema (Lower Limbs) (n=358,358,66,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.47" spread="0.70"/>
                    <measurement group_id="O2" value="-0.59" spread="0.74"/>
                    <measurement group_id="O3" value="-0.15" spread="0.44"/>
                    <measurement group_id="O4" value="-0.13" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Induration (Head\Neck) (n=358,358,66,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.37" spread="0.67"/>
                    <measurement group_id="O2" value="-0.48" spread="0.78"/>
                    <measurement group_id="O3" value="-0.20" spread="0.53"/>
                    <measurement group_id="O4" value="-0.08" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Induration (Upper Limbs) (n=358,358,66,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.42" spread="0.67"/>
                    <measurement group_id="O2" value="-0.53" spread="0.74"/>
                    <measurement group_id="O3" value="-0.35" spread="0.62"/>
                    <measurement group_id="O4" value="-0.11" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Induration (Trunk) (n=358,358,66,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.40" spread="0.72"/>
                    <measurement group_id="O2" value="-0.53" spread="0.74"/>
                    <measurement group_id="O3" value="-0.21" spread="0.48"/>
                    <measurement group_id="O4" value="-0.14" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Induration (Lower Limbs) (n=358,358,66,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.41" spread="0.66"/>
                    <measurement group_id="O2" value="-0.52" spread="0.65"/>
                    <measurement group_id="O3" value="-0.21" spread="0.45"/>
                    <measurement group_id="O4" value="-0.27" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Scaling (Head\Neck) (n=358,358,66,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.47" spread="0.67"/>
                    <measurement group_id="O2" value="-0.56" spread="0.86"/>
                    <measurement group_id="O3" value="-0.30" spread="0.80"/>
                    <measurement group_id="O4" value="-0.17" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Scaling (Upper Limbs) (n=358,358,66,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.45" spread="0.72"/>
                    <measurement group_id="O2" value="-0.63" spread="0.81"/>
                    <measurement group_id="O3" value="-0.29" spread="0.55"/>
                    <measurement group_id="O4" value="-0.20" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Scaling (Trunk) (n=358,358,66,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.48" spread="0.75"/>
                    <measurement group_id="O2" value="-0.60" spread="0.81"/>
                    <measurement group_id="O3" value="-0.23" spread="0.70"/>
                    <measurement group_id="O4" value="-0.30" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Scaling (Lower Limbs) (n=358,358,66,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.48" spread="0.74"/>
                    <measurement group_id="O2" value="-0.57" spread="0.74"/>
                    <measurement group_id="O3" value="-0.24" spread="0.66"/>
                    <measurement group_id="O4" value="-0.23" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Erythema (Head\Neck) (n=352,350,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.84" spread="1.04"/>
                    <measurement group_id="O2" value="-0.90" spread="1.01"/>
                    <measurement group_id="O3" value="-0.48" spread="0.87"/>
                    <measurement group_id="O4" value="-0.33" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Erythema (Upper Limbs) (n=352,350,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.86" spread="0.88"/>
                    <measurement group_id="O2" value="-1.03" spread="0.84"/>
                    <measurement group_id="O3" value="-0.42" spread="0.73"/>
                    <measurement group_id="O4" value="-0.20" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Erythema (Trunk) (n=352,350,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.86" spread="0.88"/>
                    <measurement group_id="O2" value="-1.08" spread="0.95"/>
                    <measurement group_id="O3" value="-0.37" spread="0.86"/>
                    <measurement group_id="O4" value="-0.33" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Erythema (Lower Limbs) (n=352,350,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.86" spread="0.89"/>
                    <measurement group_id="O2" value="-1.04" spread="0.87"/>
                    <measurement group_id="O3" value="-0.35" spread="0.62"/>
                    <measurement group_id="O4" value="-0.30" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Induration (Head\Neck) (n=352,350,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.79" spread="0.97"/>
                    <measurement group_id="O2" value="-0.85" spread="1.00"/>
                    <measurement group_id="O3" value="-0.40" spread="0.68"/>
                    <measurement group_id="O4" value="-0.27" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Induration (Upper Limbs) (n=352,350,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.82" spread="0.88"/>
                    <measurement group_id="O2" value="-0.91" spread="0.85"/>
                    <measurement group_id="O3" value="-0.46" spread="0.69"/>
                    <measurement group_id="O4" value="-0.15" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Induration (Trunk) (n=352,350,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.79" spread="0.89"/>
                    <measurement group_id="O2" value="-0.95" spread="0.90"/>
                    <measurement group_id="O3" value="-0.37" spread="0.88"/>
                    <measurement group_id="O4" value="-0.18" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Induration (Lower Limbs) (n=352,350,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.85" spread="0.85"/>
                    <measurement group_id="O2" value="-0.96" spread="0.82"/>
                    <measurement group_id="O3" value="-0.35" spread="0.60"/>
                    <measurement group_id="O4" value="-0.27" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Scaling (Head\Neck) (n=352,350,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.88" spread="1.00"/>
                    <measurement group_id="O2" value="-0.99" spread="1.07"/>
                    <measurement group_id="O3" value="-0.54" spread="0.95"/>
                    <measurement group_id="O4" value="-0.30" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Scaling (Upper Limbs) (n=352,350,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.86" spread="0.97"/>
                    <measurement group_id="O2" value="-1.00" spread="0.93"/>
                    <measurement group_id="O3" value="-0.40" spread="0.72"/>
                    <measurement group_id="O4" value="-0.33" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Scaling (Trunk) (n=352,350,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.81" spread="0.93"/>
                    <measurement group_id="O2" value="-1.03" spread="0.96"/>
                    <measurement group_id="O3" value="-0.37" spread="0.84"/>
                    <measurement group_id="O4" value="-0.36" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Scaling (Lower Limbs) (n=352,350,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.87" spread="0.96"/>
                    <measurement group_id="O2" value="-0.97" spread="0.94"/>
                    <measurement group_id="O3" value="-0.45" spread="0.73"/>
                    <measurement group_id="O4" value="-0.33" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Erythema (Head\Neck) (n=347,350,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.05" spread="1.16"/>
                    <measurement group_id="O2" value="-1.28" spread="1.11"/>
                    <measurement group_id="O3" value="-0.45" spread="1.03"/>
                    <measurement group_id="O4" value="-0.39" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Erythema (Upper Limbs) (n=347,350,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.10" spread="1.04"/>
                    <measurement group_id="O2" value="-1.41" spread="0.99"/>
                    <measurement group_id="O3" value="-0.40" spread="0.70"/>
                    <measurement group_id="O4" value="-0.32" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Erythema (Trunk) (n=347,350,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.18" spread="1.10"/>
                    <measurement group_id="O2" value="-1.54" spread="1.03"/>
                    <measurement group_id="O3" value="-0.52" spread="0.87"/>
                    <measurement group_id="O4" value="-0.53" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Erythema (Lower Limbs) (n=347,350,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.22" spread="1.10"/>
                    <measurement group_id="O2" value="-1.48" spread="1.00"/>
                    <measurement group_id="O3" value="-0.51" spread="0.73"/>
                    <measurement group_id="O4" value="-0.36" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Induration (Head\Neck) (n=347,350,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.02" spread="1.10"/>
                    <measurement group_id="O2" value="-1.21" spread="1.10"/>
                    <measurement group_id="O3" value="-0.45" spread="0.87"/>
                    <measurement group_id="O4" value="-0.35" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Induration (Upper Limbs) (n=347,350,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.07" spread="0.98"/>
                    <measurement group_id="O2" value="-1.26" spread="0.99"/>
                    <measurement group_id="O3" value="-0.55" spread="0.75"/>
                    <measurement group_id="O4" value="-0.24" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Induration (Trunk) (n=347,350,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.14" spread="1.05"/>
                    <measurement group_id="O2" value="-1.36" spread="1.06"/>
                    <measurement group_id="O3" value="-0.54" spread="0.89"/>
                    <measurement group_id="O4" value="-0.33" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Induration (Lower Limbs) (n=347,350,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.16" spread="1.06"/>
                    <measurement group_id="O2" value="-1.42" spread="0.99"/>
                    <measurement group_id="O3" value="-0.48" spread="0.69"/>
                    <measurement group_id="O4" value="-0.32" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Scaling (Head\Neck) (n=347,350,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.12" spread="1.17"/>
                    <measurement group_id="O2" value="-1.39" spread="1.16"/>
                    <measurement group_id="O3" value="-0.52" spread="1.03"/>
                    <measurement group_id="O4" value="-0.36" spread="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Scaling (Upper Limbs) (n=347,350,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.08" spread="1.07"/>
                    <measurement group_id="O2" value="-1.33" spread="1.08"/>
                    <measurement group_id="O3" value="-0.49" spread="0.77"/>
                    <measurement group_id="O4" value="-0.41" spread="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Scaling (Trunk) (n=347,350,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.18" spread="1.11"/>
                    <measurement group_id="O2" value="-1.40" spread="1.12"/>
                    <measurement group_id="O3" value="-0.57" spread="0.87"/>
                    <measurement group_id="O4" value="-0.58" spread="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Scaling (Lower Limbs) (n=347,350,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.17" spread="1.11"/>
                    <measurement group_id="O2" value="-1.44" spread="1.09"/>
                    <measurement group_id="O3" value="-0.55" spread="0.81"/>
                    <measurement group_id="O4" value="-0.42" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Erythema (Head\Neck) (n=345,345,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.18" spread="1.21"/>
                    <measurement group_id="O2" value="-1.41" spread="1.16"/>
                    <measurement group_id="O3" value="-0.58" spread="1.03"/>
                    <measurement group_id="O4" value="-0.41" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Erythema (Upper Limbs) (n=345,345,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.26" spread="1.15"/>
                    <measurement group_id="O2" value="-1.61" spread="1.06"/>
                    <measurement group_id="O3" value="-0.48" spread="0.79"/>
                    <measurement group_id="O4" value="-0.39" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Erythema (Trunk) (n=345,345,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.32" spread="1.22"/>
                    <measurement group_id="O2" value="-1.80" spread="1.15"/>
                    <measurement group_id="O3" value="-0.43" spread="1.00"/>
                    <measurement group_id="O4" value="-0.55" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Erythema (Lower Limbs) (n=345,345,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.40" spread="1.17"/>
                    <measurement group_id="O2" value="-1.79" spread="1.10"/>
                    <measurement group_id="O3" value="-0.60" spread="0.72"/>
                    <measurement group_id="O4" value="-0.50" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Induration (Head\Neck) (n=345,345,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.16" spread="1.18"/>
                    <measurement group_id="O2" value="-1.32" spread="1.15"/>
                    <measurement group_id="O3" value="-0.60" spread="0.97"/>
                    <measurement group_id="O4" value="-0.45" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Induration (Upper Limbs)(n=345,345,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.21" spread="1.14"/>
                    <measurement group_id="O2" value="-1.47" spread="1.05"/>
                    <measurement group_id="O3" value="-0.66" spread="0.78"/>
                    <measurement group_id="O4" value="-0.36" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Induration (Trunk) (n=345,345,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.25" spread="1.17"/>
                    <measurement group_id="O2" value="-1.65" spread="1.14"/>
                    <measurement group_id="O3" value="-0.63" spread="0.88"/>
                    <measurement group_id="O4" value="-0.44" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Induration (Lower Limbs)(n=345,345,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.33" spread="1.18"/>
                    <measurement group_id="O2" value="-1.72" spread="1.09"/>
                    <measurement group_id="O3" value="-0.57" spread="0.68"/>
                    <measurement group_id="O4" value="-0.44" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Scaling (Head\Neck) (n=345,345,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.28" spread="1.20"/>
                    <measurement group_id="O2" value="-1.52" spread="1.20"/>
                    <measurement group_id="O3" value="-0.57" spread="1.06"/>
                    <measurement group_id="O4" value="-0.48" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Scaling (Upper Limbs) (n=345,345,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.24" spread="1.22"/>
                    <measurement group_id="O2" value="-1.52" spread="1.17"/>
                    <measurement group_id="O3" value="-0.51" spread="0.95"/>
                    <measurement group_id="O4" value="-0.48" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Scaling (Trunk) (n=345,345,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.30" spread="1.19"/>
                    <measurement group_id="O2" value="-1.65" spread="1.16"/>
                    <measurement group_id="O3" value="-0.46" spread="0.90"/>
                    <measurement group_id="O4" value="-0.52" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Scaling (Lower Limbs) (n=345,345,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.41" spread="1.17"/>
                    <measurement group_id="O2" value="-1.76" spread="1.13"/>
                    <measurement group_id="O3" value="-0.63" spread="0.84"/>
                    <measurement group_id="O4" value="-0.44" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Erythema (Head\Neck) (n=323,335,66,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.28" spread="1.26"/>
                    <measurement group_id="O2" value="-1.48" spread="1.19"/>
                    <measurement group_id="O3" value="-0.65" spread="0.97"/>
                    <measurement group_id="O4" value="-0.35" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Erythema (Upper Limbs) (n=323,335,66,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.41" spread="1.19"/>
                    <measurement group_id="O2" value="-1.76" spread="1.12"/>
                    <measurement group_id="O3" value="-0.53" spread="0.86"/>
                    <measurement group_id="O4" value="-0.39" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Erythema (Trunk) (n=323,335,66,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.45" spread="1.23"/>
                    <measurement group_id="O2" value="-1.90" spread="1.18"/>
                    <measurement group_id="O3" value="-0.65" spread="1.10"/>
                    <measurement group_id="O4" value="-0.50" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Erythema (Lower Limbs) (n=323,335,66,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.59" spread="1.23"/>
                    <measurement group_id="O2" value="-1.94" spread="1.17"/>
                    <measurement group_id="O3" value="-0.62" spread="0.84"/>
                    <measurement group_id="O4" value="-0.45" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Induration (Head\Neck) (n=323,335,66,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.22" spread="1.22"/>
                    <measurement group_id="O2" value="-1.37" spread="1.16"/>
                    <measurement group_id="O3" value="-0.71" spread="1.00"/>
                    <measurement group_id="O4" value="-0.44" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Induration (Upper Limbs)(n=323,335,66,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.35" spread="1.19"/>
                    <measurement group_id="O2" value="-1.58" spread="1.14"/>
                    <measurement group_id="O3" value="-0.65" spread="0.83"/>
                    <measurement group_id="O4" value="-0.35" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Induration (Trunk) (n=323,335,66,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.37" spread="1.18"/>
                    <measurement group_id="O2" value="-1.75" spread="1.21"/>
                    <measurement group_id="O3" value="-0.70" spread="1.01"/>
                    <measurement group_id="O4" value="-0.42" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Induration (Lower Limbs)(n=323,335,66,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.54" spread="1.22"/>
                    <measurement group_id="O2" value="-1.88" spread="1.19"/>
                    <measurement group_id="O3" value="-0.64" spread="0.76"/>
                    <measurement group_id="O4" value="-0.47" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Scaling (Head\Neck) (n=323,335,66,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.37" spread="1.26"/>
                    <measurement group_id="O2" value="-1.57" spread="1.24"/>
                    <measurement group_id="O3" value="-0.74" spread="1.06"/>
                    <measurement group_id="O4" value="-0.48" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Scaling (Upper Limbs) (n=323,335,66,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.35" spread="1.22"/>
                    <measurement group_id="O2" value="-1.63" spread="1.20"/>
                    <measurement group_id="O3" value="-0.47" spread="0.88"/>
                    <measurement group_id="O4" value="-0.47" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Scaling (Trunk) (n=323,335,66,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.44" spread="1.16"/>
                    <measurement group_id="O2" value="-1.76" spread="1.17"/>
                    <measurement group_id="O3" value="-0.53" spread="1.00"/>
                    <measurement group_id="O4" value="-0.65" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Scaling (Lower Limbs) (n=323,335,66,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.56" spread="1.17"/>
                    <measurement group_id="O2" value="-1.89" spread="1.22"/>
                    <measurement group_id="O3" value="-0.62" spread="0.91"/>
                    <measurement group_id="O4" value="-0.47" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Erythema (Head\Neck) (n=312,321,66,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.37" spread="1.20"/>
                    <measurement group_id="O2" value="-1.57" spread="1.25"/>
                    <measurement group_id="O3" value="-1.30" spread="0.99"/>
                    <measurement group_id="O4" value="-1.02" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Erythema (Upper Limbs) (n=312,321,66,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.58" spread="1.18"/>
                    <measurement group_id="O2" value="-1.84" spread="1.13"/>
                    <measurement group_id="O3" value="-1.35" spread="0.92"/>
                    <measurement group_id="O4" value="-1.12" spread="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Erythema (Trunk) (n=312,321,66,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.63" spread="1.20"/>
                    <measurement group_id="O2" value="-2.03" spread="1.16"/>
                    <measurement group_id="O3" value="-1.42" spread="1.02"/>
                    <measurement group_id="O4" value="-1.40" spread="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Erythema (Lower Limbs) (n=312,321,66,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.77" spread="1.20"/>
                    <measurement group_id="O2" value="-2.06" spread="1.18"/>
                    <measurement group_id="O3" value="-1.42" spread="0.82"/>
                    <measurement group_id="O4" value="-1.34" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Induration (Head\Neck) (n=312,321,66,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.29" spread="1.20"/>
                    <measurement group_id="O2" value="-1.44" spread="1.18"/>
                    <measurement group_id="O3" value="-1.30" spread="0.96"/>
                    <measurement group_id="O4" value="-1.03" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Induration (Upper Limbs)(n=312,321,66,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.48" spread="1.18"/>
                    <measurement group_id="O2" value="-1.65" spread="1.13"/>
                    <measurement group_id="O3" value="-1.33" spread="0.79"/>
                    <measurement group_id="O4" value="-1.15" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Induration (Trunk) (n=312,321,66,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.53" spread="1.16"/>
                    <measurement group_id="O2" value="-1.83" spread="1.21"/>
                    <measurement group_id="O3" value="-1.36" spread="1.00"/>
                    <measurement group_id="O4" value="-1.28" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Induration (Lower Limbs)(n=312,321,66,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.68" spread="1.22"/>
                    <measurement group_id="O2" value="-1.93" spread="1.21"/>
                    <measurement group_id="O3" value="-1.32" spread="0.95"/>
                    <measurement group_id="O4" value="-1.32" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Scaling (Head\Neck) (n=312,321,66,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.47" spread="1.21"/>
                    <measurement group_id="O2" value="-1.63" spread="1.26"/>
                    <measurement group_id="O3" value="-1.35" spread="1.17"/>
                    <measurement group_id="O4" value="-1.15" spread="1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Scaling (Upper Limbs) (n=312,321,66,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.52" spread="1.18"/>
                    <measurement group_id="O2" value="-1.69" spread="1.21"/>
                    <measurement group_id="O3" value="-1.05" spread="1.01"/>
                    <measurement group_id="O4" value="-1.14" spread="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Scaling (Trunk) (n=312,321,66,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.60" spread="1.12"/>
                    <measurement group_id="O2" value="-1.84" spread="1.20"/>
                    <measurement group_id="O3" value="-1.17" spread="1.02"/>
                    <measurement group_id="O4" value="-1.28" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Scaling (Lower Limbs) (n=312,321,66,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.68" spread="1.19"/>
                    <measurement group_id="O2" value="-1.94" spread="1.23"/>
                    <measurement group_id="O3" value="-1.23" spread="1.11"/>
                    <measurement group_id="O4" value="-1.18" spread="1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28: Erythema (Head\Neck) (n=300,307,61,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.47" spread="1.24"/>
                    <measurement group_id="O2" value="-1.59" spread="1.23"/>
                    <measurement group_id="O3" value="-1.80" spread="1.08"/>
                    <measurement group_id="O4" value="-1.70" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28: Erythema (Upper Limbs) (n=300,307,61,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.67" spread="1.24"/>
                    <measurement group_id="O2" value="-1.92" spread="1.13"/>
                    <measurement group_id="O3" value="-1.67" spread="1.04"/>
                    <measurement group_id="O4" value="-1.89" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28: Erythema (Trunk) (n=300,307,61,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.77" spread="1.29"/>
                    <measurement group_id="O2" value="-2.15" spread="1.17"/>
                    <measurement group_id="O3" value="-1.89" spread="0.98"/>
                    <measurement group_id="O4" value="-2.13" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28: Erythema (Lower Limbs) (n=300,307,61,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.95" spread="1.22"/>
                    <measurement group_id="O2" value="-2.23" spread="1.22"/>
                    <measurement group_id="O3" value="-1.92" spread="0.99"/>
                    <measurement group_id="O4" value="-2.11" spread="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28: Induration (Head\Neck) (n=300,307,61,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.40" spread="1.20"/>
                    <measurement group_id="O2" value="-1.53" spread="1.16"/>
                    <measurement group_id="O3" value="-1.69" spread="1.13"/>
                    <measurement group_id="O4" value="-1.64" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28: Induration (Upper Limbs)(n=300,307,61,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.58" spread="1.23"/>
                    <measurement group_id="O2" value="-1.75" spread="1.13"/>
                    <measurement group_id="O3" value="-1.70" spread="0.95"/>
                    <measurement group_id="O4" value="-1.92" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28: Induration (Trunk) (n=300,307,61,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.66" spread="1.19"/>
                    <measurement group_id="O2" value="-1.92" spread="1.21"/>
                    <measurement group_id="O3" value="-1.80" spread="1.01"/>
                    <measurement group_id="O4" value="-1.93" spread="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28: Induration (Lower Limbs)(n=300,307,61,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.81" spread="1.27"/>
                    <measurement group_id="O2" value="-2.11" spread="1.21"/>
                    <measurement group_id="O3" value="-1.89" spread="1.00"/>
                    <measurement group_id="O4" value="-2.11" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28: Scaling (Head\Neck) (n=300,307,61,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.55" spread="1.28"/>
                    <measurement group_id="O2" value="-1.71" spread="1.23"/>
                    <measurement group_id="O3" value="-1.72" spread="1.29"/>
                    <measurement group_id="O4" value="-1.79" spread="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28: Scaling (Upper Limbs) (n=300,307,61,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.59" spread="1.28"/>
                    <measurement group_id="O2" value="-1.81" spread="1.22"/>
                    <measurement group_id="O3" value="-1.48" spread="1.03"/>
                    <measurement group_id="O4" value="-1.84" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28: Scaling (Trunk) (n=300,307,61,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.72" spread="1.23"/>
                    <measurement group_id="O2" value="-1.97" spread="1.14"/>
                    <measurement group_id="O3" value="-1.61" spread="1.07"/>
                    <measurement group_id="O4" value="-1.90" spread="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28: Scaling (Lower Limbs) (n=300,307,61,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.81" spread="1.24"/>
                    <measurement group_id="O2" value="-2.12" spread="1.21"/>
                    <measurement group_id="O3" value="-1.80" spread="1.09"/>
                    <measurement group_id="O4" value="-1.95" spread="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Erythema (Head\Neck) (n=203,242,53,47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.78" spread="1.15"/>
                    <measurement group_id="O2" value="-1.69" spread="1.16"/>
                    <measurement group_id="O3" value="-1.83" spread="1.14"/>
                    <measurement group_id="O4" value="-1.81" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Erythema (Upper Limbs) (n=203,242,53,47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.02" spread="1.15"/>
                    <measurement group_id="O2" value="-2.11" spread="1.09"/>
                    <measurement group_id="O3" value="-1.75" spread="1.12"/>
                    <measurement group_id="O4" value="-2.40" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Erythema (Trunk) (n=203,242,53,47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.19" spread="1.14"/>
                    <measurement group_id="O2" value="-2.40" spread="1.03"/>
                    <measurement group_id="O3" value="-2.11" spread="0.95"/>
                    <measurement group_id="O4" value="-2.45" spread="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Erythema (Lower Limbs) (n=203,242,53,47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.34" spread="1.10"/>
                    <measurement group_id="O2" value="-2.45" spread="1.11"/>
                    <measurement group_id="O3" value="-2.21" spread="1.10"/>
                    <measurement group_id="O4" value="-2.68" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Induration (Head\Neck) (n=203,242,53,47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.68" spread="1.10"/>
                    <measurement group_id="O2" value="-1.56" spread="1.14"/>
                    <measurement group_id="O3" value="-1.72" spread="1.26"/>
                    <measurement group_id="O4" value="-1.72" spread="1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Induration (Upper Limbs)(n=203,242,53,47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.94" spread="1.09"/>
                    <measurement group_id="O2" value="-1.93" spread="1.04"/>
                    <measurement group_id="O3" value="-1.70" spread="1.01"/>
                    <measurement group_id="O4" value="-2.32" spread="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Induration (Trunk) (n=203,242,53,47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.09" spread="1.02"/>
                    <measurement group_id="O2" value="-2.15" spread="1.10"/>
                    <measurement group_id="O3" value="-2.00" spread="0.98"/>
                    <measurement group_id="O4" value="-2.30" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Induration (Lower Limbs)(n=203,242,53,47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.29" spread="1.10"/>
                    <measurement group_id="O2" value="-2.28" spread="1.15"/>
                    <measurement group_id="O3" value="-2.04" spread="1.00"/>
                    <measurement group_id="O4" value="-2.64" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Scaling (Head\Neck) (n=203,242,53,47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.85" spread="1.18"/>
                    <measurement group_id="O2" value="-1.77" spread="1.27"/>
                    <measurement group_id="O3" value="-1.87" spread="1.35"/>
                    <measurement group_id="O4" value="-1.96" spread="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Scaling (Upper Limbs) (n=203,242,53,47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.95" spread="1.22"/>
                    <measurement group_id="O2" value="-2.01" spread="1.19"/>
                    <measurement group_id="O3" value="-1.55" spread="0.99"/>
                    <measurement group_id="O4" value="-2.34" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Scaling (Trunk) (n=203,242,53,47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.15" spread="1.07"/>
                    <measurement group_id="O2" value="-2.20" spread="1.07"/>
                    <measurement group_id="O3" value="-1.81" spread="1.06"/>
                    <measurement group_id="O4" value="-2.26" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Scaling (Lower Limbs) (n=203,242,53,47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.20" spread="1.16"/>
                    <measurement group_id="O2" value="-2.30" spread="1.19"/>
                    <measurement group_id="O3" value="-2.00" spread="1.09"/>
                    <measurement group_id="O4" value="-2.57" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Erythema (Head\Neck) (n=180,219,47,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.81" spread="1.08"/>
                    <measurement group_id="O2" value="-1.75" spread="1.18"/>
                    <measurement group_id="O3" value="-1.70" spread="1.20"/>
                    <measurement group_id="O4" value="-1.74" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Erythema (Upper Limbs) (n=180,219,47,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.95" spread="1.13"/>
                    <measurement group_id="O2" value="-2.13" spread="1.04"/>
                    <measurement group_id="O3" value="-1.77" spread="1.16"/>
                    <measurement group_id="O4" value="-2.46" spread="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Erythema (Trunk) (n=180,219,47,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.22" spread="1.12"/>
                    <measurement group_id="O2" value="-2.31" spread="1.13"/>
                    <measurement group_id="O3" value="-2.15" spread="1.02"/>
                    <measurement group_id="O4" value="-2.52" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Erythema (Lower Limbs) (n=180,219,47,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.29" spread="1.16"/>
                    <measurement group_id="O2" value="-2.50" spread="1.12"/>
                    <measurement group_id="O3" value="-2.26" spread="1.13"/>
                    <measurement group_id="O4" value="-2.61" spread="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Induration (Head\Neck) (n=180,219,47,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.65" spread="1.11"/>
                    <measurement group_id="O2" value="-1.69" spread="1.13"/>
                    <measurement group_id="O3" value="-1.68" spread="1.09"/>
                    <measurement group_id="O4" value="-1.72" spread="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Induration (Upper Limbs)(n=180,219,47,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.86" spread="1.12"/>
                    <measurement group_id="O2" value="-1.95" spread="1.07"/>
                    <measurement group_id="O3" value="-1.70" spread="1.04"/>
                    <measurement group_id="O4" value="-2.24" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Induration (Trunk) (n=180,219,47,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.08" spread="1.03"/>
                    <measurement group_id="O2" value="-2.11" spread="1.16"/>
                    <measurement group_id="O3" value="-2.04" spread="1.04"/>
                    <measurement group_id="O4" value="-2.24" spread="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Induration (Lower Limbs)(n=180,219,47,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.17" spread="1.17"/>
                    <measurement group_id="O2" value="-2.30" spread="1.18"/>
                    <measurement group_id="O3" value="-2.13" spread="1.10"/>
                    <measurement group_id="O4" value="-2.54" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Scaling (Head\Neck) (n=180,219,47,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.86" spread="1.16"/>
                    <measurement group_id="O2" value="-1.87" spread="1.23"/>
                    <measurement group_id="O3" value="-1.68" spread="1.29"/>
                    <measurement group_id="O4" value="-1.89" spread="1.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Scaling (Upper Limbs) (n=180,219,47,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.87" spread="1.20"/>
                    <measurement group_id="O2" value="-1.99" spread="1.11"/>
                    <measurement group_id="O3" value="-1.53" spread="1.10"/>
                    <measurement group_id="O4" value="-2.26" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Scaling (Trunk) (n=180,219,47,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.17" spread="1.05"/>
                    <measurement group_id="O2" value="-2.16" spread="1.08"/>
                    <measurement group_id="O3" value="-1.85" spread="1.12"/>
                    <measurement group_id="O4" value="-2.28" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Scaling (Lower Limbs) (n=180,219,47,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.12" spread="1.16"/>
                    <measurement group_id="O2" value="-2.35" spread="1.16"/>
                    <measurement group_id="O3" value="-1.98" spread="1.24"/>
                    <measurement group_id="O4" value="-2.52" spread="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52</title>
        <description>The PASI quantifies the severity of a participant's psoriasis based on both, &quot;lesion severity&quot; and &quot;percent of BSA&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.</description>
        <time_frame>Baseline, Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
        <population>FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, CP-690,550 5 mg</title>
            <description>Participants who were re-assigned to this group from placebo at Week 16 and thereafter received CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, CP-690,550 10 mg</title>
            <description>Participants who were re-assigned to this group from placebo at Week 16 and thereafter received CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52</title>
          <description>The PASI quantifies the severity of a participant's psoriasis based on both, &quot;lesion severity&quot; and &quot;percent of BSA&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.</description>
          <population>FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="359"/>
                <count group_id="O2" value="358"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.50" spread="1.11"/>
                    <measurement group_id="O2" value="-24.86" spread="1.11"/>
                    <measurement group_id="O3" value="-8.99" spread="2.59"/>
                    <measurement group_id="O4" value="-5.85" spread="2.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.60" spread="1.45"/>
                    <measurement group_id="O2" value="-43.08" spread="1.46"/>
                    <measurement group_id="O3" value="-15.75" spread="3.38"/>
                    <measurement group_id="O4" value="-10.76" spread="3.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-47.72" spread="1.68"/>
                    <measurement group_id="O2" value="-60.48" spread="1.68"/>
                    <measurement group_id="O3" value="-20.27" spread="3.89"/>
                    <measurement group_id="O4" value="-13.02" spread="3.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-54.07" spread="1.83"/>
                    <measurement group_id="O2" value="-69.11" spread="1.83"/>
                    <measurement group_id="O3" value="-23.02" spread="4.21"/>
                    <measurement group_id="O4" value="-15.26" spread="4.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-57.25" spread="1.97"/>
                    <measurement group_id="O2" value="-72.71" spread="1.96"/>
                    <measurement group_id="O3" value="-25.66" spread="4.51"/>
                    <measurement group_id="O4" value="-13.33" spread="4.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-63.73" spread="1.74"/>
                    <measurement group_id="O2" value="-75.05" spread="1.73"/>
                    <measurement group_id="O3" value="-56.71" spread="3.93"/>
                    <measurement group_id="O4" value="-49.48" spread="3.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-68.62" spread="1.69"/>
                    <measurement group_id="O2" value="-78.91" spread="1.67"/>
                    <measurement group_id="O3" value="-73.49" spread="3.75"/>
                    <measurement group_id="O4" value="-76.64" spread="3.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-67.06" spread="1.82"/>
                    <measurement group_id="O2" value="-76.36" spread="1.77"/>
                    <measurement group_id="O3" value="-73.52" spread="3.93"/>
                    <measurement group_id="O4" value="-81.21" spread="4.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-64.15" spread="1.91"/>
                    <measurement group_id="O2" value="-74.61" spread="1.85"/>
                    <measurement group_id="O3" value="-70.60" spread="4.11"/>
                    <measurement group_id="O4" value="-80.94" spread="4.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Body Surface Area (BSA) With Psoriasis</title>
        <description>Assessment of BSA with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. Body regions are assigned specific number of handprints with percentage [Head and neck = 10% (10 handprints), upper extremities = 20% (20 handprints), Trunk (including axillae and groin) = 30% (30 handprints), lower extremities (including buttocks) = 40% (40 handprints)]. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis. The total BSA affected was the summation of individual regions affected.</description>
        <time_frame>Baseline, Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
        <population>FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Here n signifies those participants who were evaluable for this measure at specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, CP-690,550 5 mg</title>
            <description>Participants who were re-assigned to this group from placebo at Week 16 and thereafter received CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, CP-690,550 10 mg</title>
            <description>Participants who were re-assigned to this group from placebo at Week 16 and thereafter received CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Body Surface Area (BSA) With Psoriasis</title>
          <description>Assessment of BSA with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. Body regions are assigned specific number of handprints with percentage [Head and neck = 10% (10 handprints), upper extremities = 20% (20 handprints), Trunk (including axillae and groin) = 30% (30 handprints), lower extremities (including buttocks) = 40% (40 handprints)]. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis. The total BSA affected was the summation of individual regions affected.</description>
          <population>FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Here n signifies those participants who were evaluable for this measure at specified time point for each arm, respectively.</population>
          <units>percentage of BSA</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="363"/>
                <count group_id="O2" value="360"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n = 363, 360, 66, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.48" spread="16.42"/>
                    <measurement group_id="O2" value="31.13" spread="17.64"/>
                    <measurement group_id="O3" value="28.03" spread="16.99"/>
                    <measurement group_id="O4" value="30.17" spread="16.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n = 358, 358, 66, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.08" spread="16.85"/>
                    <measurement group_id="O2" value="27.86" spread="17.24"/>
                    <measurement group_id="O3" value="28.21" spread="19.27"/>
                    <measurement group_id="O4" value="30.32" spread="16.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n = 352, 350, 65, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.69" spread="16.56"/>
                    <measurement group_id="O2" value="22.79" spread="17.52"/>
                    <measurement group_id="O3" value="27.15" spread="20.08"/>
                    <measurement group_id="O4" value="29.52" spread="17.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n = 347, 350, 65, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.99" spread="16.28"/>
                    <measurement group_id="O2" value="16.49" spread="16.23"/>
                    <measurement group_id="O3" value="26.82" spread="19.93"/>
                    <measurement group_id="O4" value="29.43" spread="17.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n = 345, 345, 65, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.73" spread="16.03"/>
                    <measurement group_id="O2" value="12.64" spread="15.01"/>
                    <measurement group_id="O3" value="25.89" spread="20.50"/>
                    <measurement group_id="O4" value="29.02" spread="17.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n = 323, 335, 66, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.08" spread="15.75"/>
                    <measurement group_id="O2" value="9.48" spread="12.99"/>
                    <measurement group_id="O3" value="25.89" spread="21.77"/>
                    <measurement group_id="O4" value="29.14" spread="19.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n = 312, 321, 66, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.77" spread="14.23"/>
                    <measurement group_id="O2" value="7.59" spread="11.45"/>
                    <measurement group_id="O3" value="18.57" spread="20.49"/>
                    <measurement group_id="O4" value="21.73" spread="17.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 (n = 300, 307, 61, 61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.92" spread="13.07"/>
                    <measurement group_id="O2" value="6.05" spread="9.36"/>
                    <measurement group_id="O3" value="9.54" spread="15.85"/>
                    <measurement group_id="O4" value="9.96" spread="12.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40 (n = 203, 242, 53, 47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.37" spread="7.58"/>
                    <measurement group_id="O2" value="3.51" spread="6.03"/>
                    <measurement group_id="O3" value="4.47" spread="6.96"/>
                    <measurement group_id="O4" value="3.02" spread="4.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n = 180, 219, 47, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.42" spread="6.93"/>
                    <measurement group_id="O2" value="2.94" spread="5.29"/>
                    <measurement group_id="O3" value="3.79" spread="4.37"/>
                    <measurement group_id="O4" value="2.09" spread="2.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Total Body Surface Area (BSA) With Psoriasis at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52</title>
        <description>Assessment of BSA with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. Body regions are assigned specific number of handprints with percentage [Head and neck = 10% (10 handprints), upper extremities = 20% (20 handprints), Trunk (including axillae and groin) = 30% (30 handprints), lower extremities (including buttocks) = 40% (40 handprints)]. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis. The total BSA affected was the summation of individual regions affected.</description>
        <time_frame>Baseline, Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
        <population>FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, CP-690,550 5 mg</title>
            <description>Participants who were re-assigned to this group from placebo at Week 16 and thereafter received CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, CP-690,550 10 mg</title>
            <description>Participants who were re-assigned to this group from placebo at Week 16 and thereafter received CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Total Body Surface Area (BSA) With Psoriasis at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52</title>
          <description>Assessment of BSA with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. Body regions are assigned specific number of handprints with percentage [Head and neck = 10% (10 handprints), upper extremities = 20% (20 handprints), Trunk (including axillae and groin) = 30% (30 handprints), lower extremities (including buttocks) = 40% (40 handprints)]. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis. The total BSA affected was the summation of individual regions affected.</description>
          <population>FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="359"/>
                <count group_id="O2" value="358"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.89" spread="0.97"/>
                    <measurement group_id="O2" value="-10.44" spread="0.97"/>
                    <measurement group_id="O3" value="-1.92" spread="2.25"/>
                    <measurement group_id="O4" value="-1.23" spread="2.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.31" spread="1.58"/>
                    <measurement group_id="O2" value="-26.73" spread="1.58"/>
                    <measurement group_id="O3" value="-5.29" spread="3.67"/>
                    <measurement group_id="O4" value="-1.81" spread="3.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.86" spread="1.93"/>
                    <measurement group_id="O2" value="-46.27" spread="1.93"/>
                    <measurement group_id="O3" value="-6.73" spread="4.46"/>
                    <measurement group_id="O4" value="-1.57" spread="4.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-45.72" spread="2.13"/>
                    <measurement group_id="O2" value="-59.20" spread="2.13"/>
                    <measurement group_id="O3" value="-9.62" spread="4.91"/>
                    <measurement group_id="O4" value="-0.84" spread="4.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-51.87" spread="2.41"/>
                    <measurement group_id="O2" value="-67.12" spread="2.41"/>
                    <measurement group_id="O3" value="-11.22" spread="5.50"/>
                    <measurement group_id="O4" value="2.03" spread="5.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-58.67" spread="2.22"/>
                    <measurement group_id="O2" value="-71.96" spread="2.21"/>
                    <measurement group_id="O3" value="-37.66" spread="5.03"/>
                    <measurement group_id="O4" value="-26.49" spread="5.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-64.74" spread="2.27"/>
                    <measurement group_id="O2" value="-76.82" spread="2.24"/>
                    <measurement group_id="O3" value="-66.75" spread="5.03"/>
                    <measurement group_id="O4" value="-64.11" spread="5.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-73.29" spread="1.72"/>
                    <measurement group_id="O2" value="-80.78" spread="1.67"/>
                    <measurement group_id="O3" value="-73.67" spread="3.69"/>
                    <measurement group_id="O4" value="-79.92" spread="3.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-74.95" spread="1.55"/>
                    <measurement group_id="O2" value="-82.36" spread="1.48"/>
                    <measurement group_id="O3" value="-74.84" spread="3.26"/>
                    <measurement group_id="O4" value="-84.79" spread="3.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Psoriasis Area and Severity Index 50 (PASI 50) Response</title>
        <description>The PASI quantifies the severity of a participant's psoriasis based on both, &quot;lesion severity&quot; and &quot;percent of BSA&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 50 response was defined as at least 50% reduction in PASI relative to Baseline. Percentage of participants with PASI 50 response is reported.</description>
        <time_frame>Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
        <population>FAS: all randomized participants who received at least 1 dose of the randomized investigational drug (CP-690,550 or placebo). Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. NRI method was used to impute missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, CP-690,550 5 mg</title>
            <description>Participants who were re-assigned to this group from placebo at Week 16 and thereafter received CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, CP-690,550 10 mg</title>
            <description>Participants who were re-assigned to this group from placebo at Week 16 and thereafter received CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Psoriasis Area and Severity Index 50 (PASI 50) Response</title>
          <description>The PASI quantifies the severity of a participant's psoriasis based on both, &quot;lesion severity&quot; and &quot;percent of BSA&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 50 response was defined as at least 50% reduction in PASI relative to Baseline. Percentage of participants with PASI 50 response is reported.</description>
          <population>FAS: all randomized participants who received at least 1 dose of the randomized investigational drug (CP-690,550 or placebo). Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. NRI method was used to impute missing values.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="363"/>
                <count group_id="O2" value="360"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.09" lower_limit="6.13" upper_limit="12.05"/>
                    <measurement group_id="O2" value="17.22" lower_limit="13.32" upper_limit="21.12"/>
                    <measurement group_id="O3" value="3.03" lower_limit="0.00" upper_limit="7.17"/>
                    <measurement group_id="O4" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.65" lower_limit="24.00" upper_limit="33.30"/>
                    <measurement group_id="O2" value="39.72" lower_limit="34.67" upper_limit="44.78"/>
                    <measurement group_id="O3" value="9.09" lower_limit="2.16" upper_limit="16.03"/>
                    <measurement group_id="O4" value="1.52" lower_limit="0.00" upper_limit="4.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.93" lower_limit="42.79" upper_limit="53.07"/>
                    <measurement group_id="O2" value="65.56" lower_limit="60.65" upper_limit="70.46"/>
                    <measurement group_id="O3" value="18.18" lower_limit="8.88" upper_limit="27.49"/>
                    <measurement group_id="O4" value="12.12" lower_limit="4.25" upper_limit="20.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.95" lower_limit="53.89" upper_limit="64.01"/>
                    <measurement group_id="O2" value="73.89" lower_limit="69.35" upper_limit="78.43"/>
                    <measurement group_id="O3" value="24.24" lower_limit="13.90" upper_limit="34.58"/>
                    <measurement group_id="O4" value="12.12" lower_limit="4.25" upper_limit="20.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.33" lower_limit="55.30" upper_limit="65.36"/>
                    <measurement group_id="O2" value="76.94" lower_limit="72.59" upper_limit="81.30"/>
                    <measurement group_id="O3" value="22.73" lower_limit="12.62" upper_limit="32.84"/>
                    <measurement group_id="O4" value="21.21" lower_limit="11.35" upper_limit="31.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.12" lower_limit="61.25" upper_limit="70.98"/>
                    <measurement group_id="O2" value="75.83" lower_limit="71.41" upper_limit="80.26"/>
                    <measurement group_id="O3" value="63.64" lower_limit="52.03" upper_limit="75.24"/>
                    <measurement group_id="O4" value="54.55" lower_limit="42.53" upper_limit="66.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.39" lower_limit="61.53" upper_limit="71.25"/>
                    <measurement group_id="O2" value="76.11" lower_limit="71.71" upper_limit="80.52"/>
                    <measurement group_id="O3" value="77.27" lower_limit="67.16" upper_limit="87.38"/>
                    <measurement group_id="O4" value="83.33" lower_limit="74.34" upper_limit="92.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.99" lower_limit="48.87" upper_limit="59.12"/>
                    <measurement group_id="O2" value="63.61" lower_limit="58.64" upper_limit="68.58"/>
                    <measurement group_id="O3" value="75.76" lower_limit="65.42" upper_limit="86.10"/>
                    <measurement group_id="O4" value="71.21" lower_limit="60.29" upper_limit="82.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.21" lower_limit="43.07" upper_limit="53.35"/>
                    <measurement group_id="O2" value="59.44" lower_limit="54.37" upper_limit="64.52"/>
                    <measurement group_id="O3" value="66.67" lower_limit="55.29" upper_limit="78.04"/>
                    <measurement group_id="O4" value="69.70" lower_limit="58.61" upper_limit="80.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Psoriasis Area and Severity Index 90 (PASI 90) Response</title>
        <description>The PASI quantifies the severity of a participant's psoriasis based on both, &quot;lesion severity&quot; and &quot;percent of BSA&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 90 response was defined as at least 90% reduction in PASI relative to Baseline. Percentage of participants with PASI 90 response up to Week 52 is reported.</description>
        <time_frame>Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
        <population>FAS: all randomized participants who received at least 1 dose of the randomized investigational drug (CP-690,550 or placebo). Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. NRI method was used to impute missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, CP-690,550 5 mg</title>
            <description>Participants who were re-assigned to this group from placebo at Week 16 and thereafter received CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, CP-690,550 10 mg</title>
            <description>Participants who were re-assigned to this group from placebo at Week 16 and thereafter received CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Psoriasis Area and Severity Index 90 (PASI 90) Response</title>
          <description>The PASI quantifies the severity of a participant's psoriasis based on both, &quot;lesion severity&quot; and &quot;percent of BSA&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 90 response was defined as at least 90% reduction in PASI relative to Baseline. Percentage of participants with PASI 90 response up to Week 52 is reported.</description>
          <population>FAS: all randomized participants who received at least 1 dose of the randomized investigational drug (CP-690,550 or placebo). Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. NRI method was used to impute missing values.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="363"/>
                <count group_id="O2" value="360"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28" lower_limit="0.00" upper_limit="0.81"/>
                    <measurement group_id="O2" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O3" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O4" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.65" lower_limit="0.34" upper_limit="2.96"/>
                    <measurement group_id="O2" value="3.89" lower_limit="1.89" upper_limit="5.89"/>
                    <measurement group_id="O3" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O4" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.64" lower_limit="6.61" upper_limit="12.68"/>
                    <measurement group_id="O2" value="18.61" lower_limit="14.59" upper_limit="22.63"/>
                    <measurement group_id="O3" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O4" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.43" lower_limit="11.71" upper_limit="19.14"/>
                    <measurement group_id="O2" value="28.06" lower_limit="23.41" upper_limit="32.70"/>
                    <measurement group_id="O3" value="1.52" lower_limit="0.00" upper_limit="4.46"/>
                    <measurement group_id="O4" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.83" lower_limit="15.73" upper_limit="23.94"/>
                    <measurement group_id="O2" value="39.44" lower_limit="34.40" upper_limit="44.49"/>
                    <measurement group_id="O3" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O4" value="1.52" lower_limit="0.00" upper_limit="4.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.14" lower_limit="18.80" upper_limit="27.48"/>
                    <measurement group_id="O2" value="40.28" lower_limit="35.21" upper_limit="45.34"/>
                    <measurement group_id="O3" value="7.58" lower_limit="1.19" upper_limit="13.96"/>
                    <measurement group_id="O4" value="9.09" lower_limit="2.16" upper_limit="16.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.13" lower_limit="26.37" upper_limit="35.89"/>
                    <measurement group_id="O2" value="43.61" lower_limit="38.49" upper_limit="48.73"/>
                    <measurement group_id="O3" value="25.76" lower_limit="15.21" upper_limit="36.31"/>
                    <measurement group_id="O4" value="39.39" lower_limit="27.61" upper_limit="51.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.10" lower_limit="23.48" upper_limit="32.72"/>
                    <measurement group_id="O2" value="41.39" lower_limit="36.30" upper_limit="46.48"/>
                    <measurement group_id="O3" value="34.85" lower_limit="23.35" upper_limit="46.34"/>
                    <measurement group_id="O4" value="54.55" lower_limit="42.53" upper_limit="66.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.42" lower_limit="19.06" upper_limit="27.77"/>
                    <measurement group_id="O2" value="36.94" lower_limit="31.96" upper_limit="41.93"/>
                    <measurement group_id="O3" value="31.82" lower_limit="20.58" upper_limit="43.06"/>
                    <measurement group_id="O4" value="53.03" lower_limit="40.99" upper_limit="65.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Psoriasis Area and Severity Index (PASI) Score of at Least 125% of Baseline PASI Score</title>
        <description>The PASI quantifies the severity of a participant's psoriasis based on both, &quot;lesion severity&quot; and &quot;percent of BSA&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. Percentage of participants with PASI score of at least 125% of baseline PASI score are reported.</description>
        <time_frame>Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
        <population>FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Here n signifies those participants who were evaluable for this measure at specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, CP-690,550 5 mg</title>
            <description>Participants who were re-assigned to this group from placebo at Week 16 and thereafter received CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, CP-690,550 10 mg</title>
            <description>Participants who were re-assigned to this group from placebo at Week 16 and thereafter received CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Psoriasis Area and Severity Index (PASI) Score of at Least 125% of Baseline PASI Score</title>
          <description>The PASI quantifies the severity of a participant's psoriasis based on both, &quot;lesion severity&quot; and &quot;percent of BSA&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. Percentage of participants with PASI score of at least 125% of baseline PASI score are reported.</description>
          <population>FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Here n signifies those participants who were evaluable for this measure at specified time point for each arm, respectively.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="363"/>
                <count group_id="O2" value="360"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n = 358, 358, 66, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.56" lower_limit="0.00" upper_limit="1.33"/>
                    <measurement group_id="O2" value="1.12" lower_limit="0.03" upper_limit="2.21"/>
                    <measurement group_id="O3" value="4.55" lower_limit="0.00" upper_limit="9.57"/>
                    <measurement group_id="O4" value="3.13" lower_limit="0.00" upper_limit="7.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n = 352, 350, 65, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.14" lower_limit="0.03" upper_limit="2.24"/>
                    <measurement group_id="O2" value="0.57" lower_limit="0.00" upper_limit="1.36"/>
                    <measurement group_id="O3" value="1.54" lower_limit="0.00" upper_limit="4.53"/>
                    <measurement group_id="O4" value="4.55" lower_limit="0.00" upper_limit="9.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n = 347, 350, 65, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.02" lower_limit="0.54" upper_limit="3.50"/>
                    <measurement group_id="O2" value="0.29" lower_limit="0.00" upper_limit="0.84"/>
                    <measurement group_id="O3" value="3.08" lower_limit="0.00" upper_limit="7.28"/>
                    <measurement group_id="O4" value="7.58" lower_limit="1.19" upper_limit="13.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n = 345, 345, 65, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.90" lower_limit="1.13" upper_limit="4.67"/>
                    <measurement group_id="O2" value="1.16" lower_limit="0.03" upper_limit="2.29"/>
                    <measurement group_id="O3" value="6.15" lower_limit="0.31" upper_limit="12.00"/>
                    <measurement group_id="O4" value="9.09" lower_limit="2.16" upper_limit="16.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n = 323, 335, 66, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.48" lower_limit="0.78" upper_limit="4.17"/>
                    <measurement group_id="O2" value="0.90" lower_limit="0.00" upper_limit="1.90"/>
                    <measurement group_id="O3" value="6.06" lower_limit="0.30" upper_limit="11.82"/>
                    <measurement group_id="O4" value="12.12" lower_limit="4.25" upper_limit="20.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n = 312, 321, 66, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.60" lower_limit="0.21" upper_limit="3.00"/>
                    <measurement group_id="O2" value="0.62" lower_limit="0.00" upper_limit="1.48"/>
                    <measurement group_id="O3" value="1.52" lower_limit="0.00" upper_limit="4.46"/>
                    <measurement group_id="O4" value="4.62" lower_limit="0.00" upper_limit="9.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 (n = 300, 307, 61, 61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="0.00" upper_limit="2.13"/>
                    <measurement group_id="O2" value="0.33" lower_limit="0.00" upper_limit="0.96"/>
                    <measurement group_id="O3" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O4" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40 (n = 203, 242, 53, 47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O2" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O3" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O4" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n = 180, 219, 47, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O2" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O3" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O4" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nail Psoriasis Severity Index (NAPSI) Score</title>
        <description>The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop [salmon patch dyschromia]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 [absence of psoriasis] to 4 [presence of psoriasis in all 4 quadrants]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores = more severe psoriasis.</description>
        <time_frame>Baseline, Week 8, 16, 20, 28, 40, 52</time_frame>
        <population>FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Here 'N' (number of participants analyzed) signifies participants evaluable for this measure and n signifies participants evaluable at specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, CP-690,550 5 mg</title>
            <description>Participants who were re-assigned to this group from placebo at Week 16 and thereafter received CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, CP-690,550 10 mg</title>
            <description>Participants who were re-assigned to this group from placebo at Week 16 and thereafter received CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Nail Psoriasis Severity Index (NAPSI) Score</title>
          <description>The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop [salmon patch dyschromia]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 [absence of psoriasis] to 4 [presence of psoriasis in all 4 quadrants]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores = more severe psoriasis.</description>
          <population>FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Here 'N' (number of participants analyzed) signifies participants evaluable for this measure and n signifies participants evaluable at specified time point for each arm, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="247"/>
                <count group_id="O2" value="250"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=247,250,34,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.64" spread="20.65"/>
                    <measurement group_id="O2" value="28.24" spread="20.89"/>
                    <measurement group_id="O3" value="26.76" spread="18.33"/>
                    <measurement group_id="O4" value="23.91" spread="16.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=236,242,33,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.32" spread="20.60"/>
                    <measurement group_id="O2" value="22.47" spread="19.43"/>
                    <measurement group_id="O3" value="25.55" spread="18.50"/>
                    <measurement group_id="O4" value="24.61" spread="16.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=215,233,34,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.09" spread="18.79"/>
                    <measurement group_id="O2" value="16.53" spread="17.87"/>
                    <measurement group_id="O3" value="27.82" spread="17.64"/>
                    <measurement group_id="O4" value="25.46" spread="18.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=210,227,34,45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.53" spread="17.35"/>
                    <measurement group_id="O2" value="12.96" spread="16.11"/>
                    <measurement group_id="O3" value="23.97" spread="18.18"/>
                    <measurement group_id="O4" value="21.18" spread="18.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 (n=202,213,30,44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.42" spread="16.17"/>
                    <measurement group_id="O2" value="9.49" spread="13.92"/>
                    <measurement group_id="O3" value="16.77" spread="14.69"/>
                    <measurement group_id="O4" value="14.77" spread="17.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40 (n=125,167,24,33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.36" spread="10.04"/>
                    <measurement group_id="O2" value="7.19" spread="12.71"/>
                    <measurement group_id="O3" value="5.67" spread="7.92"/>
                    <measurement group_id="O4" value="8.85" spread="11.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=110,148,21,32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.94" spread="9.48"/>
                    <measurement group_id="O2" value="6.73" spread="12.44"/>
                    <measurement group_id="O3" value="5.90" spread="8.92"/>
                    <measurement group_id="O4" value="6.66" spread="9.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score at Week 8, 16, 20, 28, 40 and 52</title>
        <description>The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop [salmon patch dyschromia]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 [absence of psoriasis] to 4 [presence of psoriasis in all 4 quadrants]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores = more severe psoriasis.</description>
        <time_frame>Baseline, Week 8, 16, 20, 28, 40, 52</time_frame>
        <population>FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Here 'N' (number of participants analyzed) signifies participants evaluable for this measure and n signifies participants evaluable at specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, CP-690,550 5 mg</title>
            <description>Participants who were re-assigned to this group from placebo at Week 16 and thereafter received CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, CP-690,550 10 mg</title>
            <description>Participants who were re-assigned to this group from placebo at Week 16 and thereafter received CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score at Week 8, 16, 20, 28, 40 and 52</title>
          <description>The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop [salmon patch dyschromia]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 [absence of psoriasis] to 4 [presence of psoriasis in all 4 quadrants]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores = more severe psoriasis.</description>
          <population>FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Here 'N' (number of participants analyzed) signifies participants evaluable for this measure and n signifies participants evaluable at specified time point for each arm, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="247"/>
                <count group_id="O2" value="250"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 8 (n= 236, 242, 33, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.58" spread="10.98"/>
                    <measurement group_id="O2" value="-5.55" spread="12.64"/>
                    <measurement group_id="O3" value="-0.82" spread="7.26"/>
                    <measurement group_id="O4" value="0.70" spread="6.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 16 (n= 215, 233, 34, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.91" spread="13.93"/>
                    <measurement group_id="O2" value="-11.70" spread="16.68"/>
                    <measurement group_id="O3" value="1.06" spread="9.37"/>
                    <measurement group_id="O4" value="1.54" spread="11.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 20 (n= 210, 227, 34, 45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.51" spread="15.17"/>
                    <measurement group_id="O2" value="-15.16" spread="17.51"/>
                    <measurement group_id="O3" value="-2.79" spread="11.83"/>
                    <measurement group_id="O4" value="-2.53" spread="13.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 28 (n= 202, 213, 30, 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.08" spread="16.53"/>
                    <measurement group_id="O2" value="-19.07" spread="18.62"/>
                    <measurement group_id="O3" value="-10.30" spread="13.90"/>
                    <measurement group_id="O4" value="-8.50" spread="14.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 40 (n= 125, 167, 24, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.40" spread="17.47"/>
                    <measurement group_id="O2" value="-21.63" spread="19.61"/>
                    <measurement group_id="O3" value="-16.38" spread="15.34"/>
                    <measurement group_id="O4" value="-13.21" spread="13.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 52 (n= 110, 148, 21, 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.49" spread="17.03"/>
                    <measurement group_id="O2" value="-22.28" spread="20.33"/>
                    <measurement group_id="O3" value="-17.19" spread="14.32"/>
                    <measurement group_id="O4" value="-15.97" spread="12.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Affected Nails</title>
        <description>Nail psoriasis is evaluated by the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop [salmon patch dyschromia]). Total number psoriasis affected nails (presence of psoriatic manifestations on the nail matrix/nail bed) were assessed and reported.</description>
        <time_frame>Baseline, Week 8, 16, 20, 28, 40, 52</time_frame>
        <population>FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Here 'N' (number of participants analyzed) signifies participants evaluable for this measure and n signifies participants evaluable at specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, CP-690,550 5 mg</title>
            <description>Participants who were re-assigned to this group from placebo at Week 16 and thereafter received CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, CP-690,550 10 mg</title>
            <description>Participants who were re-assigned to this group from placebo at Week 16 and thereafter received CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Affected Nails</title>
          <description>Nail psoriasis is evaluated by the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop [salmon patch dyschromia]). Total number psoriasis affected nails (presence of psoriatic manifestations on the nail matrix/nail bed) were assessed and reported.</description>
          <population>FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Here 'N' (number of participants analyzed) signifies participants evaluable for this measure and n signifies participants evaluable at specified time point for each arm, respectively.</population>
          <units>nails</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="247"/>
                <count group_id="O2" value="250"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n= 247, 250, 34, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.21" spread="3.14"/>
                    <measurement group_id="O2" value="7.71" spread="3.12"/>
                    <measurement group_id="O3" value="7.73" spread="3.05"/>
                    <measurement group_id="O4" value="7.24" spread="3.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n= 234, 242, 32, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.87" spread="3.58"/>
                    <measurement group_id="O2" value="6.65" spread="3.80"/>
                    <measurement group_id="O3" value="8.00" spread="3.01"/>
                    <measurement group_id="O4" value="7.48" spread="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n= 215, 233, 33, 45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.25" spread="3.79"/>
                    <measurement group_id="O2" value="5.44" spread="4.16"/>
                    <measurement group_id="O3" value="8.27" spread="2.65"/>
                    <measurement group_id="O4" value="7.56" spread="3.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n= 209, 227, 33, 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.53" spread="3.83"/>
                    <measurement group_id="O2" value="4.65" spread="4.13"/>
                    <measurement group_id="O3" value="7.48" spread="3.01"/>
                    <measurement group_id="O4" value="6.43" spread="3.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 (n= 202, 213, 30, 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.77" spread="3.92"/>
                    <measurement group_id="O2" value="3.76" spread="4.03"/>
                    <measurement group_id="O3" value="6.63" spread="3.32"/>
                    <measurement group_id="O4" value="5.09" spread="3.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40 (n= 125, 167, 24, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.49" spread="3.68"/>
                    <measurement group_id="O2" value="2.91" spread="3.61"/>
                    <measurement group_id="O3" value="3.13" spread="3.69"/>
                    <measurement group_id="O4" value="3.94" spread="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n= 110, 148, 21, 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.44" spread="3.60"/>
                    <measurement group_id="O2" value="2.64" spread="3.57"/>
                    <measurement group_id="O3" value="3.10" spread="3.70"/>
                    <measurement group_id="O4" value="3.25" spread="3.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score at Week 8, 16, 20, 28, 40 and 52</title>
        <description>The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop [salmon patch dyschromia]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 [absence of psoriasis] to 4 [presence of psoriasis in all 4 quadrants]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores = more severe psoriasis.</description>
        <time_frame>Baseline, Week 8, 16, 20, 28, 40, 52</time_frame>
        <population>FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, CP-690,550 5 mg</title>
            <description>Participants who were re-assigned to this group from placebo at Week 16 and thereafter received CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, CP-690,550 10 mg</title>
            <description>Participants who were re-assigned to this group from placebo at Week 16 and thereafter received CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score at Week 8, 16, 20, 28, 40 and 52</title>
          <description>The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop [salmon patch dyschromia]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 [absence of psoriasis] to 4 [presence of psoriasis in all 4 quadrants]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores = more severe psoriasis.</description>
          <population>FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="238"/>
                <count group_id="O2" value="242"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percent Change at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.58" spread="6.46"/>
                    <measurement group_id="O2" value="-19.37" spread="6.40"/>
                    <measurement group_id="O3" value="16.91" spread="17.18"/>
                    <measurement group_id="O4" value="36.22" spread="14.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Change at Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.13" spread="9.39"/>
                    <measurement group_id="O2" value="-42.26" spread="9.16"/>
                    <measurement group_id="O3" value="78.80" spread="24.22"/>
                    <measurement group_id="O4" value="50.19" spread="20.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Change at Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.74" spread="9.20"/>
                    <measurement group_id="O2" value="-52.62" spread="8.93"/>
                    <measurement group_id="O3" value="43.82" spread="23.46"/>
                    <measurement group_id="O4" value="38.66" spread="20.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Change at Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-43.52" spread="7.22"/>
                    <measurement group_id="O2" value="-65.20" spread="7.06"/>
                    <measurement group_id="O3" value="12.39" spread="18.71"/>
                    <measurement group_id="O4" value="-18.71" spread="15.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Change at Week 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-64.55" spread="4.05"/>
                    <measurement group_id="O2" value="-75.41" spread="3.57"/>
                    <measurement group_id="O3" value="-57.01" spread="9.38"/>
                    <measurement group_id="O4" value="-54.83" spread="8.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Change at Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-58.27" spread="5.98"/>
                    <measurement group_id="O2" value="-73.56" spread="5.54"/>
                    <measurement group_id="O3" value="-45.67" spread="14.67"/>
                    <measurement group_id="O4" value="-72.42" spread="12.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Nail Psoriasis Severity Index 75 (NAPSI 75) Response</title>
        <description>The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop [salmon patch dyschromia]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 [absence of psoriasis] to 4 [presence of psoriasis in all 4 quadrants]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores = more severe psoriasis. NAPSI 75 response was defined as at least a 75% reduction in NAPSI relative to Baseline. Percentage of participants with NAPSI 75 response is reported.</description>
        <time_frame>Week 8, 16, 20, 28, 40, 52</time_frame>
        <population>FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure. NRI method was used to impute missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, CP-690,550 5 mg</title>
            <description>Participants who were re-assigned to this group from placebo at Week 16 and thereafter received CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, CP-690,550 10 mg</title>
            <description>Participants who were re-assigned to this group from placebo at Week 16 and thereafter received CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Nail Psoriasis Severity Index 75 (NAPSI 75) Response</title>
          <description>The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop [salmon patch dyschromia]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 [absence of psoriasis] to 4 [presence of psoriasis in all 4 quadrants]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores = more severe psoriasis. NAPSI 75 response was defined as at least a 75% reduction in NAPSI relative to Baseline. Percentage of participants with NAPSI 75 response is reported.</description>
          <population>FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure. NRI method was used to impute missing values.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="247"/>
                <count group_id="O2" value="250"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.72" lower_limit="6.02" upper_limit="13.41"/>
                    <measurement group_id="O2" value="14.40" lower_limit="10.05" upper_limit="18.75"/>
                    <measurement group_id="O3" value="8.82" lower_limit="0.00" upper_limit="18.36"/>
                    <measurement group_id="O4" value="4.35" lower_limit="0.00" upper_limit="10.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.98" lower_limit="10.53" upper_limit="19.43"/>
                    <measurement group_id="O2" value="29.20" lower_limit="23.56" upper_limit="34.84"/>
                    <measurement group_id="O3" value="5.88" lower_limit="0.00" upper_limit="13.79"/>
                    <measurement group_id="O4" value="6.52" lower_limit="0.00" upper_limit="13.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.05" lower_limit="15.97" upper_limit="26.14"/>
                    <measurement group_id="O2" value="39.20" lower_limit="33.15" upper_limit="45.25"/>
                    <measurement group_id="O3" value="8.82" lower_limit="0.00" upper_limit="18.36"/>
                    <measurement group_id="O4" value="23.91" lower_limit="11.59" upper_limit="36.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.17" lower_limit="25.40" upper_limit="36.95"/>
                    <measurement group_id="O2" value="49.20" lower_limit="43.00" upper_limit="55.40"/>
                    <measurement group_id="O3" value="17.65" lower_limit="4.83" upper_limit="30.46"/>
                    <measurement group_id="O4" value="28.26" lower_limit="15.25" upper_limit="41.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.34" lower_limit="22.72" upper_limit="33.96"/>
                    <measurement group_id="O2" value="48.80" lower_limit="42.60" upper_limit="55.00"/>
                    <measurement group_id="O3" value="41.18" lower_limit="24.63" upper_limit="57.72"/>
                    <measurement group_id="O4" value="36.96" lower_limit="23.01" upper_limit="50.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.51" lower_limit="20.07" upper_limit="30.94"/>
                    <measurement group_id="O2" value="41.20" lower_limit="35.10" upper_limit="47.30"/>
                    <measurement group_id="O3" value="35.29" lower_limit="19.23" upper_limit="51.36"/>
                    <measurement group_id="O4" value="43.48" lower_limit="29.15" upper_limit="57.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Nail Psoriasis Severity Index 100 (NAPSI 100) Response</title>
        <description>The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop [salmon patch dyschromia]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 [absence of psoriasis] to 4 [presence of psoriasis in all 4 quadrants]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores = more severe psoriasis. NAPSI 100 response was defined as at least a 100% reduction in NAPSI relative to Baseline. Percentage of participants with NAPSI 100 response is reported.</description>
        <time_frame>Week 8, 16, 20, 28, 40, 52</time_frame>
        <population>FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure. NRI method was used to impute missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, CP-690,550 5 mg</title>
            <description>Participants who were re-assigned to this group from placebo at Week 16 and thereafter received CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, CP-690,550 10 mg</title>
            <description>Participants who were re-assigned to this group from placebo at Week 16 and thereafter received CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Nail Psoriasis Severity Index 100 (NAPSI 100) Response</title>
          <description>The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop [salmon patch dyschromia]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 [absence of psoriasis] to 4 [presence of psoriasis in all 4 quadrants]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores = more severe psoriasis. NAPSI 100 response was defined as at least a 100% reduction in NAPSI relative to Baseline. Percentage of participants with NAPSI 100 response is reported.</description>
          <population>FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure. NRI method was used to impute missing values.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="247"/>
                <count group_id="O2" value="250"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.10" lower_limit="4.70" upper_limit="11.50"/>
                    <measurement group_id="O2" value="12.40" lower_limit="8.31" upper_limit="16.49"/>
                    <measurement group_id="O3" value="5.88" lower_limit="0.00" upper_limit="13.79"/>
                    <measurement group_id="O4" value="4.35" lower_limit="0.00" upper_limit="10.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.12" lower_limit="6.36" upper_limit="13.88"/>
                    <measurement group_id="O2" value="20.00" lower_limit="15.04" upper_limit="24.96"/>
                    <measurement group_id="O3" value="5.88" lower_limit="0.00" upper_limit="13.79"/>
                    <measurement group_id="O4" value="4.35" lower_limit="0.00" upper_limit="10.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.77" lower_limit="9.47" upper_limit="18.06"/>
                    <measurement group_id="O2" value="27.20" lower_limit="21.68" upper_limit="32.72"/>
                    <measurement group_id="O3" value="8.82" lower_limit="0.00" upper_limit="18.36"/>
                    <measurement group_id="O4" value="13.04" lower_limit="3.31" upper_limit="22.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.43" lower_limit="14.50" upper_limit="24.37"/>
                    <measurement group_id="O2" value="32.00" lower_limit="26.22" upper_limit="37.78"/>
                    <measurement group_id="O3" value="5.88" lower_limit="0.00" upper_limit="13.79"/>
                    <measurement group_id="O4" value="17.39" lower_limit="6.44" upper_limit="28.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.22" lower_limit="13.40" upper_limit="23.03"/>
                    <measurement group_id="O2" value="30.40" lower_limit="24.70" upper_limit="36.10"/>
                    <measurement group_id="O3" value="29.41" lower_limit="14.10" upper_limit="44.73"/>
                    <measurement group_id="O4" value="26.09" lower_limit="13.40" upper_limit="38.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.79" lower_limit="11.24" upper_limit="20.34"/>
                    <measurement group_id="O2" value="28.80" lower_limit="23.19" upper_limit="34.41"/>
                    <measurement group_id="O3" value="29.41" lower_limit="14.10" upper_limit="44.73"/>
                    <measurement group_id="O4" value="28.26" lower_limit="15.25" upper_limit="41.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Itch Severity Item (ISI) Score</title>
        <description>ISI assessed severity of itch (pruritus) due to psoriasis. ISI is a single item, horizontal numeric rating scale. Participants were asked to rate &quot;your worst itching due to psoriasis over the past 24 hours&quot; on a numeric rating scale anchored by the terms &quot;No itching&quot; (0) and &quot;Worst possible itching&quot; (10) at the ends for post baseline time points. Baseline ISI is average of scores on 7 days prior to start of study treatment.</description>
        <time_frame>Baseline, Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
        <population>FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Here n signifies those participants who were evaluable for this measure at specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, CP-690,550 5 mg</title>
            <description>Participants who were re-assigned to this group from placebo at Week 16 and thereafter received CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, CP-690,550 10 mg</title>
            <description>Participants who were re-assigned to this group from placebo at Week 16 and thereafter received CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Itch Severity Item (ISI) Score</title>
          <description>ISI assessed severity of itch (pruritus) due to psoriasis. ISI is a single item, horizontal numeric rating scale. Participants were asked to rate &quot;your worst itching due to psoriasis over the past 24 hours&quot; on a numeric rating scale anchored by the terms &quot;No itching&quot; (0) and &quot;Worst possible itching&quot; (10) at the ends for post baseline time points. Baseline ISI is average of scores on 7 days prior to start of study treatment.</description>
          <population>FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Here n signifies those participants who were evaluable for this measure at specified time point for each arm, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="363"/>
                <count group_id="O2" value="360"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=343,341,62,58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.49" spread="2.81"/>
                    <measurement group_id="O2" value="5.59" spread="2.72"/>
                    <measurement group_id="O3" value="5.64" spread="2.65"/>
                    <measurement group_id="O4" value="5.94" spread="2.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n=357,358,66,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.74" spread="2.51"/>
                    <measurement group_id="O2" value="3.32" spread="2.56"/>
                    <measurement group_id="O3" value="5.45" spread="2.87"/>
                    <measurement group_id="O4" value="5.61" spread="3.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=351,350,64,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.89" spread="2.44"/>
                    <measurement group_id="O2" value="2.41" spread="2.28"/>
                    <measurement group_id="O3" value="5.36" spread="2.86"/>
                    <measurement group_id="O4" value="5.56" spread="3.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=347,348,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.56" spread="2.60"/>
                    <measurement group_id="O2" value="1.87" spread="2.20"/>
                    <measurement group_id="O3" value="5.51" spread="2.94"/>
                    <measurement group_id="O4" value="5.50" spread="3.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=343,344,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.38" spread="2.66"/>
                    <measurement group_id="O2" value="1.62" spread="2.18"/>
                    <measurement group_id="O3" value="4.83" spread="3.11"/>
                    <measurement group_id="O4" value="5.42" spread="3.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=322,335,66,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.44" spread="2.70"/>
                    <measurement group_id="O2" value="1.48" spread="2.14"/>
                    <measurement group_id="O3" value="4.82" spread="3.11"/>
                    <measurement group_id="O4" value="5.83" spread="3.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=312,319,66,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.94" spread="2.20"/>
                    <measurement group_id="O2" value="1.43" spread="2.23"/>
                    <measurement group_id="O3" value="2.48" spread="2.27"/>
                    <measurement group_id="O4" value="2.48" spread="2.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 (n=293,306,61,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.96" spread="2.41"/>
                    <measurement group_id="O2" value="1.41" spread="2.11"/>
                    <measurement group_id="O3" value="2.02" spread="2.31"/>
                    <measurement group_id="O4" value="1.62" spread="2.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40 (n=202,242,53,47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.47" spread="2.15"/>
                    <measurement group_id="O2" value="1.01" spread="1.77"/>
                    <measurement group_id="O3" value="1.43" spread="2.03"/>
                    <measurement group_id="O4" value="0.83" spread="1.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=179,218,47,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.35" spread="2.00"/>
                    <measurement group_id="O2" value="0.83" spread="1.53"/>
                    <measurement group_id="O3" value="1.60" spread="2.09"/>
                    <measurement group_id="O4" value="0.93" spread="1.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Itch Severity Item (ISI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52</title>
        <description>ISI assessed severity of itch (pruritus) due to psoriasis. ISI is a single item, horizontal numeric rating scale. Participants were asked to rate &quot;your worst itching due to psoriasis over the past 24 hours&quot; on a numeric rating scale anchored by the terms &quot;No itching&quot; (0) and &quot;Worst possible itching&quot; (10) at the ends.</description>
        <time_frame>Baseline, Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
        <population>FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, CP-690,550 5 mg</title>
            <description>Participants who were re-assigned to this group from placebo at Week 16 and thereafter received CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, CP-690,550 10 mg</title>
            <description>Participants who were re-assigned to this group from placebo at Week 16 and thereafter received CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Itch Severity Item (ISI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52</title>
          <description>ISI assessed severity of itch (pruritus) due to psoriasis. ISI is a single item, horizontal numeric rating scale. Participants were asked to rate &quot;your worst itching due to psoriasis over the past 24 hours&quot; on a numeric rating scale anchored by the terms &quot;No itching&quot; (0) and &quot;Worst possible itching&quot; (10) at the ends.</description>
          <population>FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="340"/>
                <count group_id="O2" value="339"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.76" spread="0.10"/>
                    <measurement group_id="O2" value="-2.25" spread="0.11"/>
                    <measurement group_id="O3" value="-0.13" spread="0.25"/>
                    <measurement group_id="O4" value="-0.06" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.62" spread="0.11"/>
                    <measurement group_id="O2" value="-3.16" spread="0.11"/>
                    <measurement group_id="O3" value="-0.27" spread="0.26"/>
                    <measurement group_id="O4" value="-0.11" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.95" spread="0.13"/>
                    <measurement group_id="O2" value="-3.72" spread="0.13"/>
                    <measurement group_id="O3" value="-0.01" spread="0.29"/>
                    <measurement group_id="O4" value="-0.18" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.02" spread="0.13"/>
                    <measurement group_id="O2" value="-3.91" spread="0.13"/>
                    <measurement group_id="O3" value="-0.79" spread="0.30"/>
                    <measurement group_id="O4" value="-0.25" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.85" spread="0.14"/>
                    <measurement group_id="O2" value="-3.97" spread="0.14"/>
                    <measurement group_id="O3" value="-0.77" spread="0.31"/>
                    <measurement group_id="O4" value="0.17" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.31" spread="0.13"/>
                    <measurement group_id="O2" value="-3.98" spread="0.13"/>
                    <measurement group_id="O3" value="-3.11" spread="0.29"/>
                    <measurement group_id="O4" value="-3.16" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.25" spread="0.14"/>
                    <measurement group_id="O2" value="-3.94" spread="0.13"/>
                    <measurement group_id="O3" value="-3.59" spread="0.30"/>
                    <measurement group_id="O4" value="-4.16" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.07" spread="0.15"/>
                    <measurement group_id="O2" value="-3.88" spread="0.14"/>
                    <measurement group_id="O3" value="-3.84" spread="0.32"/>
                    <measurement group_id="O4" value="-4.40" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.05" spread="0.15"/>
                    <measurement group_id="O2" value="-3.89" spread="0.14"/>
                    <measurement group_id="O3" value="-3.50" spread="0.32"/>
                    <measurement group_id="O4" value="-4.17" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dermatology Life Quality Index (DLQI) Score</title>
        <description>The DLQI is a 10 item general dermatology questionnaire that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI item response options are rated by the participant from 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.</description>
        <time_frame>Baseline, Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
        <population>FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Here n signifies those participants who were evaluable for this measure at specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, CP-690,550 5 mg</title>
            <description>Participants who were re-assigned to this group from placebo at Week 16 and thereafter received CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, CP-690,550 10 mg</title>
            <description>Participants who were re-assigned to this group from placebo at Week 16 and thereafter received CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Dermatology Life Quality Index (DLQI) Score</title>
          <description>The DLQI is a 10 item general dermatology questionnaire that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI item response options are rated by the participant from 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.</description>
          <population>FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Here n signifies those participants who were evaluable for this measure at specified time point for each arm, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="363"/>
                <count group_id="O2" value="360"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=363,359,66,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.46" spread="6.89"/>
                    <measurement group_id="O2" value="12.87" spread="6.91"/>
                    <measurement group_id="O3" value="13.83" spread="6.97"/>
                    <measurement group_id="O4" value="14.68" spread="6.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n=356,357,66,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.65" spread="6.11"/>
                    <measurement group_id="O2" value="8.32" spread="6.45"/>
                    <measurement group_id="O3" value="11.44" spread="7.02"/>
                    <measurement group_id="O4" value="12.67" spread="7.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=351,349,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.98" spread="5.97"/>
                    <measurement group_id="O2" value="6.50" spread="5.94"/>
                    <measurement group_id="O3" value="11.45" spread="6.87"/>
                    <measurement group_id="O4" value="13.05" spread="7.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=345,347,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.88" spread="6.00"/>
                    <measurement group_id="O2" value="4.95" spread="5.58"/>
                    <measurement group_id="O3" value="10.89" spread="6.23"/>
                    <measurement group_id="O4" value="13.05" spread="7.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=340,344,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.36" spread="6.06"/>
                    <measurement group_id="O2" value="4.17" spread="5.10"/>
                    <measurement group_id="O3" value="10.29" spread="6.82"/>
                    <measurement group_id="O4" value="13.06" spread="7.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=319,331,66,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.45" spread="6.07"/>
                    <measurement group_id="O2" value="3.85" spread="5.17"/>
                    <measurement group_id="O3" value="10.05" spread="6.23"/>
                    <measurement group_id="O4" value="12.83" spread="7.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=310,319,66,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.28" spread="5.18"/>
                    <measurement group_id="O2" value="3.26" spread="4.67"/>
                    <measurement group_id="O3" value="5.89" spread="4.88"/>
                    <measurement group_id="O4" value="7.17" spread="6.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 (n=289,303,61,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.94" spread="5.05"/>
                    <measurement group_id="O2" value="3.24" spread="4.83"/>
                    <measurement group_id="O3" value="4.34" spread="4.88"/>
                    <measurement group_id="O4" value="3.46" spread="4.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40 (n=200,239,53,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.53" spread="4.11"/>
                    <measurement group_id="O2" value="2.11" spread="3.79"/>
                    <measurement group_id="O3" value="3.25" spread="4.43"/>
                    <measurement group_id="O4" value="1.63" spread="2.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=177,216,47,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.86" spread="4.35"/>
                    <measurement group_id="O2" value="1.91" spread="3.72"/>
                    <measurement group_id="O3" value="3.40" spread="4.43"/>
                    <measurement group_id="O4" value="1.78" spread="2.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52</title>
        <description>The DLQI is a 10 item general dermatology questionnaire that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI item response options are rated by the participant from 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.</description>
        <time_frame>Baseline, Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
        <population>FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, CP-690,550 5 mg</title>
            <description>Participants who were re-assigned to this group from placebo at Week 16 and thereafter received CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, CP-690,550 10 mg</title>
            <description>Participants who were re-assigned to this group from placebo at Week 16 and thereafter received CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52</title>
          <description>The DLQI is a 10 item general dermatology questionnaire that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI item response options are rated by the participant from 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.</description>
          <population>FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="358"/>
                <count group_id="O2" value="357"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.02" spread="0.23"/>
                    <measurement group_id="O2" value="-4.56" spread="0.23"/>
                    <measurement group_id="O3" value="-1.94" spread="0.54"/>
                    <measurement group_id="O4" value="-1.07" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.65" spread="0.25"/>
                    <measurement group_id="O2" value="-6.41" spread="0.25"/>
                    <measurement group_id="O3" value="-1.90" spread="0.57"/>
                    <measurement group_id="O4" value="-0.77" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.68" spread="0.27"/>
                    <measurement group_id="O2" value="-7.95" spread="0.27"/>
                    <measurement group_id="O3" value="-2.45" spread="0.61"/>
                    <measurement group_id="O4" value="-0.77" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.09" spread="0.27"/>
                    <measurement group_id="O2" value="-8.70" spread="0.27"/>
                    <measurement group_id="O3" value="-3.08" spread="0.63"/>
                    <measurement group_id="O4" value="-0.75" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.97" spread="0.29"/>
                    <measurement group_id="O2" value="-8.90" spread="0.28"/>
                    <measurement group_id="O3" value="-3.33" spread="0.65"/>
                    <measurement group_id="O4" value="-0.98" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.01" spread="0.27"/>
                    <measurement group_id="O2" value="-9.42" spread="0.27"/>
                    <measurement group_id="O3" value="-7.48" spread="0.61"/>
                    <measurement group_id="O4" value="-6.48" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.25" spread="0.28"/>
                    <measurement group_id="O2" value="-9.36" spread="0.28"/>
                    <measurement group_id="O3" value="-9.02" spread="0.62"/>
                    <measurement group_id="O4" value="-9.72" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.50" spread="0.30"/>
                    <measurement group_id="O2" value="-9.51" spread="0.29"/>
                    <measurement group_id="O3" value="-9.26" spread="0.63"/>
                    <measurement group_id="O4" value="-10.89" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.26" spread="0.31"/>
                    <measurement group_id="O2" value="-9.56" spread="0.30"/>
                    <measurement group_id="O3" value="-9.23" spread="0.65"/>
                    <measurement group_id="O4" value="-10.90" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>36-Item Short-Form Health Survey Version 2, Acute (SF-36)</title>
        <description>36-Item Short-Form Health Survey (SF-36) is a standardized survey evaluating 8 aspects of functional health and well-being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. These 8 aspects are summarized as physical and mental health summary scores. The score range for the physical and mental health scores is 0-100 (100=highest level of functioning).</description>
        <time_frame>Baseline, Week 16, 28, 52</time_frame>
        <population>FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Here n signifies those participants who were evaluable for this measure at specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, CP-690,550 5 mg</title>
            <description>Participants who were re-assigned to this group from placebo at Week 16 and thereafter received CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, CP-690,550 10 mg</title>
            <description>Participants who were re-assigned to this group from placebo at Week 16 and thereafter received CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>36-Item Short-Form Health Survey Version 2, Acute (SF-36)</title>
          <description>36-Item Short-Form Health Survey (SF-36) is a standardized survey evaluating 8 aspects of functional health and well-being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. These 8 aspects are summarized as physical and mental health summary scores. The score range for the physical and mental health scores is 0-100 (100=highest level of functioning).</description>
          <population>FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Here n signifies those participants who were evaluable for this measure at specified time point for each arm, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="363"/>
                <count group_id="O2" value="360"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Physical Health Score (n=358,355,66,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.36" spread="9.10"/>
                    <measurement group_id="O2" value="47.02" spread="9.05"/>
                    <measurement group_id="O3" value="47.12" spread="8.95"/>
                    <measurement group_id="O4" value="44.86" spread="9.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Mental Health Score (n=358,355,66,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.98" spread="12.53"/>
                    <measurement group_id="O2" value="43.35" spread="11.57"/>
                    <measurement group_id="O3" value="42.53" spread="11.77"/>
                    <measurement group_id="O4" value="42.97" spread="11.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Physical Health Score (n=318,329,65,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.83" spread="8.34"/>
                    <measurement group_id="O2" value="50.99" spread="8.63"/>
                    <measurement group_id="O3" value="48.04" spread="8.75"/>
                    <measurement group_id="O4" value="45.60" spread="8.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Mental Health Score (n=318,329,65,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.23" spread="10.93"/>
                    <measurement group_id="O2" value="49.06" spread="9.50"/>
                    <measurement group_id="O3" value="44.47" spread="10.77"/>
                    <measurement group_id="O4" value="43.07" spread="12.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28: Physical Health Score (n=286,303,60,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.01" spread="7.67"/>
                    <measurement group_id="O2" value="51.92" spread="7.86"/>
                    <measurement group_id="O3" value="51.11" spread="8.08"/>
                    <measurement group_id="O4" value="49.63" spread="8.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28: Mental Health Score (n=286,303,60,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.59" spread="10.47"/>
                    <measurement group_id="O2" value="49.64" spread="9.35"/>
                    <measurement group_id="O3" value="48.63" spread="9.57"/>
                    <measurement group_id="O4" value="49.69" spread="9.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Physical Health Score (n=177,216,46,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.98" spread="7.10"/>
                    <measurement group_id="O2" value="52.42" spread="7.93"/>
                    <measurement group_id="O3" value="50.90" spread="8.75"/>
                    <measurement group_id="O4" value="52.12" spread="7.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Mental Health Score (n=177,216,46,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.05" spread="10.33"/>
                    <measurement group_id="O2" value="50.73" spread="8.38"/>
                    <measurement group_id="O3" value="50.77" spread="9.43"/>
                    <measurement group_id="O4" value="49.58" spread="9.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hospital Anxiety and Depression Scale (HADS) Score</title>
        <description>HADS: 14-item questionnaire that screens for the presence of anxiety and depression symptoms. There are 7 items comprising the anxiety subscale, and 7 items comprising the depression subscale. Each item has response option ranging from 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score ranges from 0 to 21 for each subscale; higher score indicates greater severity of anxiety or depression symptoms.</description>
        <time_frame>Baseline, Week 4, 16, 28, 52</time_frame>
        <population>FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Here n signifies those participants who were evaluable for this measure at specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, CP-690,550 5 mg</title>
            <description>Participants who were re-assigned to this group from placebo at Week 16 and thereafter received CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, CP-690,550 10 mg</title>
            <description>Participants who were re-assigned to this group from placebo at Week 16 and thereafter received CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Hospital Anxiety and Depression Scale (HADS) Score</title>
          <description>HADS: 14-item questionnaire that screens for the presence of anxiety and depression symptoms. There are 7 items comprising the anxiety subscale, and 7 items comprising the depression subscale. Each item has response option ranging from 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score ranges from 0 to 21 for each subscale; higher score indicates greater severity of anxiety or depression symptoms.</description>
          <population>FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Here n signifies those participants who were evaluable for this measure at specified time point for each arm, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="363"/>
                <count group_id="O2" value="360"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Anxiety Subscale (n=362,358,66,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.58" spread="4.21"/>
                    <measurement group_id="O2" value="6.21" spread="4.08"/>
                    <measurement group_id="O3" value="6.94" spread="4.21"/>
                    <measurement group_id="O4" value="7.06" spread="4.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Depression Subscale (n=362,358,66,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.20" spread="4.27"/>
                    <measurement group_id="O2" value="5.09" spread="4.09"/>
                    <measurement group_id="O3" value="5.61" spread="3.98"/>
                    <measurement group_id="O4" value="5.68" spread="3.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Anxiety Subscale (n=350,349,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.66" spread="3.96"/>
                    <measurement group_id="O2" value="5.30" spread="3.90"/>
                    <measurement group_id="O3" value="6.82" spread="4.11"/>
                    <measurement group_id="O4" value="6.70" spread="4.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Depression Subscale (n=350,349,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.34" spread="3.59"/>
                    <measurement group_id="O2" value="4.23" spread="3.75"/>
                    <measurement group_id="O3" value="5.28" spread="4.06"/>
                    <measurement group_id="O4" value="5.26" spread="4.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Anxiety Subscale (n=317,333,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.50" spread="4.18"/>
                    <measurement group_id="O2" value="4.74" spread="3.76"/>
                    <measurement group_id="O3" value="6.20" spread="4.39"/>
                    <measurement group_id="O4" value="6.85" spread="4.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Depression Subscale (n=317,333,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.97" spread="3.87"/>
                    <measurement group_id="O2" value="3.51" spread="3.71"/>
                    <measurement group_id="O3" value="4.92" spread="3.65"/>
                    <measurement group_id="O4" value="5.50" spread="4.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28: Anxiety Subscale (n=286,304,60,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.98" spread="4.04"/>
                    <measurement group_id="O2" value="4.47" spread="4.00"/>
                    <measurement group_id="O3" value="4.60" spread="3.89"/>
                    <measurement group_id="O4" value="4.82" spread="3.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28: Depression Subscale (n=286,304,60,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.63" spread="3.64"/>
                    <measurement group_id="O2" value="3.21" spread="3.65"/>
                    <measurement group_id="O3" value="3.65" spread="3.66"/>
                    <measurement group_id="O4" value="3.59" spread="3.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Anxiety Subscale (n=177,215,46,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.97" spread="3.65"/>
                    <measurement group_id="O2" value="3.84" spread="3.88"/>
                    <measurement group_id="O3" value="4.33" spread="4.21"/>
                    <measurement group_id="O4" value="4.00" spread="3.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52:Depression Subscale (n= 177, 215, 46, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.05" spread="3.48"/>
                    <measurement group_id="O2" value="2.80" spread="3.49"/>
                    <measurement group_id="O3" value="3.11" spread="3.16"/>
                    <measurement group_id="O4" value="3.09" spread="3.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Work Limitation Questionnaire (WLQ) Index Score</title>
        <description>WLQ: participant-reported 25-item scale to evaluate degree to which health problems interfere with an ability to perform job roles along 4 dimensions: Time Management scale (5 items); Physical Demands scale (6 items); Mental-Interpersonal Demands Scale (9 items); Output Demands Scale (5 items). All the scales ranged from 0 (limited none of the time) to 100 (limited all of the time). The WLQ Index score is the weighted sum of the scores from the 4 WLQ scales (total score: 0 [no loss] to 100 [complete loss of work]).</description>
        <time_frame>Baseline, Week 4, 16, 28, 52</time_frame>
        <population>FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Here n signifies those participants who were evaluable for this measure at specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, CP-690,550 5 mg</title>
            <description>Participants who were re-assigned to this group from placebo at Week 16 and thereafter received CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, CP-690,550 10 mg</title>
            <description>Participants who were re-assigned to this group from placebo at Week 16 and thereafter received CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Work Limitation Questionnaire (WLQ) Index Score</title>
          <description>WLQ: participant-reported 25-item scale to evaluate degree to which health problems interfere with an ability to perform job roles along 4 dimensions: Time Management scale (5 items); Physical Demands scale (6 items); Mental-Interpersonal Demands Scale (9 items); Output Demands Scale (5 items). All the scales ranged from 0 (limited none of the time) to 100 (limited all of the time). The WLQ Index score is the weighted sum of the scores from the 4 WLQ scales (total score: 0 [no loss] to 100 [complete loss of work]).</description>
          <population>FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Here n signifies those participants who were evaluable for this measure at specified time point for each arm, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="363"/>
                <count group_id="O2" value="360"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n= 309, 305, 55, 56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.40" spread="6.38"/>
                    <measurement group_id="O2" value="7.90" spread="6.51"/>
                    <measurement group_id="O3" value="7.16" spread="5.84"/>
                    <measurement group_id="O4" value="8.40" spread="6.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n= 291, 298, 53, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.92" spread="6.68"/>
                    <measurement group_id="O2" value="6.64" spread="6.42"/>
                    <measurement group_id="O3" value="6.67" spread="6.41"/>
                    <measurement group_id="O4" value="9.66" spread="6.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n= 273, 279, 51, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.68" spread="6.37"/>
                    <measurement group_id="O2" value="5.72" spread="5.93"/>
                    <measurement group_id="O3" value="6.53" spread="5.97"/>
                    <measurement group_id="O4" value="7.13" spread="5.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 (n= 241, 254, 51, 53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.12" spread="6.37"/>
                    <measurement group_id="O2" value="5.77" spread="6.29"/>
                    <measurement group_id="O3" value="6.03" spread="6.29"/>
                    <measurement group_id="O4" value="6.24" spread="6.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n= 148, 183, 41, 41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.02" spread="6.26"/>
                    <measurement group_id="O2" value="5.95" spread="6.65"/>
                    <measurement group_id="O3" value="6.73" spread="6.54"/>
                    <measurement group_id="O4" value="5.29" spread="6.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Patient Global Assessment (PtGA) Scale Response</title>
        <description>The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5-point scale (0=clear [no psoriasis]; 1=almost clear; 2=mild; 3=moderate; 4=severe).</description>
        <time_frame>Baseline, Week 2, 4, 8, 12, 16, 20, 28, 40, 52</time_frame>
        <population>FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Here n signifies those participants who were evaluable for this measure at specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, CP-690,550 5 mg</title>
            <description>Participants who were re-assigned to this group from placebo at Week 16 and thereafter received CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, CP-690,550 10 mg</title>
            <description>Participants who were re-assigned to this group from placebo at Week 16 and thereafter received CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Patient Global Assessment (PtGA) Scale Response</title>
          <description>The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5-point scale (0=clear [no psoriasis]; 1=almost clear; 2=mild; 3=moderate; 4=severe).</description>
          <population>FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Here n signifies those participants who were evaluable for this measure at specified time point for each arm, respectively.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="363"/>
                <count group_id="O2" value="360"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Clear (n = 360, 359, 66, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Almost Clear (n = 360, 359, 66, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Mild (n = 360, 359, 66, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9"/>
                    <measurement group_id="O2" value="3.6"/>
                    <measurement group_id="O3" value="3.0"/>
                    <measurement group_id="O4" value="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Moderate (n = 360, 359, 66, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.3"/>
                    <measurement group_id="O2" value="35.7"/>
                    <measurement group_id="O3" value="31.8"/>
                    <measurement group_id="O4" value="34.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Severe (n = 360, 359, 66, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.8"/>
                    <measurement group_id="O2" value="60.7"/>
                    <measurement group_id="O3" value="65.2"/>
                    <measurement group_id="O4" value="63.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Clear (n = 357, 358, 66, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.3"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Almost Clear (n = 357, 358, 66, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                    <measurement group_id="O2" value="3.9"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Mild (n = 357, 358, 66, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8"/>
                    <measurement group_id="O2" value="17.6"/>
                    <measurement group_id="O3" value="7.6"/>
                    <measurement group_id="O4" value="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Moderate (n = 357, 358, 66, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.0"/>
                    <measurement group_id="O2" value="48.0"/>
                    <measurement group_id="O3" value="37.9"/>
                    <measurement group_id="O4" value="40.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Severe (n = 357, 358, 66, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.1"/>
                    <measurement group_id="O2" value="30.2"/>
                    <measurement group_id="O3" value="54.5"/>
                    <measurement group_id="O4" value="53.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Clear (n = 350, 348, 65, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.9"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Almost Clear (n = 350, 348, 65, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0"/>
                    <measurement group_id="O2" value="12.1"/>
                    <measurement group_id="O3" value="1.5"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Mild (n = 350, 348, 65, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.6"/>
                    <measurement group_id="O2" value="29.9"/>
                    <measurement group_id="O3" value="7.7"/>
                    <measurement group_id="O4" value="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Moderate (n = 350, 348, 65, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.9"/>
                    <measurement group_id="O2" value="40.5"/>
                    <measurement group_id="O3" value="46.2"/>
                    <measurement group_id="O4" value="36.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Severe (n = 350, 348, 65, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.6"/>
                    <measurement group_id="O2" value="16.7"/>
                    <measurement group_id="O3" value="44.6"/>
                    <measurement group_id="O4" value="58.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Clear (n = 345, 346, 65, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7"/>
                    <measurement group_id="O2" value="3.8"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Almost Clear (n = 345, 346, 65, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.7"/>
                    <measurement group_id="O2" value="27.7"/>
                    <measurement group_id="O3" value="1.5"/>
                    <measurement group_id="O4" value="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Mild (n = 345, 346, 65, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.3"/>
                    <measurement group_id="O2" value="28.9"/>
                    <measurement group_id="O3" value="12.3"/>
                    <measurement group_id="O4" value="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Moderate (n = 345, 346, 65, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.1"/>
                    <measurement group_id="O2" value="27.2"/>
                    <measurement group_id="O3" value="43.1"/>
                    <measurement group_id="O4" value="39.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Severe (n = 345, 346, 65, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.1"/>
                    <measurement group_id="O2" value="12.4"/>
                    <measurement group_id="O3" value="43.1"/>
                    <measurement group_id="O4" value="53.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Clear (n = 341, 344, 65, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8"/>
                    <measurement group_id="O2" value="8.7"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Almost Clear (n = 341, 344, 65, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.9"/>
                    <measurement group_id="O2" value="35.2"/>
                    <measurement group_id="O3" value="3.1"/>
                    <measurement group_id="O4" value="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Mild (n = 341, 344, 65, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.6"/>
                    <measurement group_id="O2" value="27.9"/>
                    <measurement group_id="O3" value="23.1"/>
                    <measurement group_id="O4" value="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Moderate (n = 341, 344, 65, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.3"/>
                    <measurement group_id="O2" value="19.5"/>
                    <measurement group_id="O3" value="32.3"/>
                    <measurement group_id="O4" value="33.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Severe (n = 341, 344, 65, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.3"/>
                    <measurement group_id="O2" value="8.7"/>
                    <measurement group_id="O3" value="41.5"/>
                    <measurement group_id="O4" value="55.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Clear (n = 320, 331, 66, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4"/>
                    <measurement group_id="O2" value="10.9"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Almost Clear (n = 320, 331, 66, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.4"/>
                    <measurement group_id="O2" value="37.8"/>
                    <measurement group_id="O3" value="6.1"/>
                    <measurement group_id="O4" value="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Mild (n = 320, 331, 66, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.6"/>
                    <measurement group_id="O2" value="24.8"/>
                    <measurement group_id="O3" value="15.2"/>
                    <measurement group_id="O4" value="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Moderate (n = 320, 331, 66, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.5"/>
                    <measurement group_id="O2" value="19.0"/>
                    <measurement group_id="O3" value="42.4"/>
                    <measurement group_id="O4" value="25.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Severe (n = 320, 331, 66, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0"/>
                    <measurement group_id="O2" value="7.6"/>
                    <measurement group_id="O3" value="36.4"/>
                    <measurement group_id="O4" value="60.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Clear (n = 311, 319, 65, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1"/>
                    <measurement group_id="O2" value="16.3"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Almost Clear (n = 311, 319, 65, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.1"/>
                    <measurement group_id="O2" value="35.7"/>
                    <measurement group_id="O3" value="23.1"/>
                    <measurement group_id="O4" value="20.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Mild (n = 311, 319, 65, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.6"/>
                    <measurement group_id="O2" value="27.3"/>
                    <measurement group_id="O3" value="26.2"/>
                    <measurement group_id="O4" value="20.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Moderate (n = 311, 319, 65, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.5"/>
                    <measurement group_id="O2" value="13.5"/>
                    <measurement group_id="O3" value="46.2"/>
                    <measurement group_id="O4" value="35.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Severe (n = 311, 319, 65, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7"/>
                    <measurement group_id="O2" value="7.2"/>
                    <measurement group_id="O3" value="4.6"/>
                    <measurement group_id="O4" value="21.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28: Clear (n = 290, 303, 61, 61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.7"/>
                    <measurement group_id="O2" value="20.8"/>
                    <measurement group_id="O3" value="6.6"/>
                    <measurement group_id="O4" value="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28: Almost Clear (n = 290, 303, 61, 61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.9"/>
                    <measurement group_id="O2" value="40.6"/>
                    <measurement group_id="O3" value="32.8"/>
                    <measurement group_id="O4" value="39.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28: Mild (n = 290, 303, 61, 61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.3"/>
                    <measurement group_id="O2" value="17.5"/>
                    <measurement group_id="O3" value="39.3"/>
                    <measurement group_id="O4" value="29.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28: Moderate (n = 290, 303, 61, 61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.2"/>
                    <measurement group_id="O2" value="15.8"/>
                    <measurement group_id="O3" value="19.7"/>
                    <measurement group_id="O4" value="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28: Severe (n = 290, 303, 61, 61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9"/>
                    <measurement group_id="O2" value="5.3"/>
                    <measurement group_id="O3" value="1.6"/>
                    <measurement group_id="O4" value="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Clear (n = 200, 239, 53, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.5"/>
                    <measurement group_id="O2" value="30.5"/>
                    <measurement group_id="O3" value="11.3"/>
                    <measurement group_id="O4" value="28.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Almost Clear (n = 200, 239, 53, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.0"/>
                    <measurement group_id="O2" value="41.4"/>
                    <measurement group_id="O3" value="50.9"/>
                    <measurement group_id="O4" value="56.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Mild (n = 200, 239, 53, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.5"/>
                    <measurement group_id="O2" value="15.5"/>
                    <measurement group_id="O3" value="20.8"/>
                    <measurement group_id="O4" value="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Moderate (n = 200, 239, 53, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0"/>
                    <measurement group_id="O2" value="11.3"/>
                    <measurement group_id="O3" value="15.1"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Severe (n = 200, 239, 53, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0"/>
                    <measurement group_id="O2" value="1.3"/>
                    <measurement group_id="O3" value="1.9"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Clear (n = 177, 216, 47, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.1"/>
                    <measurement group_id="O2" value="32.9"/>
                    <measurement group_id="O3" value="19.1"/>
                    <measurement group_id="O4" value="34.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Almost Clear (n = 177, 216, 47, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.8"/>
                    <measurement group_id="O2" value="39.8"/>
                    <measurement group_id="O3" value="31.9"/>
                    <measurement group_id="O4" value="45.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Mild (n = 177, 216, 47, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.5"/>
                    <measurement group_id="O2" value="15.3"/>
                    <measurement group_id="O3" value="23.4"/>
                    <measurement group_id="O4" value="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Moderate (n = 177, 216, 47, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.4"/>
                    <measurement group_id="O2" value="9.3"/>
                    <measurement group_id="O3" value="21.3"/>
                    <measurement group_id="O4" value="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Severe (n = 177, 216, 47, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2"/>
                    <measurement group_id="O2" value="2.8"/>
                    <measurement group_id="O3" value="4.3"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response</title>
        <description>The PSSM is a single, 7 point item that evaluates overall participant satisfaction with the study treatment. Response options range from &quot;very dissatisfied&quot; to &quot;very satisfied&quot; with the study treatment.</description>
        <time_frame>Week 16, 28, 52</time_frame>
        <population>FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Here n signifies those participants who were evaluable for this measure at specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, CP-690,550 5 mg</title>
            <description>Participants who were re-assigned to this group from placebo at Week 16 and thereafter received CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, CP-690,550 10 mg</title>
            <description>Participants who were re-assigned to this group from placebo at Week 16 and thereafter received CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response</title>
          <description>The PSSM is a single, 7 point item that evaluates overall participant satisfaction with the study treatment. Response options range from &quot;very dissatisfied&quot; to &quot;very satisfied&quot; with the study treatment.</description>
          <population>FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Here n signifies those participants who were evaluable for this measure at specified time point for each arm, respectively.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="363"/>
                <count group_id="O2" value="360"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week16:Not Satisfied/Dissatisfied(n=317,332,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0"/>
                    <measurement group_id="O2" value="6.3"/>
                    <measurement group_id="O3" value="12.3"/>
                    <measurement group_id="O4" value="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16:Slightly Dissatisfied (n=317,332,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2"/>
                    <measurement group_id="O2" value="1.5"/>
                    <measurement group_id="O3" value="9.2"/>
                    <measurement group_id="O4" value="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16:Slightly Satisfied (n=317,332,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9"/>
                    <measurement group_id="O2" value="6.9"/>
                    <measurement group_id="O3" value="9.2"/>
                    <measurement group_id="O4" value="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16:Somewhat Dissatisfied (n=317,332,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0"/>
                    <measurement group_id="O2" value="3.0"/>
                    <measurement group_id="O3" value="9.2"/>
                    <measurement group_id="O4" value="18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16:Somewhat Satisfied (n=317,332,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.1"/>
                    <measurement group_id="O2" value="22.9"/>
                    <measurement group_id="O3" value="16.9"/>
                    <measurement group_id="O4" value="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16:Very Dissatisfied (n=317,332,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4"/>
                    <measurement group_id="O2" value="4.2"/>
                    <measurement group_id="O3" value="29.2"/>
                    <measurement group_id="O4" value="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16:Very Satisfied (n=317,332,65,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.5"/>
                    <measurement group_id="O2" value="55.1"/>
                    <measurement group_id="O3" value="13.8"/>
                    <measurement group_id="O4" value="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week28:Not Satisfied/Dissatisfied(n=285,303,60,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1"/>
                    <measurement group_id="O2" value="4.0"/>
                    <measurement group_id="O3" value="1.7"/>
                    <measurement group_id="O4" value="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28:Slightly Dissatisfied (n=285,303,60,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6"/>
                    <measurement group_id="O2" value="3.3"/>
                    <measurement group_id="O3" value="1.7"/>
                    <measurement group_id="O4" value="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28:Slightly Satisfied (n=285,303,60,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5"/>
                    <measurement group_id="O2" value="6.9"/>
                    <measurement group_id="O3" value="11.7"/>
                    <measurement group_id="O4" value="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28:Somewhat Dissatisfied (n=285,303,60,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9"/>
                    <measurement group_id="O2" value="0.7"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28:Somewhat Satisfied (n=285,303,60,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.0"/>
                    <measurement group_id="O2" value="26.1"/>
                    <measurement group_id="O3" value="40.0"/>
                    <measurement group_id="O4" value="31.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28:Very Dissatisfied (n=285,303,60,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5"/>
                    <measurement group_id="O2" value="3.6"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28:Very Satisfied (n=285,303,60,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.5"/>
                    <measurement group_id="O2" value="55.4"/>
                    <measurement group_id="O3" value="45.0"/>
                    <measurement group_id="O4" value="59.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week52:Not Satisfied/Dissatisfied(n=176,217,46,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8"/>
                    <measurement group_id="O2" value="0.9"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52:Slightly Dissatisfied (n=176,217,46,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                    <measurement group_id="O2" value="0.9"/>
                    <measurement group_id="O3" value="2.2"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52:Slightly Satisfied (n=176,217,46,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1"/>
                    <measurement group_id="O2" value="5.5"/>
                    <measurement group_id="O3" value="13.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52:Somewhat Dissatisfied (n=176,217,46,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3"/>
                    <measurement group_id="O2" value="0.9"/>
                    <measurement group_id="O3" value="2.2"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52:Somewhat Satisfied (n=176,217,46,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.5"/>
                    <measurement group_id="O2" value="25.3"/>
                    <measurement group_id="O3" value="34.8"/>
                    <measurement group_id="O4" value="28.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52:Very Dissatisfied (n=176,217,46,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.9"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52:Very Satisfied (n=176,217,46,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.1"/>
                    <measurement group_id="O2" value="65.4"/>
                    <measurement group_id="O3" value="47.8"/>
                    <measurement group_id="O4" value="71.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Joint Pain Assessment (JPA) Score</title>
        <description>The JPA assesses severity of joint pain. The JPA is a horizontal numeric rating scale. Participants were asked to select the number that best describes any joint pain that participant may have experienced over the past 24 hours with response options ranging from 0-no joint pain to 10-worst possible joint pain.</description>
        <time_frame>Baseline, Week 4, 16, 28, 52</time_frame>
        <population>FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Here n signifies those participants who were evaluable for this measure at specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, CP-690,550 5 mg</title>
            <description>Participants who were re-assigned to this group from placebo at Week 16 and thereafter received CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, CP-690,550 10 mg</title>
            <description>Participants who were re-assigned to this group from placebo at Week 16 and thereafter received CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Joint Pain Assessment (JPA) Score</title>
          <description>The JPA assesses severity of joint pain. The JPA is a horizontal numeric rating scale. Participants were asked to select the number that best describes any joint pain that participant may have experienced over the past 24 hours with response options ranging from 0-no joint pain to 10-worst possible joint pain.</description>
          <population>FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Here n signifies those participants who were evaluable for this measure at specified time point for each arm, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="363"/>
                <count group_id="O2" value="360"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n= 363, 359, 66, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.42" spread="3.21"/>
                    <measurement group_id="O2" value="2.96" spread="2.99"/>
                    <measurement group_id="O3" value="3.00" spread="2.94"/>
                    <measurement group_id="O4" value="3.69" spread="3.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n= 351, 349, 64, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.24" spread="2.57"/>
                    <measurement group_id="O2" value="2.13" spread="2.56"/>
                    <measurement group_id="O3" value="3.13" spread="2.68"/>
                    <measurement group_id="O4" value="3.18" spread="3.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n= 319, 333, 65, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.41" spread="2.76"/>
                    <measurement group_id="O2" value="1.89" spread="2.59"/>
                    <measurement group_id="O3" value="3.20" spread="3.07"/>
                    <measurement group_id="O4" value="3.45" spread="3.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 (n= 287, 304, 60, 60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.08" spread="2.53"/>
                    <measurement group_id="O2" value="1.71" spread="2.46"/>
                    <measurement group_id="O3" value="1.93" spread="2.18"/>
                    <measurement group_id="O4" value="1.93" spread="2.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n= 176, 215, 46, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.60" spread="2.25"/>
                    <measurement group_id="O2" value="1.38" spread="2.25"/>
                    <measurement group_id="O3" value="1.46" spread="2.24"/>
                    <measurement group_id="O4" value="1.50" spread="2.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Euro Quality of Life 5 Dimensions (EQ-5D) - Health State Profile Utility Score</title>
        <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (&quot;confined to bed&quot;). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.</description>
        <time_frame>Baseline, Week 16, 28, 40, 52</time_frame>
        <population>FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Here n signifies those participants who were evaluable for this measure at specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, CP-690,550 5 mg</title>
            <description>Participants who were re-assigned to this group from placebo at Week 16 and thereafter received CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, CP-690,550 10 mg</title>
            <description>Participants who were re-assigned to this group from placebo at Week 16 and thereafter received CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Euro Quality of Life 5 Dimensions (EQ-5D) - Health State Profile Utility Score</title>
          <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (&quot;confined to bed&quot;). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.</description>
          <population>FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Here n signifies those participants who were evaluable for this measure at specified time point for each arm, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="363"/>
                <count group_id="O2" value="360"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n= 363, 359, 66, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77" spread="0.19"/>
                    <measurement group_id="O2" value="0.77" spread="0.19"/>
                    <measurement group_id="O3" value="0.78" spread="0.17"/>
                    <measurement group_id="O4" value="0.74" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n= 319, 333, 65, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.86" spread="0.16"/>
                    <measurement group_id="O2" value="0.88" spread="0.15"/>
                    <measurement group_id="O3" value="0.81" spread="0.18"/>
                    <measurement group_id="O4" value="0.76" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 (n= 288, 303, 60, 61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.86" spread="0.15"/>
                    <measurement group_id="O2" value="0.89" spread="0.14"/>
                    <measurement group_id="O3" value="0.89" spread="0.14"/>
                    <measurement group_id="O4" value="0.88" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40 (n= 201, 239, 53, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.91" spread="0.13"/>
                    <measurement group_id="O2" value="0.91" spread="0.15"/>
                    <measurement group_id="O3" value="0.92" spread="0.14"/>
                    <measurement group_id="O4" value="0.90" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n= 176, 217, 47, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.89" spread="0.12"/>
                    <measurement group_id="O2" value="0.90" spread="0.14"/>
                    <measurement group_id="O3" value="0.89" spread="0.14"/>
                    <measurement group_id="O4" value="0.90" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Euro Quality of Life 5 Dimensions (EQ-5D) - Visual Analog Scale (VAS)</title>
        <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 millimeter (mm) (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state.</description>
        <time_frame>Baseline, Week 16, 28, 40, 52</time_frame>
        <population>FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Here n signifies those participants who were evaluable for this measure at specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, CP-690,550 5 mg</title>
            <description>Participants who were re-assigned to this group from placebo at Week 16 and thereafter received CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, CP-690,550 10 mg</title>
            <description>Participants who were re-assigned to this group from placebo at Week 16 and thereafter received CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Euro Quality of Life 5 Dimensions (EQ-5D) - Visual Analog Scale (VAS)</title>
          <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 millimeter (mm) (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state.</description>
          <population>FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Here n signifies those participants who were evaluable for this measure at specified time point for each arm, respectively.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="363"/>
                <count group_id="O2" value="360"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n= 361, 359, 65, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.28" spread="22.53"/>
                    <measurement group_id="O2" value="66.97" spread="22.63"/>
                    <measurement group_id="O3" value="68.65" spread="21.20"/>
                    <measurement group_id="O4" value="65.24" spread="19.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n= 316, 330, 64, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.00" spread="18.96"/>
                    <measurement group_id="O2" value="77.95" spread="17.36"/>
                    <measurement group_id="O3" value="69.00" spread="17.95"/>
                    <measurement group_id="O4" value="59.85" spread="22.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 (n= 287, 303, 60, 61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.99" spread="17.89"/>
                    <measurement group_id="O2" value="78.89" spread="17.38"/>
                    <measurement group_id="O3" value="76.37" spread="18.10"/>
                    <measurement group_id="O4" value="79.13" spread="12.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40 (n= 201, 240, 53, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.47" spread="17.74"/>
                    <measurement group_id="O2" value="83.84" spread="15.09"/>
                    <measurement group_id="O3" value="82.96" spread="12.25"/>
                    <measurement group_id="O4" value="83.80" spread="12.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n= 175, 216, 47, 45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.23" spread="17.42"/>
                    <measurement group_id="O2" value="84.59" spread="13.80"/>
                    <measurement group_id="O3" value="81.23" spread="14.54"/>
                    <measurement group_id="O4" value="82.38" spread="13.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Interaction With Healthcare Professional</title>
        <description>The Psoriasis Health Care Resource Utilization (Ps-HCRU) questionnaire is a short questionnaire designed to assess healthcare resource use and the impact of psoriasis on work. The first section assesses direct costs associated with healthcare resource use (interactions with healthcare providers such as general practitioners, Dermatologist, Rheumatologist). Baseline is the latest pre-dose measurement. Week 16 includes all reported log data to Week 16 (excluding Baseline). Participants may have response in more than 1 category. Data was not analyzed beyond Week 16 as per study teams decision because Week 0 - 16 period was considered sufficient to provide clear reflection of Ps-HCRU endpoint.</description>
        <time_frame>Baseline, Week 16</time_frame>
        <population>FAS included all participants who were randomized to the study and received at least 1 dose of the randomized investigational drug (CP-690,550 or placebo). Here 'N' (number of participants analyzed) signifies participants evaluable for this measure and n signifies participants evaluable at specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 tablet orally twice daily up to Week 16. Participants in this group were re-randomized to CP-690,550 5 mg or CP-690,550 10 mg treatment at Week 16.</description>
          </group>
        </group_list>
        <measure>
          <title>Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Interaction With Healthcare Professional</title>
          <description>The Psoriasis Health Care Resource Utilization (Ps-HCRU) questionnaire is a short questionnaire designed to assess healthcare resource use and the impact of psoriasis on work. The first section assesses direct costs associated with healthcare resource use (interactions with healthcare providers such as general practitioners, Dermatologist, Rheumatologist). Baseline is the latest pre-dose measurement. Week 16 includes all reported log data to Week 16 (excluding Baseline). Participants may have response in more than 1 category. Data was not analyzed beyond Week 16 as per study teams decision because Week 0 - 16 period was considered sufficient to provide clear reflection of Ps-HCRU endpoint.</description>
          <population>FAS included all participants who were randomized to the study and received at least 1 dose of the randomized investigational drug (CP-690,550 or placebo). Here 'N' (number of participants analyzed) signifies participants evaluable for this measure and n signifies participants evaluable at specified time point for each arm, respectively.</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: General Practitioner (n= 28, 39, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Dermatologist (n= 28, 39, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Rheumatologist (n= 28, 39, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Cardiologist (n= 28, 39, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Gastroenterologist (n= 28, 39, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Psychiatrist (n= 28, 39, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Surgeon (n= 28, 39, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Nurse (n= 28, 39, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Other (n= 28, 39, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: General Practitioner (n= 56, 57, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Dermatologist (n= 56, 57, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Rheumatologist (n= 56, 57, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Cardiologist (n= 56, 57, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Gastroenterologist (n= 56, 57, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Psychiatrist (n= 56, 57, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Surgeon (n= 56, 57, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Nurse (n= 56, 57, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Other (n= 56, 57, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Impact of Psoriasis on Work</title>
        <description>The Psoriasis Health Care Resource Utilization (Ps-HCRU) questionnaire is a short questionnaire designed to assess healthcare resource use and the impact of psoriasis on work. The second section assesses indirect costs associated with absenteeism due to psoriasis and the impact of psoriasis on productivity at work. Participants employed at the time of assessment answered (Yes/No [Y/N]): &quot;Were you absent or on sick leave from work due to psoriasis today?&quot;, and participants unemployed (UEmp) at the time of assessment answered (Yes/No): &quot;Are you unemployed due to your psoriasis?&quot; Baseline is the latest pre-dose measurement. Week 16 includes all reported log up to Week 16 (excluding Baseline). Data was not analyzed beyond Week 16 as per study teams decision because Week 0 - 16 period was considered sufficient to provide clear reflection of Ps-HCRU endpoint.</description>
        <time_frame>Baseline, Week 16</time_frame>
        <population>FAS included all participants who were randomized to the study and received at least 1 dose of the randomized investigational drug (CP-690,550 or placebo). Here n signifies those participants who were evaluable for this measure at specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 tablet orally twice daily up to Week 16. Participants in this group were re-randomized to CP-690,550 5 mg or CP-690,550 10 mg treatment at Week 16.</description>
          </group>
        </group_list>
        <measure>
          <title>Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Impact of Psoriasis on Work</title>
          <description>The Psoriasis Health Care Resource Utilization (Ps-HCRU) questionnaire is a short questionnaire designed to assess healthcare resource use and the impact of psoriasis on work. The second section assesses indirect costs associated with absenteeism due to psoriasis and the impact of psoriasis on productivity at work. Participants employed at the time of assessment answered (Yes/No [Y/N]): &quot;Were you absent or on sick leave from work due to psoriasis today?&quot;, and participants unemployed (UEmp) at the time of assessment answered (Yes/No): &quot;Are you unemployed due to your psoriasis?&quot; Baseline is the latest pre-dose measurement. Week 16 includes all reported log up to Week 16 (excluding Baseline). Data was not analyzed beyond Week 16 as per study teams decision because Week 0 - 16 period was considered sufficient to provide clear reflection of Ps-HCRU endpoint.</description>
          <population>FAS included all participants who were randomized to the study and received at least 1 dose of the randomized investigational drug (CP-690,550 or placebo). Here n signifies those participants who were evaluable for this measure at specified time point for each arm, respectively.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="363"/>
                <count group_id="O2" value="360"/>
                <count group_id="O3" value="177"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Emp, Absent/Sick Leave:Y (n=237,232,114)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Emp, Absent/Sick Leave:N (n=237,232,114)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="182"/>
                    <measurement group_id="O2" value="185"/>
                    <measurement group_id="O3" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: UEmp, due to Psoriasis:Y (n=97,103,49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: UEmp, due to Psoriasis:N (n=97,103,49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="79"/>
                    <measurement group_id="O3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Emp, Absent/Sick Leave:Y (n=224,221,88)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Emp, Absent/Sick Leave:N (n=224,221,88)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="177"/>
                    <measurement group_id="O2" value="184"/>
                    <measurement group_id="O3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: UEmp, due to Psoriasis:Y (n=77,87,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16:UEmp, due to Psoriasis: N (n=77,87,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="74"/>
                    <measurement group_id="O3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Healthcare Resource Use Events and Employment Status</title>
        <description>The Psoriasis Health Care Resource Utilization (Ps-HCRU) questionnaire is a short questionnaire designed to assess healthcare resource use and the impact of psoriasis on work. The first section assesses direct costs associated with healthcare resource use, and the second section assesses indirect costs associated with absenteeism due to psoriasis and the impact of psoriasis on productivity at work. Percentage of participants reporting healthcare resource use events and employment status, work impacted events due to psoriasis, and absence or sick leave for work due to psoriasis at Week 16 are reported. Data was not analyzed beyond Week 16 as per study teams decision because Week 0 - 16 period was considered sufficient to provide clear reflection of Ps-HCRU endpoint.</description>
        <time_frame>Week 16</time_frame>
        <population>FAS included all participants who were randomized to the study and received at least 1 dose of the randomized investigational drug (CP-690,550 or placebo). Here n signifies those participants who were evaluable (answered respective question for this measure) for specified parameter for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 tablet orally twice daily up to Week 16. Participants in this group were re-randomized to CP-690,550 5 mg or CP-690,550 10 mg treatment at Week 16.</description>
          </group>
        </group_list>
        <measure>
          <title>Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Healthcare Resource Use Events and Employment Status</title>
          <description>The Psoriasis Health Care Resource Utilization (Ps-HCRU) questionnaire is a short questionnaire designed to assess healthcare resource use and the impact of psoriasis on work. The first section assesses direct costs associated with healthcare resource use, and the second section assesses indirect costs associated with absenteeism due to psoriasis and the impact of psoriasis on productivity at work. Percentage of participants reporting healthcare resource use events and employment status, work impacted events due to psoriasis, and absence or sick leave for work due to psoriasis at Week 16 are reported. Data was not analyzed beyond Week 16 as per study teams decision because Week 0 - 16 period was considered sufficient to provide clear reflection of Ps-HCRU endpoint.</description>
          <population>FAS included all participants who were randomized to the study and received at least 1 dose of the randomized investigational drug (CP-690,550 or placebo). Here n signifies those participants who were evaluable (answered respective question for this measure) for specified parameter for each arm, respectively.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="363"/>
                <count group_id="O2" value="360"/>
                <count group_id="O3" value="177"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Healthcare Resource Use Events (n=30,37,5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00"/>
                    <measurement group_id="O2" value="94.59"/>
                    <measurement group_id="O3" value="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Employment (n=301,310,130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.42"/>
                    <measurement group_id="O2" value="71.94"/>
                    <measurement group_id="O3" value="66.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Work Impacted Events (n=79,88,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.66"/>
                    <measurement group_id="O2" value="14.77"/>
                    <measurement group_id="O3" value="14.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absence/Sick Leave Due to Psoriasis (n=224,221,90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.98"/>
                    <measurement group_id="O2" value="16.74"/>
                    <measurement group_id="O3" value="27.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Work Hours and Absent Hours</title>
        <description>The Psoriasis Health Care Resource Utilization (Ps-HCRU) questionnaire is a short questionnaire designed to assess healthcare resource use and the impact of psoriasis on work. The first section assesses direct costs associated with healthcare resource use, and the second section assesses indirect costs associated with absenteeism due to psoriasis and the impact of psoriasis on productivity at work. Baseline is the latest pre-dose measurement. Participants reported hours scheduled to work and hours absent from work. Data was not analyzed beyond Week 16 as per study teams decision because Week 0 - 16 period was considered sufficient to provide clear reflection of Ps-HCRU endpoint.</description>
        <time_frame>Baseline, Week 16</time_frame>
        <population>FAS included all participants who were randomized to the study and received at least 1 dose of the randomized investigational drug (CP-690,550 or placebo). Here 'N' (number of participants analyzed) signifies participants evaluable for this measure and n signifies participants evaluable for specified parameter for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 tablet orally twice daily up to Week 16. Participants in this group were re-randomized to CP-690,550 5 mg or CP-690,550 10 mg treatment at Week 16.</description>
          </group>
        </group_list>
        <measure>
          <title>Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Work Hours and Absent Hours</title>
          <description>The Psoriasis Health Care Resource Utilization (Ps-HCRU) questionnaire is a short questionnaire designed to assess healthcare resource use and the impact of psoriasis on work. The first section assesses direct costs associated with healthcare resource use, and the second section assesses indirect costs associated with absenteeism due to psoriasis and the impact of psoriasis on productivity at work. Baseline is the latest pre-dose measurement. Participants reported hours scheduled to work and hours absent from work. Data was not analyzed beyond Week 16 as per study teams decision because Week 0 - 16 period was considered sufficient to provide clear reflection of Ps-HCRU endpoint.</description>
          <population>FAS included all participants who were randomized to the study and received at least 1 dose of the randomized investigational drug (CP-690,550 or placebo). Here 'N' (number of participants analyzed) signifies participants evaluable for this measure and n signifies participants evaluable for specified parameter for each arm, respectively.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Hours Scheduled to Work (n=54,48,25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.61" spread="1.31"/>
                    <measurement group_id="O2" value="8.15" spread="1.75"/>
                    <measurement group_id="O3" value="7.92" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Hours Absent From Work (n=54,47,27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.15" spread="3.09"/>
                    <measurement group_id="O2" value="6.00" spread="3.03"/>
                    <measurement group_id="O3" value="5.81" spread="2.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Hours Scheduled to Work (n=47,39,25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.49" spread="1.80"/>
                    <measurement group_id="O2" value="8.31" spread="1.08"/>
                    <measurement group_id="O3" value="8.40" spread="1.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Hours Absent From Work (n=46,38,24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.41" spread="3.15"/>
                    <measurement group_id="O2" value="5.24" spread="2.39"/>
                    <measurement group_id="O3" value="5.88" spread="2.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Percent Absent Hours</title>
        <description>The Psoriasis Health Care Resource Utilization (Ps-HCRU) questionnaire is a short questionnaire designed to assess healthcare resource use and the impact of psoriasis on work. The first section assesses direct costs associated with healthcare resource use, and the second section assesses indirect costs associated with absenteeism due to psoriasis and the impact of psoriasis on productivity at work. Baseline is the latest pre-dose measurement. Participants reported hours scheduled to work and hours absent from work. Percent absent hours = (hours absent from work/hours scheduled to work) multiplied by 100. Data was not analyzed beyond Week 16 as per study teams decision because Week 0 - 16 period was considered sufficient to provide clear reflection of Ps-HCRU endpoint.</description>
        <time_frame>Baseline, Week 16</time_frame>
        <population>FAS included all participants who were randomized to the study and received at least 1 dose of the randomized investigational drug (CP-690,550 or placebo). Here 'N' (number of participants analyzed) signifies participants evaluable for this measure and n signifies participants evaluable at specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 tablet orally twice daily up to Week 16. Participants in this group were re-randomized to CP-690,550 5 mg or CP-690,550 10 mg treatment at Week 16.</description>
          </group>
        </group_list>
        <measure>
          <title>Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Percent Absent Hours</title>
          <description>The Psoriasis Health Care Resource Utilization (Ps-HCRU) questionnaire is a short questionnaire designed to assess healthcare resource use and the impact of psoriasis on work. The first section assesses direct costs associated with healthcare resource use, and the second section assesses indirect costs associated with absenteeism due to psoriasis and the impact of psoriasis on productivity at work. Baseline is the latest pre-dose measurement. Participants reported hours scheduled to work and hours absent from work. Percent absent hours = (hours absent from work/hours scheduled to work) multiplied by 100. Data was not analyzed beyond Week 16 as per study teams decision because Week 0 - 16 period was considered sufficient to provide clear reflection of Ps-HCRU endpoint.</description>
          <population>FAS included all participants who were randomized to the study and received at least 1 dose of the randomized investigational drug (CP-690,550 or placebo). Here 'N' (number of participants analyzed) signifies participants evaluable for this measure and n signifies participants evaluable at specified time point for each arm, respectively.</population>
          <units>percentage of scheduled hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=53,47,25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.32" spread="33.29"/>
                    <measurement group_id="O2" value="72.84" spread="32.96"/>
                    <measurement group_id="O3" value="75.76" spread="30.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=46,38,24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.15" spread="35.08"/>
                    <measurement group_id="O2" value="65.21" spread="31.55"/>
                    <measurement group_id="O3" value="71.81" spread="30.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Psoriasis Affecting Ability to Work</title>
        <description>The Psoriasis Health Care Resource Utilization (Ps-HCRU) questionnaire is a short questionnaire designed to assess healthcare resource use and the impact of psoriasis on work. The first section assesses direct costs associated with healthcare resource use, and the second section assesses indirect costs associated with absenteeism due to psoriasis and the impact of psoriasis on productivity at work. Baseline is the latest pre-dose measurement. Participants rate how much psoriasis affected their ability to work by reporting a number from 0 to 10, where 0 means ability to work was not affected by psoriasis, and 10 means ability to work was completely affected by psoriasis. Data was not analyzed beyond Week 16 as per study teams decision because Week 0 - 16 period was considered sufficient to provide clear reflection of Ps-HCRU endpoint.</description>
        <time_frame>Baseline, Week 16</time_frame>
        <population>FAS included all participants who were randomized to the study and received at least 1 dose of the randomized investigational drug (CP-690,550 or placebo). Here 'N' (number of participants analyzed) signifies participants evaluable for this measure and n signifies participants evaluable at specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 tablet orally twice daily up to Week 16. Participants in this group were re-randomized to CP-690,550 5 mg or CP-690,550 10 mg treatment at Week 16.</description>
          </group>
        </group_list>
        <measure>
          <title>Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Psoriasis Affecting Ability to Work</title>
          <description>The Psoriasis Health Care Resource Utilization (Ps-HCRU) questionnaire is a short questionnaire designed to assess healthcare resource use and the impact of psoriasis on work. The first section assesses direct costs associated with healthcare resource use, and the second section assesses indirect costs associated with absenteeism due to psoriasis and the impact of psoriasis on productivity at work. Baseline is the latest pre-dose measurement. Participants rate how much psoriasis affected their ability to work by reporting a number from 0 to 10, where 0 means ability to work was not affected by psoriasis, and 10 means ability to work was completely affected by psoriasis. Data was not analyzed beyond Week 16 as per study teams decision because Week 0 - 16 period was considered sufficient to provide clear reflection of Ps-HCRU endpoint.</description>
          <population>FAS included all participants who were randomized to the study and received at least 1 dose of the randomized investigational drug (CP-690,550 or placebo). Here 'N' (number of participants analyzed) signifies participants evaluable for this measure and n signifies participants evaluable at specified time point for each arm, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="363"/>
                <count group_id="O2" value="360"/>
                <count group_id="O3" value="177"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=238,234,114)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.23" spread="2.81"/>
                    <measurement group_id="O2" value="2.13" spread="2.64"/>
                    <measurement group_id="O3" value="2.89" spread="3.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=223,222,89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.13" spread="2.13"/>
                    <measurement group_id="O2" value="1.26" spread="2.60"/>
                    <measurement group_id="O3" value="1.94" spread="2.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Family Dermatology Life Quality Index (FDLQI) Score</title>
        <description>The FDLQI is a 10-item questionnaire that examine the impact of health-related quality of life issues associated with living with a person with a skin condition (example, emotional distress, personal relationships, reactions of other people, social life, caregiving) over the last month. The FDLQI need to be completed by a family member (for example, spouse or partner, parent) who currently lives with the participant. Each question is scored on a scale from 0 (Not at all/ Not relevant) to 3 (Very much). Total score is calculated by summing the score of each item resulting in a maximum score of '30' and a minimum score of '0'. Higher scores indicate greater impairment to quality of life.</description>
        <time_frame>Baseline, Week 16, 52</time_frame>
        <population>FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Here 'N' (number of participants analyzed) signifies participants evaluable for this measure and n signifies participants evaluable at specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, CP-690,550 5 mg</title>
            <description>Participants who were re-assigned to this group from placebo at Week 16 and thereafter received CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, CP-690,550 10 mg</title>
            <description>Participants who were re-assigned to this group from placebo at Week 16 and thereafter received CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Family Dermatology Life Quality Index (FDLQI) Score</title>
          <description>The FDLQI is a 10-item questionnaire that examine the impact of health-related quality of life issues associated with living with a person with a skin condition (example, emotional distress, personal relationships, reactions of other people, social life, caregiving) over the last month. The FDLQI need to be completed by a family member (for example, spouse or partner, parent) who currently lives with the participant. Each question is scored on a scale from 0 (Not at all/ Not relevant) to 3 (Very much). Total score is calculated by summing the score of each item resulting in a maximum score of '30' and a minimum score of '0'. Higher scores indicate greater impairment to quality of life.</description>
          <population>FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Here 'N' (number of participants analyzed) signifies participants evaluable for this measure and n signifies participants evaluable at specified time point for each arm, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n= 22, 27, 5, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.45" spread="7.40"/>
                    <measurement group_id="O2" value="9.41" spread="7.45"/>
                    <measurement group_id="O3" value="9.40" spread="3.78"/>
                    <measurement group_id="O4" value="8.80" spread="3.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n= 17, 17, 5, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.76" spread="4.25"/>
                    <measurement group_id="O2" value="3.53" spread="4.16"/>
                    <measurement group_id="O3" value="6.20" spread="5.26"/>
                    <measurement group_id="O4" value="6.40" spread="4.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n= 6, 9, 3, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.17" spread="2.40"/>
                    <measurement group_id="O2" value="2.00" spread="4.21"/>
                    <measurement group_id="O3" value="5.67" spread="3.51"/>
                    <measurement group_id="O4" value="0.50" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Same event may appear as both AE/SAE; distinct events are presented. An event may be categorized as serious in 1 subject and as nonserious in another subject, or 1 subject may have experienced both a serious and nonserious event during the study. Adverse events for participants (n=45) who were not re-randomized at week 16, are reported separately.</desc>
      <group_list>
        <group group_id="E1">
          <title>CP-690,550 5 mg</title>
          <description>CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
        </group>
        <group group_id="E2">
          <title>CP-690,550 10 mg</title>
          <description>CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
        </group>
        <group group_id="E3">
          <title>Placebo, CP-690,550 5 mg</title>
          <description>Placebo matched to CP-690,550 tablet orally twice daily up to Week 16 and thereafter CP-690,550 5 mg tablet orally twice daily up to Week 52.</description>
        </group>
        <group group_id="E4">
          <title>Placebo, CP-690,550 10 mg</title>
          <description>Placebo matched to CP-690,550 tablet orally twice daily up to Week 16 and thereafter CP-690,550 10 mg tablet orally twice daily up to Week 52.</description>
        </group>
        <group group_id="E5">
          <title>Placebo</title>
          <description>Participants who received placebo matched to CP-690,550 tablet orally twice daily up to Week 16 but were not re-randomized to CP-690,550 treatment.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Myocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Tooth disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Umbilical hernia, obstructive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Pelvic mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Burn infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Meningitis aseptic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Staphylococcal skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod sting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Mycobacterium test positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Malignant melanoma in situ</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Prostate cancer stage II</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcohol abuse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Obsessive-compulsive disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pustular psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="189" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="222" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="38" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="22" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Eosinophilia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Hyperthermia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Bacterial test positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Low density lipoprotein increased</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Psoriatic arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Skin papilloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

